

2015 Aetna Value Plan

Abilify

Products Affected

- ABILIFY ORAL TABLET

ST Criteria	Trial of 1 month each of: 1 generic (aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone) PLUS Latuda
QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Abilify

Products Affected

- ABILIFY ORAL SOLUTION

QL Criteria	10 ML Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Abilify Discmelt

Products Affected

- ABILIFY DISCMELT

ST Criteria	Documented step through ABILIFY ORAL TABLET
QL Criteria	1 tab Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Absorica

Products Affected

- ABSORICA

PA Criteria	Criteria Details
Covered Uses	severe recalcitrant nodular or cystic acne
Exclusion Criteria	
Required Medical Information	Member already has evidence of scarring and member is enrolled in the FDA iPLEDGE program (females of childbearing potential ONLY)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	5 months
Other Criteria	For coverage of additional quantities (greater than 2 capsules per day) member must meet the following criteria: Patient requires more than 2 capsules per day to reach the appropriate dose for weight, and this is the members FIRST course of therapy or member now requires a second course of therapy and it has been at least 8 weeks after the first course was initiated (2 month holiday), and member has recieved a cumulative dose of less than 120 mg/kg during a course of therapy lasting 20 weeks or less.
ST Criteria	Documented step through ONE GENERIC ORAL ANTIBIOTIC prescribed for treatment of acne (i.e., MINOCYCLINE OR DOXYCYCLINE)
Notes/References	
Revision Date	Prior Authorization: October 05, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Abstral

Products Affected

- ABSTRAL

PA Criteria	Criteria Details
Covered Uses	For pain due to malignant diagnosis only
Exclusion Criteria	Use in non-malignant pain
Required Medical Information	A. Documentation of already receiving and who are tolerant to opioid therapy, and documentation on intolerance of two (2) other immediate-release opioids including morphine, hydrocodone, oxycodone, or hydromorphone.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months
Other Criteria	FOR SUBSYS: Documentation of intolerance to Actiq. FOR ABSTRAL, FENTORA, LAZANDA, and ONSOLIS: Documentation of intolerance to Actiq AND Subsys.
Notes/References	
Revision Date	Prior Authorization: September 29, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Acamprosate Calcium

Products Affected

- *acamprosate calcium*

QL Criteria	6 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Aceon

Products Affected

- ACEON ORAL TABLET 8 MG

QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Aceon

Products Affected

- ACEON ORAL TABLET 4 MG

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Aciphex

Products Affected

- ACIPHEX

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	FOR HIGH DOSE ACIPHEX (UP TO 40mg/day): Documentation of trial/failure of one of the following high dose agents: 80 mg/day of Prilosec OTC/Prilosec or Protonix, 60 mg/day of Prevacid 24H OTC OR 80 mg/day of Nexium.
ST Criteria	Documentation of trial and failure of Nexium AND ONE of the following: Prilosec OTC/ Prilosec*, Prevacid 24H OTC, Zegerid OTC, or Protonix*
QL Criteria	1 tab Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 29, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Acitretin

Products Affected

- *acitretin oral capsule 10 mg, 25 mg*

QL Criteria	2 caps Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Actemra

Products Affected

- ACTEMRA SUBCUTANEOUS*

QL Criteria	1 syringe Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Actiq

Products Affected

- ACTIQ

PA Criteria	Criteria Details
Covered Uses	For pain due to malignant diagnosis only
Exclusion Criteria	Use in non-malignant pain
Required Medical Information	A. Documentation of already receiving and who are tolerant to opioid therapy, and documentation on intolerance of two (2) other immediate-release opioids including morphine, hydrocodone, oxycodone, or hydromorphone.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months
Other Criteria	FOR SUBSYS: Documentation of intolerance to Actiq. FOR ABSTRAL, FENTORA, LAZANDA, and ONSOLIS: Documentation of intolerance to Actiq AND Subsys.
QL Criteria	4 lozenges Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 29, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Activella

Products Affected

- ACTIVELLA

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Actonel

Products Affected

- ACTONEL ORAL TABLET 150 MG

ST Criteria	Documented trial and failure of 1 month of generic alendronate weekly (70mg weekly dose)
QL Criteria	1 tablet Per 28 months
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Actonel

Products Affected

- ACTONEL ORAL TABLET 35 MG

ST Criteria	Documented trial and failure of 1 month of generic alendronate weekly (70mg weekly dose)
QL Criteria	4 tablets Per 28 months
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Actonel

Products Affected

- ACTONEL ORAL TABLET 5 MG, 30 MG

ST Criteria	Documented trial and failure of 1 month of generic alendronate weekly (70mg weekly dose)
QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Actoplus Met

Products Affected

- ACTOPLUS MET

QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Actoplus met XR

Products Affected

- ACTOPLUS MET XR ORAL TABLET
EXTENDED RELEASE 24 HR* 15-1000 MG

QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Actoplus met XR

Products Affected

- ACTOPLUS MET XR ORAL TABLET
EXTENDED RELEASE 24 HR* 30-1000 MG

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Actos

Products Affected

- ACTOS

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Acuvail

Products Affected

- ACUVAIL

QL Criteria	30 vials Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Adalat CC

Products Affected

- ADALAT CC ORAL TABLET EXTENDED
RELEASE 24 HR* 60 MG

QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Adalat CC

Products Affected

- ADALAT CC ORAL TABLET EXTENDED
RELEASE 24 HR* 30 MG, 90 MG

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Adcirca

Products Affected

- ADCIRCA

QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Adderall

Products Affected

- ADDERALL ORAL TABLET 12.5 MG, 30 MG, 15 MG, 7.5 MG, 10 MG, 5 MG

ST Criteria	Documented step through 14 days each of THREE of AMPHETAMINE/DEXTROAMPHETAMINE/ SR, DEXMETHYLPHENIDATE/ SR, DEXTROAMPHETAMINE, METHAMPHETAMINE, METHYLPHENIDATE/ ER/ SR, STRATTERA, OR VYVANSE
QL Criteria	2 tabs Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Adderall

Products Affected

- ADDERALL ORAL TABLET 20 MG

ST Criteria	Documented step through 14 days each of THREE of AMPHETAMINE/DEXTROAMPHETAMINE/ SR, DEXMETHYLPHENIDATE/ SR, DEXTROAMPHETAMINE, METHAMPHETAMINE, METHYLPHENIDATE/ ER/ SR, STRATTERA, OR VYVANSE
QL Criteria	3 tabs Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Adderall XR

Products Affected

- ADDERALL XR

PA Criteria	Criteria Details
Covered Uses	Attention deficit disorder, Attention deficit hyperactivity disorder
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis of adult ADD or ADHD OR documentation of a diagnosis of childhood ADHD onset with history of previous treatment, and documentation of symptoms significantly impacting, impairing, or compromising the patient's ability to function normally (i.e., attend/maintain academic enrollment or employment), and documentation of intolerance to appropriately dosed and administered regular/immediate acting stimulants.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Step Therapy
ST Criteria	Documented step through 14 days each of THREE of AMPHETAMINE/DEXTROAMPHETAMINE/ SR, DEXMETHYLPHENIDATE/ SR, DEXTROAMPHETAMINE, METHAMPHETAMINE, METHYLPHENIDATE/ ER/ SR, STRATTERA, OR VYVANSE
QL Criteria	1 cap Per 1 day
Notes/References	
Revision Date	Prior Authorization: October 05, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Adefovir Dipivoxil

Products Affected

- *adefovir dipivoxil*

QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Adempas

Products Affected

- ADEMPAS

QL Criteria	3 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Adrenaclick

Products Affected

- ADRENACLICK

PA Criteria	Criteria Details
Covered Uses	allergic reaction in patients who are at risk for, or have a history of, anaphylactic reaction
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	Step Therapy
ST Criteria	Documented step through AUVI-Q
QL Criteria	2 doses Per 1 fill
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Advair Diskus

Products Affected

- ADVAIR DISKUS

PA Criteria	Criteria Details
Covered Uses	Asthma (12 and above) Chronic Obstructive Pulmonary Disorder (COPD) Note: Members 4-11 years requesting Advair Diskus 100/50 for Asthma - No PA/ST applies
Exclusion Criteria	
Required Medical Information	For Asthma A. Documentation of trial and failure or intolerance to Symbicort AND Dulera For COPD A. Documentation of trial and failure or intolerance to Symbicort AND SPIRIVA
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	Step Therapy
ST Criteria	For Asthma: Documented step through one month of SYMBICORT AND DULERA. For COPD: Documented strep through one month of SYMBICORT AND SPIRIVA.
QL Criteria	1 diskus Per 1 month
Notes/References	
Revision Date	Prior Authorization: September 09, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Advair HFA

Products Affected

- ADVAIR HFA

PA Criteria	Criteria Details
Covered Uses	Asthma (12 and above)
Exclusion Criteria	
Required Medical Information	
Age Restrictions	greater than 12 years old
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Step Therapy
ST Criteria	Documented step through one month of SYMBICORT AND DULERA
QL Criteria	1 inhaler Per 1 month
Notes/References	
Revision Date	Prior Authorization: August 11, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Advicor

Products Affected

- ADVICOR ORAL TABLET EXTENDED
RELEASE 24 HR* 1000-40 MG, 500-20 MG,
750-20 MG

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Advicor

Products Affected

- ADVICOR ORAL TABLET EXTENDED
RELEASE 24 HR* 1000-20 MG

QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

AeroChamber MV

Products Affected

- AEROCHAMBER MV

QL Criteria	2 spacers Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Aerospan

Products Affected

- AEROSPAN

PA Criteria	Criteria Details
Covered Uses	Asthma
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	Step Therapy. Medical Exception for Flovent Diskus and Flovent HFA: Covered for topical steroid treatment of eosinophilic esophagitis for which other treatments have been unsatisfactory
ST Criteria	Documented step through one month of ASMANEX AND QVAR
QL Criteria	1 inhaler Per 1 month
Notes/References	
Revision Date	Prior Authorization: November 24, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Afeditab CR

Products Affected

- AFEDITAB CR ORAL TABLET EXTENDED
RELEASE 24 HR* 30 MG

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Afeditab CR

Products Affected

- AFEDITAB CR ORAL TABLET EXTENDED
RELEASE 24 HR* 60 MG

QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Afinitor

Products Affected

- AFINITOR

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Afinitor Disperz

Products Affected

- AFINITOR DISPERZ

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Afrezza

Products Affected

- AFREZZA

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes, Type 2 Diabetes
Exclusion Criteria	
Required Medical Information	Documentation of ALL of the following: (1) In patients with type 1 diabetes, concomitant use of long-acting insulin (e.g., Levamir or Lantus), (2) In all Patients, no history of chronic lung disease such as asthma or Chronic Obstructive Pulmonary Disease (COPD), and (3) Detailed medical history documenting physical examination and spirometry (FEV1) to identify potential lung disease in all patients.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Step Therapy
ST Criteria	documented trial of one month of one preferred alternative rapid-acting insulin (Humulin OR Humalog)
Notes/References	
Revision Date	Prior Authorization: October 05, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Akynzeo

Products Affected

- AKYNZEO

PA Criteria	Criteria Details
Covered Uses	Prophylaxis of chemotherapy-induced nausea and vomiting
Exclusion Criteria	
Required Medical Information	A documented diagnosis of nausea and vomiting associated with cancer chemotherapy
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	For coverage of additional quantities, a member's treating physician must request prior authorization through the Pharmacy Management Precertification Unit. Additional quantities of Akynzeo will be considered medically necessary for those members who have a documented chemotherapy regimen that requires more than two cycles of antiemetic per 30 days
ST Criteria	Documented trial of a 5HT3 receptor agonist (granisetron or ondansetron) AND Emend.
QL Criteria	2 capsules Per 1 month
Notes/References	
Revision Date	Prior Authorization: August 11, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Aldara

Products Affected

- ALDARA

QL Criteria	12 packs Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Alendronate Sodium

Products Affected

- *alendronate sodium oral tablet 10 mg*

QL Criteria	1 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Alendronate Sodium

Products Affected

- *alendronate sodium oral tablet 70 mg, 35 mg*

QL Criteria	4 tabs Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Alendronate Sodium

Products Affected

- *alendronate sodium oral solution*

QL Criteria	300 ml Per 28 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Alendronate Sodium

Products Affected

- *alendronate sodium oral tablet 40 mg, 5 mg*

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Alfuzosin HCl ER

Products Affected

- *alfuzosin hcl er*

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Alinia

Products Affected

- ALINIA ORAL SUSPENSION
RECONSTITUTED

QL Criteria	3 bottles Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Alinia

Products Affected

- ALINIA ORAL TABLET

QL Criteria	6 tabs Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Almotriptan Malate

Products Affected

- *almotriptan malate*

QL Criteria	6 tablets Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Alora

Products Affected

- ALORA

QL Criteria	1 box Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

ALPRAZolam ER

Products Affected

- *alprazolam er*

QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

ALPRAZolam XR

Products Affected

- *alprazolam xr*

QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Altavera

Products Affected

- ALTAVERA

QL Criteria	1.5 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Altoprev

Products Affected

- ALTOPREV

QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Alvesco

Products Affected

- ALVESCO

PA Criteria	Criteria Details
Covered Uses	Asthma
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	Step Therapy. Medical Exception for Flovent Diskus and Flovent HFA: Covered for topical steroid treatment of eosinophilic esophagitis for which other treatments have been unsatisfactory
ST Criteria	Documented step through one month of ASMANEX AND QVAR
QL Criteria	1 inhaler Per 1 month
Notes/References	
Revision Date	Prior Authorization: November 24, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Alyacen 1/35

Products Affected

- *alyacen 1/35*

QL Criteria	1.5 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Alyacen 7/7/7

Products Affected

- *alyacen 7/7/7*

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ambien

Products Affected

- AMBIEN

QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ambien CR

Products Affected

- AMBIEN CR

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	
Age Restrictions	17 years and older
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	
ST Criteria	Documentation of a trial and failure with Ambien IR or Sonata
QL Criteria	1 tab Per 1 Day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Amerge

Products Affected

- AMERGE

QL Criteria	9 tabs Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Amethia

Products Affected

- AMETHIA

QL Criteria	1.5 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Amethia Lo

Products Affected

- AMETHIA LO

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Amethyst

Products Affected

- AMETHYST

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Amitiza

Products Affected

- AMITIZA

ST Criteria	Documented step through LACTULOSE* OR MIRALAX*
QL Criteria	2 caps Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Amlodipine Besy-Benazepril HCl

Products Affected

- *amlodipine besy-benazepril hcl*

QL Criteria	1 cap Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Amlodipine Besylate-Valsartan

Products Affected

- *amlodipine besylate-valsartan*

QL Criteria	1 tablet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Amlodipine-Valsartan-HCTZ

Products Affected

- *amlodipine-valsartan-hctz*

QL Criteria	1 tablet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Amnesteem

Products Affected

- AMNESTEEM

PA Criteria	Criteria Details
Covered Uses	severe recalcitrant nodular or cystic acne
Exclusion Criteria	
Required Medical Information	Member already has evidence of scarring and member is enrolled in the FDA iPLEDGE program (females of childbearing potential ONLY)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	5 months
Other Criteria	For coverage of additional quantities (greater than 2 capsules per day) member must meet the following criteria: Patient requires more than 2 capsules per day to reach the appropriate dose for weight, and this is the members FIRST course of therapy or member now requires a second course of therapy and it has been at least 8 weeks after the first course was initiated (2 month holiday), and member has recieved a cumulative dose of less than 120 mg/kg during a course of therapy lasting 20 weeks or less.
ST Criteria	Documented step through ONE GENERIC ORAL ANTIBIOTIC prescribed for treatment of acne (i.e., MINOCYCLINE OR DOXYCYCLINE)
QL Criteria	2 capsules Per 1 Day
Notes/References	
Revision Date	Prior Authorization: October 05, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Amphetamine-Dextroamphet ER

Products Affected

- *amphetamine-dextroamphet er*

QL Criteria	1 cap Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Amphetamine-Dextroamphetamine

Products Affected

- *amphetamine-dextroamphetamine oral tablet*
10 mg, 30 mg, 7.5 mg, 15 mg, 12.5 mg, 5 mg

QL Criteria	2 tabs Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Amphetamine-Dextroamphetamine

Products Affected

- *amphetamine-dextroamphetamine oral tablet*
20 mg

QL Criteria	3 tabs Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ampyra

Products Affected

- AMPYRA

QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Amturnide

Products Affected

- AMTURNIDE

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	Documentation of trial and failure with use of THREE (3) antihypertensive drugs from at least TWO (2) different therapeutics subclasses.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	<p>Examples of antihypertensive drugs listed by therapeutic subclasses</p> <p>Diuretics HydroDiuril, Microzide (hydrochlorothiazide), Hygroton (chlorthalidone), Diuril (chlorthiazide), Lasix (furosemide), Midamor (amiloride), Dyazide, Maxzide (triamterene-hydrochlorothiazide)</p> <p>Beta Blockers Tenormin (atenolol), Toprol XL (metoprolol succinate), Lopressor (metoprolol tartrate), Zebeta (bisoprolol), Coreg (carvedilol), Inderal LA (propranolol)</p> <p>Calcium Channel Blockers Adalat CC, Procardia XL (nifedipine), Calan, Isoptin, Verelan (verapamil), Cardizem, Cartia (diltiazem), Norvasc (amlodipine), Sular (nisoldipine), Plendil (felodipine)</p> <p>Angiotensin Converting Enzyme Inhibitors (ACEI) & ACEI combinations Prinivil, Zestril (lisinopril), Lotensin/Lotensin HCT/Lotrel (benazepril), Vasotec (enalapril), Accupril (quinapril), Mavik (trandolapril), Univas (moexipril)</p> <p>Angiotensin Receptor Blocker (ARB) & ARB combinations Cozaar/Hyzaar (losartan), Benicar/Benicar HCT (olmesartan), Micardis/Micardis HCT (telmisartan), Diovan/Diovan HCT (valsartan), Avapro/Avalide (irbesartan), Atacand/Atacand HCT (candesartan), Teveten /Teveten HCT (eprosartan), Edarbi/Edarbyclor (azilsartan)</p>
QL Criteria	1 tab Per 1 day
Notes/References	

Revision Date	Prior Authorization: August 11, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015
----------------------	---

Androderm

Products Affected

- ANDRODERM TRANSDERMAL PATCH 24
HR 2.5 MG/24HR, 5 MG/24HR

PA Criteria	Criteria Details
Covered Uses	Primary hypogonadism or hypogonadotropic hypogonadism, gender dysphoria, gender reassignment
Exclusion Criteria	patient with carcinoma of the breast or suspected carcinoma of the prostate, patient will be using therapy for muscle building purposes
Required Medical Information	Documented diagnosis of primary hypogonadism or hypogonadotropic hypogonadism as defined by either one of the following: (1) Member has undergone bilateral orchiectomy (no total fasting serum testosterone levels required), or (2) Having two consecutive low total fasting serum testosterone levels (below the testing laboratory's reference range or below 300ng/dl if reference ranges are not available), or for persons with low normal total testosterone levels (above 300 ng/dL but below 400 ng/dL), two consecutive low free or bioavailable fasting serum testosterone levels (below the testing laboratory's reference range or less than 225 picomoles per liter (pmol/L) (6 ng/dL) if reference ranges are not available)(Note: Two morning samples drawn between 7:00 a.m. and 10:00 a.m. obtained on two different days is required for NEW starts only), or (3) Member has a documented diagnosis of gender dysphoria or documentation of undergoing gender reassignment surgery.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	Documented step through one month each of ANDROGEL AND TESTIM
Notes/References	
Revision Date	Prior Authorization: September 29, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Androderm

Products Affected

- ANDRODERM TRANSDERMAL PATCH 24
HR 2 MG/24HR, 4 MG/24HR

PA Criteria	Criteria Details
Covered Uses	Primary hypogonadism or hypogonadotropic hypogonadism, gender dysphoria, gender reassignment
Exclusion Criteria	patient with carcinoma of the breast or suspected carcinoma of the prostate, patient will be using therapy for muscle building purposes
Required Medical Information	Documented diagnosis of primary hypogonadism or hypogonadotropic hypogonadism as defined by either one of the following: (1) Member has undergone bilateral orchiectomy (no total fasting serum testosterone levels required), or (2) Having two consecutive low total fasting serum testosterone levels (below the testing laboratory's reference range or below 300ng/dl if reference ranges are not available), or for persons with low normal total testosterone levels (above 300 ng/dL but below 400 ng/dL), two consecutive low free or bioavailable fasting serum testosterone levels (below the testing laboratory's reference range or less than 225 picomoles per liter (pmol/L) (6 ng/dL) if reference ranges are not available)(Note: Two morning samples drawn between 7:00 a.m. and 10:00 a.m. obtained on two different days is required for NEW starts only), or (3) Member has a documented diagnosis of gender dysphoria or documentation of undergoing gender reassignment surgery.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	Documented step through one month each of ANDROGEL AND TESTIM
QL Criteria	1 patch Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 29, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2015 Aetna Value Plan
(Updated 12/01/2015)

AndroGel

Products Affected

- ANDROGEL TRANSDERMAL 20.25 MG/1.25GM (1.62%)

PA Criteria	Criteria Details
Covered Uses	Primary hypogonadism or hypogonadotropic hypogonadism, gender dysphoria, gender reassignment
Exclusion Criteria	patient with carcinoma of the breast or suspected carcinoma of the prostate, patient will be using therapy for muscle building purposes
Required Medical Information	Documented diagnosis of primary hypogonadism or hypogonadotropic hypogonadism as defined by either one of the following: (1) Member has undergone bilateral orchiectomy (no total fasting serum testosterone levels required), or (2) Having two consecutive low total fasting serum testosterone levels (below the testing laboratory's reference range or below 300ng/dl if reference ranges are not available), or for persons with low normal total testosterone levels (above 300 ng/dL but below 400 ng/dL), two consecutive low free or bioavailable fasting serum testosterone levels (below the testing laboratory's reference range or less than 225 picomoles per liter (pmol/L) (6 ng/dL) if reference ranges are not available)(Note: Two morning samples drawn between 7:00 a.m. and 10:00 a.m. obtained on two different days is required for NEW starts only), or (3) Member has a documented diagnosis of gender dysphoria or documentation of undergoing gender reassignment surgery.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	1.25 grams Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 29, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

AndroGel

Products Affected

- ANDROGEL TRANSDERMAL 25 MG/2.5GM (1%)

PA Criteria	Criteria Details
Covered Uses	Primary hypogonadism or hypogonadotropic hypogonadism, gender dysphoria, gender reassignment
Exclusion Criteria	patient with carcinoma of the breast or suspected carcinoma of the prostate, patient will be using therapy for muscle building purposes
Required Medical Information	Documented diagnosis of primary hypogonadism or hypogonadotropic hypogonadism as defined by either one of the following: (1) Member has undergone bilateral orchiectomy (no total fasting serum testosterone levels required), or (2) Having two consecutive low total fasting serum testosterone levels (below the testing laboratory's reference range or below 300ng/dl if reference ranges are not available), or for persons with low normal total testosterone levels (above 300 ng/dL but below 400 ng/dL), two consecutive low free or bioavailable fasting serum testosterone levels (below the testing laboratory's reference range or less than 225 picomoles per liter (pmol/L) (6 ng/dL) if reference ranges are not available)(Note: Two morning samples drawn between 7:00 a.m. and 10:00 a.m. obtained on two different days is required for NEW starts only), or (3) Member has a documented diagnosis of gender dysphoria or documentation of undergoing gender reassignment surgery.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	2.5 grams Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 29, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2015 Aetna Value Plan
(Updated 12/01/2015)

AndroGel

Products Affected

- ANDROGEL TRANSDERMAL 40.5 MG/2.5GM (1.62%)

PA Criteria	Criteria Details
Covered Uses	Primary hypogonadism or hypogonadotropic hypogonadism, gender dysphoria, gender reassignment
Exclusion Criteria	patient with carcinoma of the breast or suspected carcinoma of the prostate, patient will be using therapy for muscle building purposes
Required Medical Information	Documented diagnosis of primary hypogonadism or hypogonadotropic hypogonadism as defined by either one of the following: (1) Member has undergone bilateral orchiectomy (no total fasting serum testosterone levels required), or (2) Having two consecutive low total fasting serum testosterone levels (below the testing laboratory's reference range or below 300ng/dl if reference ranges are not available), or for persons with low normal total testosterone levels (above 300 ng/dL but below 400 ng/dL), two consecutive low free or bioavailable fasting serum testosterone levels (below the testing laboratory's reference range or less than 225 picomoles per liter (pmol/L) (6 ng/dL) if reference ranges are not available)(Note: Two morning samples drawn between 7:00 a.m. and 10:00 a.m. obtained on two different days is required for NEW starts only), or (3) Member has a documented diagnosis of gender dysphoria or documentation of undergoing gender reassignment surgery.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	5 grams Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 29, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

AndroGel

Products Affected

- ANDROGEL TRANSDERMAL 50 MG/5GM
(1%)

PA Criteria	Criteria Details
Covered Uses	Primary hypogonadism or hypogonadotropic hypogonadism, gender dysphoria, gender reassignment
Exclusion Criteria	patient with carcinoma of the breast or suspected carcinoma of the prostate, patient will be using therapy for muscle building purposes
Required Medical Information	Documented diagnosis of primary hypogonadism or hypogonadotropic hypogonadism as defined by either one of the following: (1) Member has undergone bilateral orchiectomy (no total fasting serum testosterone levels required), or (2) Having two consecutive low total fasting serum testosterone levels (below the testing laboratory's reference range or below 300ng/dl if reference ranges are not available), or for persons with low normal total testosterone levels (above 300 ng/dL but below 400 ng/dL), two consecutive low free or bioavailable fasting serum testosterone levels (below the testing laboratory's reference range or less than 225 picomoles per liter (pmol/L) (6 ng/dL) if reference ranges are not available)(Note: Two morning samples drawn between 7:00 a.m. and 10:00 a.m. obtained on two different days is required for NEW starts only), or (3) Member has a documented diagnosis of gender dysphoria or documentation of undergoing gender reassignment surgery.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	10 grams Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 29, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2015 Aetna Value Plan
(Updated 12/01/2015)

AndroGel Pump

Products Affected

- ANDROGEL PUMP TRANSDERMAL 12.5 MG/ACT (1%)

PA Criteria	Criteria Details
Covered Uses	Primary hypogonadism or hypogonadotropic hypogonadism, gender dysphoria, gender reassignment
Exclusion Criteria	patient with carcinoma of the breast or suspected carcinoma of the prostate, patient will be using therapy for muscle building purposes
Required Medical Information	Documented diagnosis of primary hypogonadism or hypogonadotropic hypogonadism as defined by either one of the following: (1) Member has undergone bilateral orchiectomy (no total fasting serum testosterone levels required), or (2) Having two consecutive low total fasting serum testosterone levels (below the testing laboratory's reference range or below 300ng/dl if reference ranges are not available), or for persons with low normal total testosterone levels (above 300 ng/dL but below 400 ng/dL), two consecutive low free or bioavailable fasting serum testosterone levels (below the testing laboratory's reference range or less than 225 picomoles per liter (pmol/L) (6 ng/dL) if reference ranges are not available)(Note: Two morning samples drawn between 7:00 a.m. and 10:00 a.m. obtained on two different days is required for NEW starts only), or (3) Member has a documented diagnosis of gender dysphoria or documentation of undergoing gender reassignment surgery.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	10 grams Per 1 fill
Notes/References	
Revision Date	Prior Authorization: September 29, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

AndroGel Pump

Products Affected

- ANDROGEL PUMP TRANSDERMAL 20.25 MG/ACT (1.62%)

PA Criteria	Criteria Details
Covered Uses	Primary hypogonadism or hypogonadotropic hypogonadism, gender dysphoria, gender reassignment
Exclusion Criteria	patient with carcinoma of the breast or suspected carcinoma of the prostate, patient will be using therapy for muscle building purposes
Required Medical Information	Documented diagnosis of primary hypogonadism or hypogonadotropic hypogonadism as defined by either one of the following: (1) Member has undergone bilateral orchiectomy (no total fasting serum testosterone levels required), or (2) Having two consecutive low total fasting serum testosterone levels (below the testing laboratory's reference range or below 300ng/dl if reference ranges are not available), or for persons with low normal total testosterone levels (above 300 ng/dL but below 400 ng/dL), two consecutive low free or bioavailable fasting serum testosterone levels (below the testing laboratory's reference range or less than 225 picomoles per liter (pmol/L) (6 ng/dL) if reference ranges are not available)(Note: Two morning samples drawn between 7:00 a.m. and 10:00 a.m. obtained on two different days is required for NEW starts only), or (3) Member has a documented diagnosis of gender dysphoria or documentation of undergoing gender reassignment surgery.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	5 grams Per 1 fill
Notes/References	
Revision Date	Prior Authorization: September 29, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2015 Aetna Value Plan
(Updated 12/01/2015)

Angeliq

Products Affected

- ANGELIQ

QL Criteria	1 tab Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Anoro Ellipta

Products Affected

- ANORO ELLIPTA

QL Criteria	1 kit Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Antara

Products Affected

- ANTARA ORAL CAPSULE 90 MG, 30 MG

QL Criteria	1 cap Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Anzemet

Products Affected

- ANZEMET ORAL

QL Criteria	10 tabs Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

APAP-Caff-Dihydrocodeine

Products Affected

- *apap-caff-dihydrocodeine oral capsule*

QL Criteria	10 capsules Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Apri

Products Affected

- APRI

QL Criteria	1.5 tabs Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Apriso

Products Affected

- APRISO

ST Criteria	Documented step through ONE of the following: ASACOL, ASACOL HD, DELZICOL, LIALDA OR PENTASA
QL Criteria	4 caps Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Aptensio XR

Products Affected

- APTENSIO XR

PA Criteria	Criteria Details
Covered Uses	Attention deficit disorder, Attention deficit hyperactivity disorder
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis of adult ADD or ADHD OR documentation of a diagnosis of childhood ADHD onset with history of previous treatment, and documentation of symptoms significantly impacting, impairing, or compromising the patient's ability to function normally (i.e., attend/maintain academic enrollment or employment), and documentation of intolerance to appropriately dosed and administered regular/immediate acting stimulants.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Step Therapy
ST Criteria	Documented step through 14 days each of THREE of AMPHETAMINE/DEXTROAMPHETAMINE/ SR, DEXMETHYLPHENIDATE/ SR, DEXTROAMPHETAMINE, METHAMPHETAMINE, METHYLPHENIDATE/ ER/ SR, STRATTERA, OR VYVANSE
QL Criteria	1 capsule Per 1 Day
Notes/References	
Revision Date	Prior Authorization: October 05, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Aptiom

Products Affected

- APTIOM ORAL TABLET 600 MG

PA Criteria	Criteria Details
Covered Uses	Partial-onset seizure
Exclusion Criteria	
Required Medical Information	A documented diagnosis of partial-onset seizures AND documented concurrent therapy with one of the following: carbamazepine, divalproex dr/er/sprinkle, gabapentin, lamotrigine, levetiracetam/ER, oxcarbazepine, phenytoin, topiramate, valproic acid, or zonisamide
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	2 tablets Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 15, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Aptiom

Products Affected

- APTIOM ORAL TABLET 800 MG

PA Criteria	Criteria Details
Covered Uses	Partial-onset seizure
Exclusion Criteria	
Required Medical Information	A documented diagnosis of partial-onset seizures AND documented concurrent therapy with one of the following: carbamazepine, divalproex dr/er/sprinkle, gabapentin, lamotrigine, levetiracetam/ER, oxcarbazepine, phenytoin, topiramate, valproic acid, or zonisamide
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	1 tablet Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 15, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Aptiom

Products Affected

- APTIOM ORAL TABLET 200 MG

PA Criteria	Criteria Details
Covered Uses	Partial-onset seizure
Exclusion Criteria	
Required Medical Information	A documented diagnosis of partial-onset seizures AND documented concurrent therapy with one of the following: carbamazepine, divalproex dr/er/sprinkle, gabapentin, lamotrigine, levetiracetam/ER, oxcarbazepine, phenytoin, topiramate, valproic acid, or zonisamide
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	6 tablets Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 15, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Aptiom

Products Affected

- APTIOM ORAL TABLET 400 MG

PA Criteria	Criteria Details
Covered Uses	Partial-onset seizure
Exclusion Criteria	
Required Medical Information	A documented diagnosis of partial-onset seizures AND documented concurrent therapy with one of the following: carbamazepine, divalproex dr/er/sprinkle, gabapentin, lamotrigine, levetiracetam/ER, oxcarbazepine, phenytoin, topiramate, valproic acid, or zonisamide
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	3 tablets Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 15, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Aptivus

Products Affected

- APTIVUS ORAL CAPSULE

QL Criteria	4 EA Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Aranelle

Products Affected

- ARANELLE

QL Criteria	1.5 tabs Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Arava

Products Affected

- ARAVA

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Pending
Other Criteria	
QL Criteria	1 tab Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 09, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Arcapta Neohaler

Products Affected

- ARCAPTA NEOHALER

PA Criteria	Criteria Details
Covered Uses	Chronic Obstructive Pulmonary Disorder (COPD)
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Step Therapy
ST Criteria	Trail of one month each of FORADIL AND SEREVENT
QL Criteria	1 cap Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 09, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Aricept

Products Affected

- ARICEPT ORAL TABLET 5 MG, 10 MG

PA Criteria	Criteria Details
Covered Uses	Alzheimer's Disease
Exclusion Criteria	
Required Medical Information	Documented diagnosis of mild, moderate, severe Alzheimer's Disease
Age Restrictions	less than 40 years old
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Notes/ References	
Revision Date	Prior Authorization: September 21, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Aricept

Products Affected

- ARICEPT ORAL TABLET 23 MG

PA Criteria	Criteria Details
Covered Uses	Alzheimer's Disease
Exclusion Criteria	
Required Medical Information	Documented diagnosis of mild, moderate, severe Alzheimer's Disease
Age Restrictions	less than 40 years old
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	1 tab Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 21, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Aricept ODT

Products Affected

- ARICEPT ODT ORAL TABLET
DISPERSIBLE 10 MG

PA Criteria	Criteria Details
Covered Uses	Alzheimer's Disease
Exclusion Criteria	
Required Medical Information	Documented diagnosis of mild, moderate, severe Alzheimer's Disease
Age Restrictions	less than 40 years old
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Notes/ References	
Revision Date	Prior Authorization: September 21, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

ARIPiprazole

Products Affected

- *aripiprazole oral solution*

QL Criteria	30 ml Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

ARIPiprazole

Products Affected

- *aripiprazole oral tablet dispersible*
- *aripiprazole oral tablet*

QL Criteria	1 tablet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Arixtra

Products Affected

- ARIXTRA

PA Criteria	Criteria Details
Covered Uses	<p>For coverage of additional quantities over 21 day supply:</p> <ol style="list-style-type: none"> 1. Perioperative management of oral anticoagulation when an invasive procedure is required based on risk 2. Prevention of VTE in patients undergoing cancer surgery and greater than 60 years of age OR who have previously experienced a VTE 3. Orthopaedic procedures, i.e. Elective hip arthroplasty or fracture repair, elective knee arthroplasty, knee arthroscopy in a high risk patient, elective spine surgery in a high risk patient 4. Treatment of VTE, PE, Superficial thrombophlebitis 5. Pregnancy 6. Neonates with VTE or children greater than 2 months of age experiencing idiopathic or secondary thromboembolism 7. Acute ST-elevated MI 8. Cancer 9. Long Distance Travel 10. Heparin Induced Thrombocytopenia (HIT) (Arixtra only)
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Pending
Other Criteria	Note: Member may receive a total of up to 21 days of initial therapy without a prior authorization for LMWH and fondaparinux
QL Criteria	1 syringe Per 1 Day
Notes/References	
Revision Date	<p>Prior Authorization: August 11, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015</p>

2015 Aetna Value Plan
(Updated 12/01/2015)

Arnuity Ellipta

Products Affected

- ARNUITY ELLIPTA

PA Criteria	Criteria Details
Covered Uses	Asthma
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 YEAR
Other Criteria	Step Therapy
ST Criteria	Documentation of a trial and failure of Asmanex and QVAR
QL Criteria	1 blister Per 1 Day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Asacol HD

Products Affected

- ASACOL HD

QL Criteria	6 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Astagraf XL

Products Affected

- ASTAGRAF XL ORAL CAPSULE
EXTENDED RELEASE 24 HOUR 1 MG

QL Criteria	4 caps Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Astagraf XL

Products Affected

- ASTAGRAF XL ORAL CAPSULE
EXTENDED RELEASE 24 HOUR 0.5 MG

QL Criteria	1 cap Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Atacand

Products Affected

- ATACAND

QL Criteria	1 tab Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Atacand HCT

Products Affected

- ATACAND HCT

QL Criteria	1 tab Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Atelvia

Products Affected

- ATELVIA

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	Documentation of a trial and failure of alendronate weekly (70mg weekly dose)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	
QL Criteria	4 tabs Per 1 month
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Atorvastatin Calcium

Products Affected

- *atorvastatin calcium oral*

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Atovaquone-Proguanil HCl

Products Affected

- *atovaquone-proguanil hcl*

QL Criteria	12 tabs Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Atralin

Products Affected

- ATRALIN

ST Criteria	Documented step through RETIN-A*
QL Criteria	50 grams Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Atrovent

Products Affected

- ATROVENT

QL Criteria	1 bottle Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Atrovent HFA

Products Affected

- ATROVENT HFA

QL Criteria	2 inhalers Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Aubagio

Products Affected

- AUBAGIO

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Augmentin XR

Products Affected

- AUGMENTIN XR

QL Criteria	40 tabs Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Auvi-Q

Products Affected

- AUVI-Q INJECTION 0.3 MG/0.3ML

QL Criteria	2 doses Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Auvi-Q

Products Affected

- AUVI-Q INJECTION 0.15 MG/0.15ML

QL Criteria	1 pack Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Avalide

Products Affected

- AVALIDE

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Avandamet

Products Affected

- AVANDAMET ORAL TABLET 2-500 MG, 2-1000 MG, 4-500 MG

PA Criteria	Criteria Details
Covered Uses	Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	A documented diagnosis of type 2 diabetes mellitus in an adult patient who is unable to achieve adequate glycemic control (HbA1C lab value greater than 6.5%) despite the use of other medications, and who, after consultation with their healthcare provider, has decided not to take Actos (pioglitazone) for medical reasons.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	2 tabs Per 1 day
Notes/References	
Revision Date	Prior Authorization: November 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Avandaryl

Products Affected

- AVANDARYL ORAL TABLET 4-4 MG, 8-4 MG, 4-1 MG, 4-2 MG

PA Criteria	Criteria Details
Covered Uses	Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	A documented diagnosis of type 2 diabetes mellitus in an adult patient who is unable to achieve adequate glycemic control (HbA1C lab value greater than 6.5%) despite the use of other medications, and who, after consultation with their healthcare provider, has decided not to take Actos (pioglitazone) for medical reasons.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	1 tab Per 1 day
Notes/References	
Revision Date	Prior Authorization: November 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Avandia

Products Affected

- AVANDIA

PA Criteria	Criteria Details
Covered Uses	Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	A documented diagnosis of type 2 diabetes mellitus in an adult patient who is unable to achieve adequate glycemic control (HbA1C lab value greater than 6.5%) despite the use of other medications, and who, after consultation with their healthcare provider, has decided not to take Actos (pioglitazone) for medical reasons.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	1 tab Per 1 day
Notes/References	
Revision Date	Prior Authorization: November 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Avapro

Products Affected

- AVAPRO

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Avelox

Products Affected

- AVELOX ORAL

QL Criteria	14 tabs Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Aviane

Products Affected

- AVIANE

QL Criteria	1.5 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

AVINza

Products Affected

- AVINZA

PA Criteria	Criteria Details
Covered Uses	Chronic pain due to malignant condition or severe pain requiring daily, around the clock, long term opioid treatment
Exclusion Criteria	
Required Medical Information	Documentation of progression through the World Health Organization analgesic ladder
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Step Therapy
ST Criteria	Documented step through one month of MORPHINE SR TAB 12HR (MS CONTIN) AND OXYMORPHONE ER (OPANA ER)
QL Criteria	2 caps Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 29, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Avita

Products Affected

- AVITA

ST Criteria	Documented step through RETIN-A*
QL Criteria	50 grams Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Avodart

Products Affected

- AVODART

ST Criteria	Documented step through PROSCAR*
QL Criteria	1 cap Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Avonex

Products Affected

- AVONEX

QL Criteria	1 kit Per 30 Dayss
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Axert

Products Affected

- AXERT

ST Criteria	Documented step through one month of THREE of the following: NARATRIPTAN, RIZATRIPTAN, SUMATRIPTAN, ZOLMITRIPTAN (NSO)
QL Criteria	6 tabs Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Axiron

Products Affected

- AXIRON

PA Criteria	Criteria Details
Covered Uses	Primary hypogonadism or hypogonadotropic hypogonadism, gender dysphoria, gender reassignment
Exclusion Criteria	patient with carcinoma of the breast or suspected carcinoma of the prostate, patient will be using therapy for muscle building purposes
Required Medical Information	Documented diagnosis of primary hypogonadism or hypogonadotropic hypogonadism as defined by either one of the following: (1) Member has undergone bilateral orchiectomy (no total fasting serum testosterone levels required), or (2) Having two consecutive low total fasting serum testosterone levels (below the testing laboratory's reference range or below 300ng/dl if reference ranges are not available), or for persons with low normal total testosterone levels (above 300 ng/dL but below 400 ng/dL), two consecutive low free or bioavailable fasting serum testosterone levels (below the testing laboratory's reference range or less than 225 picomoles per liter (pmol/L) (6 ng/dL) if reference ranges are not available)(Note: Two morning samples drawn between 7:00 a.m. and 10:00 a.m. obtained on two different days is required for NEW starts only), or (3) Member has a documented diagnosis of gender dysphoria or documentation of undergoing gender reassignment surgery.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	Documented step through one month each of ANDROGEL AND TESTIM
QL Criteria	6 mL Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 29, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Azilect

Products Affected

- AZILECT

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Azor

Products Affected

- AZOR

ST Criteria	Documented step through amlodipine in combination with TWO of the following: ATACAND*, AVAPRO*, COZAAR*, MICARDIS*
QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Azulfidine

Products Affected

- AZULFIDINE

ST Criteria	Documented step through ONE of the following: ASACOL, ASACOL HD, DELZICOL, LIALDA OR PENTASA
QL Criteria	8 tabs Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Azulfidine EN-tabs

Products Affected

- AZULFIDINE EN-TABS

ST Criteria	Documented step through ONE of the following: ASACOL, ASACOL HD, DELZICOL, LIALDA OR PENTASA
QL Criteria	8 tabs Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Azurette

Products Affected

- AZURETTE

QL Criteria	1.5 tabs Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Balsalazide Disodium

Products Affected

- *balsalazide disodium*

QL Criteria	9 caps Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Balziva

Products Affected

- BALZIVA

QL Criteria	1.5 tabs Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Banzel

Products Affected

- BANZEL ORAL TABLET

PA Criteria	Criteria Details
Covered Uses	Seizures associated with Lennox-Gastaut syndrome or refractory(therapy resistant) epilepsy
Exclusion Criteria	
Required Medical Information	A documented diagnosis of seizures associated with Lennox-Gastaut syndrome or refractory(therapy resistant) epilepsy AND Concomitant use of an anticonvulsant drug
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	8 tabs Per 1 day
Notes/References	
Revision Date	Prior Authorization: November 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Baraclude

Products Affected

- BARACLUDGE ORAL TABLET

QL Criteria	1 tab Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Beconase AQ

Products Affected

- BECONASE AQ

ST Criteria	Trial of 2 weeks each of 2 of the following: fluticasone propionate OR flunisolide nasal spray OR Triamcinolone OR Nasacort 24HR OTC (choose 1) AND Nasonex
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Belsomra

Products Affected

- BELSOMRA

ST Criteria	Trial of 1 month of one preferred generic alternative (zolpidem, zolpidem er, eszopiclone, zaleplon)
QL Criteria	1 tablet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Belviq

Products Affected

- BELVIQ

QL Criteria	2 tabs Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Benicar

Products Affected

- BENICAR

ST Criteria	Documented step through TWO of the following: ATACAND*, AVAPRO*, COZAAR*, MICARDIS*
QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Benicar HCT

Products Affected

- BENICAR HCT

ST Criteria	Documented step through TWO of the following: ATACAND HCT*, AVALIDE*, HYZAAR*, MICARDIS HCT*
QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

BenzaClin

Products Affected

- BENZACLIN

QL Criteria	50 grams Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Bepreve

Products Affected

- BEPREVE

QL Criteria	1 bottle Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Betaseron

Products Affected

- BETASERON

QL Criteria	15 vials Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Beyaz

Products Affected

- BEYAZ

QL Criteria	1.5 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Biaxin

Products Affected

- BIAXIN ORAL SUSPENSION
RECONSTITUTED

QL Criteria	150 ml Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Biaxin

Products Affected

- BIAXIN ORAL TABLET

QL Criteria	28 EA Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Biaxin XL

Products Affected

- BIAXIN XL

QL Criteria	28 tabs Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Biaxin XL Pac

Products Affected

- BIAXIN XL PAC

QL Criteria	28 tabs Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Bicalutamide

Products Affected

- *bicalutamide*

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Bimatoprost

Products Affected

- *bimatoprost ophthalmic*

QL Criteria	3 ml Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Boniva

Products Affected

- BONIVA ORAL

QL Criteria	1 tab Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Bosulif

Products Affected

- BOSULIF ORAL TABLET 500 MG

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Bosulif

Products Affected

- BOSULIF ORAL TABLET 100 MG

QL Criteria	4 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Breo Ellipta

Products Affected

- BREO ELLIPTA

PA Criteria	Criteria Details
Covered Uses	Chronic Obstructive Pulmonary Disorder (COPD) Asthma
Exclusion Criteria	
Required Medical Information	Documented diagnosis of COPD or Asthma
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Step Therapy
ST Criteria	COPD: Documented trial of one month of Symbicort AND SPIRIVA Asthma: Documented trial of one month of Symbicort AND Dulera
QL Criteria	2 blisters Per 1 days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Breo Ellipta

Products Affected

- BREO ELLIPTA

PA Criteria	Criteria Details
Covered Uses	Chronic Obstructive Pulmonary Disorder (COPD) Asthma
Exclusion Criteria	
Required Medical Information	Documented diagnosis of COPD or Asthma
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Step Therapy
ST Criteria	COPD: Documented trial of one month of Symbicort AND SPIRIVA Asthma: Documented trial of one month of Symbicort AND Dulera
QL Criteria	2 blisters Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Brevicon (28)

Products Affected

- BREVICON (28)

QL Criteria	1.5 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Briellyn

Products Affected

- *briellyn*

QL Criteria	1.5 tabs Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Brilinta

Products Affected

- BRILINTA

QL Criteria	2 tabs Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Brilinta

Products Affected

- BRILINTA

QL Criteria	2 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Brintellix

Products Affected

- BRINTELLIX

PA Criteria	Criteria Details
Covered Uses	Major depressive disorder
Exclusion Criteria	
Required Medical Information	Diagnosis of major depressive disorder
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	<p>Examples of antidepressant trials from unique therapeutic subclasses Therapeutic Subclass:Examples:</p> <p>Selective Serotonin Reuptake Inhibitors (SSRI) fluoxetine (Prozac), paroxetine (Paxil), citalopram (Celexa), sertraline (Zoloft), escitalopram (Lexapro)</p> <p>Serotonin-Norepinephrine Reuptake Inhibitors (SNRI) venlafaxine (Effexor), Effexor XR, Pristiq, Cymbalta</p> <p>Norepinephrine-Dopamine Reuptake Inhibitors (NDRI) bupropion (Wellbutrin), bupropion sustained release (Wellbutrin SR), bupropion extended release (Wellbutrin XL)</p> <p>Tricyclic Antidepressants (TCA) amitriptyline (Elavil), amoxapine (Ascendin), desipramine (Norpramin), doxepin (Sinequan), imipramine (Tofranil), nortriptyline (Pamelor), protriptyline (Vivactil), trimipramine (Surmontil)</p> <p>Tetracyclic Antidepressants mirtazapine (Remeron)</p> <p>Monoamine Oxidase Inhibitors (MAOI) phenelzine (Nardil), tranylcypromine (Parnate), isocarboxazid (Marplan), Emsam</p> <p>Therapy is required Step</p>
ST Criteria	Documentation of failure or unresponsiveness to THREE different antidepressants from at least two different therapeutic subclasses
QL Criteria	1 tab Per 1 day

Notes/ References	
Revision Date	Prior Authorization: September 09, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Brovana

Products Affected

- BROVANA

PA Criteria	Criteria Details
Covered Uses	Chronic Obstructive Pulmonary Disorder (COPD)
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Step Therapy
ST Criteria	Trail of one month each of FORADIL AND SEREVENT
QL Criteria	60 vials Per 1 fill
Notes/References	
Revision Date	Prior Authorization: September 09, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Budeprion XL

Products Affected

- BUDEPRION XL

QL Criteria	1 tab Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Budesonide

Products Affected

- *budesonide inhalation*

PA Criteria	Criteria Details
Covered Uses	Asthma
Exclusion Criteria	
Required Medical Information	For ages 5-8 documented inability to use metered dose inhalers
Age Restrictions	Less than 8 years of age
Prescriber Restrictions	
Coverage Duration	Up to the age of 8
Other Criteria	No prior authorization required for children 1-4 years of age. Medical Exception for Pulmicort Respules: Covered for topical steroid treatment of eosinophilic esophagitis for which other treatments have been unsatisfactory
Notes/References	
Revision Date	Prior Authorization: November 24, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Bunavail

Products Affected

- BUNAVAIL BUCCAL FILM 6.3-1 MG

QL Criteria	2 films Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Bunavail

Products Affected

- BUNAVAIL BUCCAL FILM 2.1-0.3 MG

QL Criteria	6 films Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Bunavail

Products Affected

- BUNAVAIL BUCCAL FILM 4.2-0.7 MG

QL Criteria	3 films Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Buprenorphine HCl

Products Affected

- *buprenorphine hcl sublingual tablet sublingual*
2 mg

PA Criteria	Criteria Details
Covered Uses	Opioid dependence
Exclusion Criteria	Medical literature does not support the concurrent use of opioids/Tramadol as part of opioid drug dependence treatment. Abstinence of opioids/Tramadol is required both during and following therapy with Suboxone/Subutex/Zubsolv/Bunavail/buprenorphine, and will only be covered when determined to be medically necessary (defined as short-term use during and following opioid dependence treatment for the treatment of acute pain related to surgery, dental procedure, or an emergency situation or for long-term use following opioid dependence treatment for the treatment of chronic pain. For long term use, the member must be treated by a single provider of their choice, opioids will only be covered when prescribed by this single provider, and this single provider is aware of past buprenorphine use for opioid dependence treatment in which an opioid dependence diagnosis). Physicians can contact (855) 746-0013 with any information related to the medical necessity for opioid/Tramadol therapy.
Required Medical Information	Prescriber provides verbal verification of patient's current and ongoing enrollment in an outpatient drug addiction treatment program/ counseling. If the member is currently enrolled, the approval will be 6 months. If the member is NOT enrolled (answer=no) and prescriber provides verbal verification of patient's agreed commitment to become enrolled in an acceptable drug addiction treatment program counseling, the approval will be for 2 months (Note: 1 time approval ONLY). If after 2 months member does not enroll in a program, then all future requests will be denied until member enrolls in a program.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months = current enrollment

PA Criteria	Criteria Details
Other Criteria	<p>For coverage of additional quantities, the following conditions must be met: FOR BUPRENORPHONE SL: Member is pregnant or breastfeeding (Up to 120 tablets in 30 days) or member has a documented contraindication, intolerance, or allergy to buprenorphine-naloxone sublingual tablet or Suboxone (will allow up to 90 tablets per month for max length of approval of 6 months). FOR SUBOXONE OR BUPRENORPHINE-NALOXONE SUBLINGUAL TABLET 2mg/0.5mg: Member's dose is being titrated by physician for 7 day induction therapy (max dose 12 mg/daily for total of 42 tablets/films in 7 days). FOR ZUBSOLBV 1.4mg/0.36mg: Member's dose is being titrated by physician for 7 day induction therapy (max dose 8.4 mg/daily for total of 42 tablets/films in 7 days). Note: Aetna considers the following as acceptable programs: Outpatient drug addiction treatment programs and/or counseling, 12- step programs focused on "drug" addiction such as Narcotics Anonymous (N.A.), Other accepted programs can be found at http://findtreatment.samhsa.gov/TreatmentLocator/faces/quickSearch.jspx. Aetna considers the following as non-acceptable programs: On-line programs such as Here to Help, 12-step programs that are not focused on "drug" addiction (ex: Alcoholics Anonymous).</p>
QL Criteria	24 tabs Per 1 month
Notes/References	
Revision Date	Prior Authorization: November 30, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Buprenorphine HCl

Products Affected

- *buprenorphine hcl sublingual tablet sublingual 8 mg*

PA Criteria	Criteria Details
Covered Uses	Opioid dependence
Exclusion Criteria	Medical literature does not support the concurrent use of opioids/Tramadol as part of opioid drug dependence treatment. Abstinence of opioids/Tramadol is required both during and following therapy with Suboxone/Subutex/Zubsolv/Bunavail/buprenorphine, and will only be covered when determined to be medically necessary (defined as short-term use during and following opioid dependence treatment for the treatment of acute pain related to surgery, dental procedure, or an emergency situation or for long-term use following opioid dependence treatment for the treatment of chronic pain. For long term use, the member must be treated by a single provider of their choice, opioids will only be covered when prescribed by this single provider, and this single provider is aware of past buprenorphine use for opioid dependence treatment in which an opioid dependence diagnosis). Physicians can contact (855) 746-0013 with any information related to the medical necessity for opioid/Tramadol therapy.
Required Medical Information	Prescriber provides verbal verification of patient's current and ongoing enrollment in an outpatient drug addiction treatment program/ counseling. If the member is currently enrolled, the approval will be 6 months. If the member is NOT enrolled (answer=no) and prescriber provides verbal verification of patient's agreed commitment to become enrolled in an acceptable drug addiction treatment program counseling, the approval will be for 2 months (Note: 1 time approval ONLY). If after 2 months member does not enroll in a program, then all future requests will be denied until member enrolls in a program.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months = current enrollement

PA Criteria	Criteria Details
Other Criteria	<p>For coverage of additional quantities, the following conditions must be met: FOR BUPRENORPHONE SL: Member is pregnant or breastfeeding (Up to 120 tablets in 30 days) or member has a documented contraindication, intolerance, or allergy to buprenorphine-naloxone sublingual tablet or Suboxone (will allow up to 90 tablets per month for max length of approval of 6 months). FOR SUBOXONE OR BUPRENORPHINE-NALOXONE SUBLINGUAL TABLET 2mg/0.5mg: Member's dose is being titrated by physician for 7 day induction therapy (max dose 12 mg/daily for total of 42 tablets/films in 7 days). FOR ZUBSOLBV 1.4mg/0.36mg: Member's dose is being titrated by physician for 7 day induction therapy (max dose 8.4 mg/daily for total of 42 tablets/films in 7 days). Note: Aetna considers the following as acceptable programs: Outpatient drug addiction treatment programs and/or counseling, 12- step programs focused on "drug" addiction such as Narcotics Anonymous (N.A.), Other accepted programs can be found at http://findtreatment.samhsa.gov/TreatmentLocator/faces/quickSearch.jspx. Aetna considers the following as non-acceptable programs: On-line programs such as Here to Help, 12-step programs that are not focused on "drug" addiction (ex: Alcoholics Anonymous).</p>
QL Criteria	8 tabs Per 1 month
Notes/References	
Revision Date	<p>Prior Authorization: November 30, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015</p>

Buprenorphine HCl-Naloxone HCl

Products Affected

- *buprenorphine hcl-naloxone hcl*

PA Criteria	Criteria Details
Covered Uses	Opioid dependence
Exclusion Criteria	<p>Medical literature does not support the concurrent use of opioids/Tramadol as part of opioid drug dependence treatment. Abstinence of opioids/Tramadol is required both during and following therapy with Suboxone/Subutex/Zubsolv/Bunavail/buprenorphine, and will only be covered when determined to be medically necessary (defined as short-term use during and following opioid dependence treatment for the treatment of acute pain related to surgery, dental procedure, or an emergency situation or for long-term use following opioid dependence treatment for the treatment of chronic pain. For long term use, the member must be treated by a single provider of their choice, opioids will only be covered when prescribed by this single provider, and this single provider is aware of past buprenorphine use for opioid dependence treatment in which an opioid dependence diagnosis). Physicians can contact (855) 746-0013 with any information related to the medical necessity for opioid/Tramadol therapy.</p>
Required Medical Information	<p>Prescriber provides verbal verification of patient's current and ongoing enrollment in an outpatient drug addiction treatment program/ counseling. If the member is currently enrolled, the approval will be 6 months. If the member is NOT enrolled (answer=no) and prescriber provides verbal verification of patient's agreed commitment to become enrolled in an acceptable drug addiction treatment program counseling, the approval will be for 2 months (Note: 1 time approval ONLY). If after 2 months member does not enroll in a program, then all future requests will be denied until member enrolls in a program.</p>
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months = current enrollement

PA Criteria	Criteria Details
Other Criteria	<p>For coverage of additional quantities, the following conditions must be met: FOR BUPRENORPHONE SL: Member is pregnant or breastfeeding (Up to 120 tablets in 30 days) or member has a documented contraindication, intolerance, or allergy to buprenorphine-naloxone sublingual tablet or Suboxone (will allow up to 90 tablets per month for max length of approval of 6 months). FOR SUBOXONE OR BUPRENORPHINE-NALOXONE SUBLINGUAL TABLET 2mg/0.5mg: Member's dose is being titrated by physician for 7 day induction therapy (max dose 12 mg/daily for total of 42 tablets/films in 7 days). FOR ZUBSOLBV 1.4mg/0.36mg: Member's dose is being titrated by physician for 7 day induction therapy (max dose 8.4 mg/daily for total of 42 tablets/films in 7 days). Note: Aetna considers the following as acceptable programs: Outpatient drug addiction treatment programs and/or counseling, 12- step programs focused on "drug" addiction such as Narcotics Anonymous (N.A.), Other accepted programs can be found at http://findtreatment.samhsa.gov/TreatmentLocator/faces/quickSearch.jspx. Aetna considers the following as non-acceptable programs: On-line programs such as Here to Help, 12-step programs that are not focused on "drug" addiction (ex: Alcoholics Anonymous).</p>
QL Criteria	3 tabs Per 1 day
Notes/References	
Revision Date	Prior Authorization: November 30, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Buproban

Products Affected

- BUPROBAN

QL Criteria	2 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

BuPROPion HCl

Products Affected

- *bupropion hcl oral*

QL Criteria	6 tabs Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

BuPROPion HCl ER (Smoking Det)

Products Affected

- *bupropion hcl er (smoking det)*

QL Criteria	2 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

BuPROPion HCl ER (SR)

Products Affected

- *bupropion hcl er (sr)*

QL Criteria	2 tabs Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

BuPROPion HCl ER (XL)

Products Affected

- *bupropion hcl er (xl)*

QL Criteria	1 tab Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Butorphanol Tartrate

Products Affected

- *butorphanol tartrate nasal*

QL Criteria	2 bottles Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Butrans

Products Affected

- BUTRANS

QL Criteria	4 patches Per 28 months
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Bydureon

Products Affected

- BYDUREON

QL Criteria	4 pens Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Bydureon

Products Affected

- BYDUREON

QL Criteria	4 vials Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Byetta 10 MCG Pen

Products Affected

- BYETTA 10 MCG PEN

QL Criteria	1 pen Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Byetta 5 MCG Pen

Products Affected

- BYETTA 5 MCG PEN

QL Criteria	1 pen Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Bystolic

Products Affected

- BYSTOLIC ORAL TABLET 10 MG, 5 MG, 2.5 MG

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Bystolic

Products Affected

- BYSTOLIC ORAL TABLET 20 MG

QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Calcitonin (Salmon)

Products Affected

- *calcitonin (salmon)*

QL Criteria	1 bottle Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Campral

Products Affected

- CAMPRAL

QL Criteria	6 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Camrese

Products Affected

- CAMRESE

QL Criteria	1.5 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Camrese Lo

Products Affected

- CAMRESE LO

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Canasa

Products Affected

- CANASA

QL Criteria	1 unit Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Candesartan Cilexetil

Products Affected

- *candesartan cilexetil*

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Candesartan Cilexetil-HCTZ

Products Affected

- *candesartan cilexetil-hctz*

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Caprelsa

Products Affected

- CAPRELSA ORAL TABLET 300 MG

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Caprelsa

Products Affected

- CAPRELSA ORAL TABLET 100 MG

QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Cardizem CD

Products Affected

- CARDIZEM CD ORAL CAPSULE
EXTENDED RELEASE 24 HOUR 180 MG,
360 MG, 120 MG, 300 MG

QL Criteria	1 cap Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Cardizem CD

Products Affected

- CARDIZEM CD ORAL CAPSULE
EXTENDED RELEASE 24 HOUR 240 MG

QL Criteria	2 caps Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Cardizem LA

Products Affected

- CARDIZEM LA ORAL TABLET
EXTENDED RELEASE 24 HR* 360 MG, 120
MG, 180 MG, 420 MG, 300 MG

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Cardizem LA

Products Affected

- CARDIZEM LA ORAL TABLET
EXTENDED RELEASE 24 HR* 240 MG

QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Cardura XL

Products Affected

- CARDURA XL

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Cartia XT

Products Affected

- CARTIA XT ORAL CAPSULE EXTENDED
RELEASE 24 HOUR 240 MG

QL Criteria	2 caps Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Cartia XT

Products Affected

- CARTIA XT ORAL CAPSULE EXTENDED
RELEASE 24 HOUR 180 MG, 120 MG, 300
MG

QL Criteria	1 cap Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Casodex

Products Affected

- CASODEX

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Catapres-TTS-1

Products Affected

- CATAPRES-TTS-1

QL Criteria	1 box Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Catapres-TTS-2

Products Affected

- CATAPRES-TTS-2

QL Criteria	1 box Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Catapres-TTS-3

Products Affected

- CATAPRES-TTS-3

QL Criteria	1 box Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Caverject

Products Affected

- CAVERJECT

QL Criteria	6 units Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Caverject Impulse

Products Affected

- CAVERJECT IMPULSE

QL Criteria	6 syringes Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Cayston

Products Affected

- CAYSTON

QL Criteria	3 vials Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Caziant

Products Affected

- CAZIAN T

QL Criteria	1.5 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Cefaclor ER

Products Affected

- *cefaclor er*

QL Criteria	14 tabs Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Cefixime

Products Affected

- *cefixime*

QL Criteria	1 bottle Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

CeleBREX

Products Affected

- CELEBREX

ST Criteria	Documented trial of 1 month each of TWO NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs)
QL Criteria	2 capsules Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Celecoxib

Products Affected

- *celecoxib oral*

ST Criteria	Documented trial of 1 month each of TWO NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs)
QL Criteria	2 capsules Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

CeleXA

Products Affected

- CELEXA

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Cenestin

Products Affected

- CENESTIN ORAL TABLET 0.9 MG, 0.625 MG, 0.45 MG

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Cerdelga

Products Affected

- CERDELGA

QL Criteria	2 caps Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Cesamet

Products Affected

- CESAMET

QL Criteria	2 caps Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Chantix

Products Affected

- CHANTIX

QL Criteria	2 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Chantix Continuing Month Pak

Products Affected

- CHANTIX CONTINUING MONTH PAK

QL Criteria	2 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Chantix Starting Month Pak

Products Affected

- CHANTIX STARTING MONTH PAK

QL Criteria	2 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Chateal

Products Affected

- CHATEAL

QL Criteria	1.5 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Cialis

Products Affected

- CIALIS ORAL TABLET 2.5 MG

QL Criteria	6 tablets Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Cialis

Products Affected

- CIALIS ORAL TABLET 10 MG, 20 MG

QL Criteria	6 tabs Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Cialis

Products Affected

- CIALIS ORAL TABLET 5 MG

PA Criteria	Criteria Details
Covered Uses	diagnosis of benign prostatic hyperplasia
Exclusion Criteria	
Required Medical Information	A documented diagnosis of diagnosis of benign prostatic hyperplasia
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Member has failed two alpha blockers (e.g. Cardura (doxazosin), Hytrin (terazosin), Flomax (tamsulosin), Uroxatral (alfuzosin), Rapaflo (silodosin) and failed one 5-alpha reductase inhibitor (e.g. Avodart (dutasteride), Proscar (finasteride), Jalyn (dutasteride/tamsulosin).
ST Criteria	Documented trial and failure of 2 alpha blockers AND 1 5-alpha reductase inhibitor
QL Criteria	6 tabs Per 1 month
Notes/References	
Revision Date	Prior Authorization: October 05, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Cimzia

Products Affected

- CIMZIA

QL Criteria	1 kit Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Cimzia Prefilled

Products Affected

- CIMZIA PREFILLED

QL Criteria	1 kit Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Cimzia Starter Kit

Products Affected

- CIMZIA STARTER KIT

QL Criteria	1 kit Per 1 year
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Cipro XR

Products Affected

- CIPRO XR ORAL TABLET EXTENDED
RELEASE 24 HR* 500 MG

QL Criteria	3 tabs Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Cipro XR

Products Affected

- CIPRO XR ORAL TABLET EXTENDED
RELEASE 24 HR* 1000 MG

QL Criteria	14 tabs Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Citalopram Hydrobromide

Products Affected

- *citalopram hydrobromide oral tablet*

QL Criteria	1 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Citalopram Hydrobromide

Products Affected

- *citalopram hydrobromide oral tablet*

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Claravis

Products Affected

- CLARAVIS

PA Criteria	Criteria Details
Covered Uses	severe recalcitrant nodular or cystic acne
Exclusion Criteria	
Required Medical Information	Member already has evidence of scarring and member is enrolled in the FDA iPLEDGE program (females of childbearing potential ONLY)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	5 months
Other Criteria	For coverage of additional quantities (greater than 2 capsules per day) member must meet the following criteria: Patient requires more than 2 capsules per day to reach the appropriate dose for weight, and this is the members FIRST course of therapy or member now requires a second course of therapy and it has been at least 8 weeks after the first course was initiated (2 month holiday), and member has recieved a cumulative dose of less than 120 mg/kg during a course of therapy lasting 20 weeks or less.
ST Criteria	Documented step through ONE GENERIC ORAL ANTIBIOTIC prescribed for treatment of acne (i.e., MINOCYCLINE OR DOXYCYCLINE)
QL Criteria	2 capsules Per 1 Day
Notes/References	
Revision Date	Prior Authorization: October 05, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Clarinet

Products Affected

- CLARINEX ORAL TABLET

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Clarinet-D 12 Hour

Products Affected

- CLARINEX-D 12 HOUR

QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Clarithromycin

Products Affected

- *clarithromycin oral suspension reconstituted*
250 mg/5ml

QL Criteria	150 ML Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Clarithromycin ER

Products Affected

- *clarithromycin er*

QL Criteria	28 tabs Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Climara

Products Affected

- CLIMARA

QL Criteria	1 box Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Climara Pro

Products Affected

- CLIMARA PRO

QL Criteria	1 box Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Clindamycin Phos-Benzoyl Perox

Products Affected

- *clindamycin phos-benzoyl perox external 1-5 %*

QL Criteria	50 grams Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

CloNIDine HCl

Products Affected

- *clonidine hcl transdermal patch weekly 0.3 mg/24hr, 0.1 mg/24hr*

QL Criteria	1 box Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

CloNIDine HCl ER

Products Affected

- *clonidine hcl er*

PA Criteria	Criteria Details
Covered Uses	Diagnosis of ADHD
Exclusion Criteria	
Required Medical Information	
Age Restrictions	18 and older subject to PA requirement
Prescriber Restrictions	
Coverage Duration	1 Year
Other Criteria	
QL Criteria	4 tabs Per 1 day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Clopidogrel Bisulfate

Products Affected

- *clopidogrel bisulfate*

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Clopidogrel Bisulfate

Products Affected

- *clopidogrel bisulfate*

QL Criteria	1 tab Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

CloZAPine

Products Affected

- *clozapine oral tablet dispersible 100 mg*
- *clozapine oral tablet 100 mg*

QL Criteria	9 tabs Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

CloZAPine

Products Affected

- *clozapine oral tablet dispersible 25 mg*
- *clozapine oral tablet 50 mg, 25 mg*

QL Criteria	3 tabs Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

CloZAPine

Products Affected

- *clozapine oral tablet 200 mg*

QL Criteria	4 tabs Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

CloZAPine

Products Affected

- *clozapine oral tablet dispersible 200 mg*

QL Criteria	4 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

CloZAPine

Products Affected

- *clozapine oral tablet dispersible 150 mg*

QL Criteria	6 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

CloZAPine

Products Affected

- *clozapine oral tablet dispersible 12.5 mg*

QL Criteria	1 tab Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Clozaril

Products Affected

- CLOZARIL ORAL TABLET 25 MG

QL Criteria	3 tabs Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Clozaril

Products Affected

- CLOZARIL ORAL TABLET 100 MG

QL Criteria	9 tabs Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Coartem

Products Affected

- COARTEM

PA Criteria	Criteria Details
Covered Uses	Treatment of malaria
Exclusion Criteria	
Required Medical Information	Diagnosis of malaria
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 days (24 tablets)
Other Criteria	
QL Criteria	24 tabs Per 1 fill
Notes/References	
Revision Date	Prior Authorization: September 09, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Colazal

Products Affected

- COLAZAL

ST Criteria	Documented step through ONE of the following: ASACOL, ASACOL HD, DELZICOL, LIALDA OR PENTASA
QL Criteria	8 caps Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Colchicine

Products Affected

- *colchicine oral tablet*

QL Criteria	2 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Colcrlys

Products Affected

- COLCRYS

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Pending
Other Criteria	<p>For coverage of additional quantities- a member's treating physician must request prior authorization through the Pharmacy Management Precertification Unit. Additional quantities of proton pump inhibitors may be considered medically necessary for those members who meet the following criteria:</p> <ol style="list-style-type: none"> 1) Member has a diagnosis of familial mediterranean fever, OR 2) Member is using drug for gout prevention, has had at least TWO acute gout attacks in one year, presence of tophi, or radiographic joint damage AND urate lowering therapy (i.e. allopurinol or Uloric) has been initiated or prescriber planning to initiate.
QL Criteria	2 tabs Per 1 Day
Notes/References	
Revision Date	<p>Prior Authorization: September 09, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015</p>

Colyte with Flavor Packs

Products Affected

- COLYTE WITH FLAVOR PACKS

QL Criteria	1 bottle Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

CombiPatch

Products Affected

- COMBIPATCH

QL Criteria	8 patch Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Combivent Respimat

Products Affected

- COMBIVENT RESPIMAT

QL Criteria	2 Inhalers Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Cometriq (100 mg Daily Dose)

Products Affected

- COMETRIQ (100 MG DAILY DOSE)

QL Criteria	2 capsules Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Cometriq (140 mg Daily Dose)

Products Affected

- COMETRIQ (140 MG DAILY DOSE)

QL Criteria	4 capsules Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Cometriq (60 mg Daily Dose)

Products Affected

- COMETRIQ (60 MG DAILY DOSE)

QL Criteria	3 capsules Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Complera

Products Affected

- COMPLERA

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Concerta

Products Affected

- CONCERTA ORAL TABLET
EXTENDEDRELEASE* 36 MG

PA Criteria	Criteria Details
Covered Uses	Attention deficit disorder, Attention deficit hyperactivity disorder
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis of adult ADD or ADHD OR documentation of a diagnosis of childhood ADHD onset with history of previous treatment, and documentation of symptoms significantly impacting, impairing, or compromising the patient's ability to function normally (i.e., attend/maintain academic enrollment or employment), and documentation of intolerance to appropriately dosed and administered regular/immediate acting stimulants.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Step Therapy
ST Criteria	Documented step through 14 days each of THREE of AMPHETAMINE/DEXTROAMPHETAMINE/ SR, DEXMETHYLPHENIDATE/ SR, DEXTROAMPHETAMINE, METHAMPHETAMINE, METHYLPHENIDATE/ ER/ SR, STRATTERA, OR VYVANSE
QL Criteria	2 tabs Per 1 day
Notes/References	
Revision Date	Prior Authorization: October 05, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Concerta

Products Affected

- CONCERTA ORAL TABLET
EXTENDEDRELEASE* 18 MG, 54 MG, 27
MG

PA Criteria	Criteria Details
Covered Uses	Attention deficit disorder, Attention deficit hyperactivity disorder
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis of adult ADD or ADHD OR documentation of a diagnosis of childhood ADHD onset with history of previous treatment, and documentation of symptoms significantly impacting, impairing, or compromising the patient's ability to function normally (i.e., attend/maintain academic enrollment or employment), and documentation of intolerance to appropriately dosed and administered regular/immediate acting stimulants.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Step Therapy
ST Criteria	Documented step through 14 days each of THREE of AMPHETAMINE/DEXTROAMPHETAMINE/ SR, DEXMETHYLPHENIDATE/ SR, DEXTROAMPHETAMINE, METHAMPHETAMINE, METHYLPHENIDATE/ ER/ SR, STRATTERA, OR VYVANSE
QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: October 05, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2015 Aetna Value Plan
(Updated 12/01/2015)

Contrace

Products Affected

- CONTRAVE

QL Criteria	4 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Cordran

Products Affected

- CORDRAN EXTERNAL TAPE

QL Criteria	1 roll Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Coreg CR

Products Affected

- COREG CR

QL Criteria	1 cap Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Corlanor

Products Affected

- CORLANOR

PA Criteria	Criteria Details
Covered Uses	FDA labeled use for heart failure (see required medical information section)
Exclusion Criteria	
Required Medical Information	Documentation of stable, symptomatic chronic heart failure with left ventricular ejection fraction \geq 35%, who are in sinus rhythm with resting heart rate \leq 70 beats per minute AND are on maximally tolerated doses of beta-blockers (bisoprolol/bisoprolol-HCTZ, carvedilol, carvedilol CR, metoprolol succinate/metoprolol succinate-HCTZ, nebivolol) OR have a documented contraindication to beta-blocker use.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Step Therapy
ST Criteria	Have a documented trial of one month of one of the following: ACE Inhibitor or ACE Inhibitor/HCTZ combination or Angiotensin-Receptor Blocker or Angiotensin-Receptor Blocker/HCTZ combination
QL Criteria	2 tablets Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 09, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Crestor

Products Affected

- CRESTOR

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Cryselle-28

Products Affected

- CRYSELLE-28

QL Criteria	1.5 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Cyclafem 1/35

Products Affected

- CYCLAFEM 1/35

QL Criteria	1.5 tabs Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Cyclessa

Products Affected

- CYCLESSA

QL Criteria	1.5 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Cycloset

Products Affected

- CYCLOSET

QL Criteria	6 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Cymbalta

Products Affected

- CYMBALTA ORAL CAPSULE DELAYED RELEASE PARTICLES 30 MG

PA Criteria	Criteria Details
Covered Uses	<p>Major depressive disorder (MDD) Diabetic peripheral neuropathic pain (DPN) Generalized anxiety disorder (GAD) Fibromyalgia Chronic musculoskeletal pain due to osteoarthritis Chronic musculoskeletal pain due to chronic low back pain</p>
Exclusion Criteria	
Required Medical Information	<p>For major depressive disorder A. Documentation of failure or unresponsiveness to THREE different antidepressants from at least two different therapeutic subclasses For DPN A. Documentation of failure to gabapentin For GAD A. Documentation of failure or unresponsiveness to THREE different antidepressants from at least two different therapeutic subclasses For fibromyalgia A. Documentation of a trial of non-pharmacologic therapies (cognitive behavioral therapies, exercise, etc.) AND B. Documentation of a trial of THREE of the following drugs/drug classes (each agent must be from a different class) 1. tricyclic antidepressant (e.g. amitriptyline), 2. muscle relaxant (e.g. cyclobenzaprine), 3. SSRI, 4. SNRI, 5. gabapentin, 6. tramadol For osteoarthritis A. Documentation of a trial of acetaminophen AND B. Documentation of a trial of TWO NSAIDs (may include COX-2 inhibitor) For chronic low back pain A. Documentation of a trial of non-pharmacologic therapies (cognitive behavioral therapies, exercise, etc.), AND B. Documentation of a trial of THREE of the following drugs/drug classes (each agent must be from a different class) 1. acetaminophen, 2. NSAID (may include COX-2 inhibitor), 3. muscle relaxant, 4. tricyclic antidepressant, 5. tramadol, 6. gabapentin</p>
Age Restrictions	
Prescriber Restrictions	

2015 Aetna Value Plan
 (Updated 12/01/2015)

PA Criteria	Criteria Details
Coverage Duration	3 years
Other Criteria	<p>For coverage of additional quantities: Member requires a dose including half tablets OR Member's dose is being titrated by physician (3-month limit) OR Member has had intolerance to drug administered as a single daily dose OR Member's dose cannot be achieved with proposed qty limits for a given strength (ex. Mm needs 375mg per day and would require 5 capsules of venlafaxine sr cap or Effexor XR 75mg to achieve dose) OR Member has a diagnosis of Diabetic Peripheral Neuropathy (DPN), Major Depressive Disorder (MDD), or General Anxiety Disorder (GAD) -For Cymbalta or duloxetine (60mg strength: 60 capsules in 30 days are allowed)</p> <p>*Note: Examples of antidepressant trials from unique therapeutic subclasses Therapeutic Subclass:Examples: Selective Serotonin Reuptake Inhibitors (SSRI) fluoxetine (Prozac), paroxetine (Paxil), citalopram (Celexa), sertraline (Zoloft), escitalopram (Lexapro) Serotonin-Norepinephrine Reuptake Inhibitors (SNRI) venlafaxine (Effexor), Effexor XR, Pristiq, Cymbalta Norepinephrine-Dopamine Reuptake Inhibitors (NDRI) bupropion (Wellbutrin), bupropion sustained release (Wellbutrin SR), bupropion extended release (Wellbutrin XL) Tricyclic Antidepressants (TCA) amitriptyline (Elavil), amoxapine (Ascendin), desipramine (Norpramin), doxepin (Sinequan), imipramine (Tofranil), nortriptyline (Pamelor), protriptyline (Vivactil), trimipramine (Surmontil) Tetracyclic Antidepressants mirtazapine (Remeron) Monoamine Oxidase Inhibitors (MAOI) phenelzine (Nardil), tranylcypromine (Parnate), isocarboxazid (Marplan), Emsam</p>
QL Criteria	2 caps Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 09, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Cymbalta

Products Affected

- CYMBALTA ORAL CAPSULE DELAYED
RELEASE PARTICLES 20 MG

PA Criteria	Criteria Details
Covered Uses	<p>Major depressive disorder (MDD) Diabetic peripheral neuropathic pain (DPN) Generalized anxiety disorder (GAD) Fibromyalgia Chronic musculoskeletal pain due to osteoarthritis Chronic musculoskeletal pain due to chronic low back pain</p>
Exclusion Criteria	
Required Medical Information	<p>For major depressive disorder A. Documentation of failure or unresponsiveness to THREE different antidepressants from at least two different therapeutic subclasses For DPN A. Documentation of failure to gabapentin For GAD A. Documentation of failure or unresponsiveness to THREE different antidepressants from at least two different therapeutic subclasses For fibromyalgia A. Documentation of a trial of non-pharmacologic therapies (cognitive behavioral therapies, exercise, etc.) AND B. Documentation of a trial of THREE of the following drugs/drug classes (each agent must be from a different class) 1. tricyclic antidepressant (e.g. amitriptyline), 2. muscle relaxant (e.g. cyclobenzaprine), 3. SSRI, 4. SNRI, 5. gabapentin, 6. tramadol For osteoarthritis A. Documentation of a trial of acetaminophen AND B. Documentation of a trial of TWO NSAIDs (may include COX-2 inhibitor) For chronic low back pain A. Documentation of a trial of non-pharmacologic therapies (cognitive behavioral therapies, exercise, etc.), AND B. Documentation of a trial of THREE of the following drugs/drug classes (each agent must be from a different class) 1. acetaminophen, 2. NSAID (may include COX-2 inhibitor), 3. muscle relaxant, 4. tricyclic antidepressant, 5. tramadol, 6. gabapentin</p>
Age Restrictions	
Prescriber Restrictions	

2015 Aetna Value Plan
(Updated 12/01/2015)

PA Criteria	Criteria Details
Coverage Duration	3 years
Other Criteria	<p>For coverage of additional quantities: Member requires a dose including half tablets OR Member's dose is being titrated by physician (3-month limit) OR Member has had intolerance to drug administered as a single daily dose OR Member's dose cannot be achieved with proposed qty limits for a given strength (ex. Mm needs 375mg per day and would require 5 capsules of venlafaxine sr cap or Effexor XR 75mg to achieve dose) OR Member has a diagnosis of Diabetic Peripheral Neuropathy (DPN), Major Depressive Disorder (MDD), or General Anxiety Disorder (GAD) -For Cymbalta or duloxetine (60mg strength: 60 capsules in 30 days are allowed)</p> <p>*Note: Examples of antidepressant trials from unique therapeutic subclasses Therapeutic Subclass:Examples: Selective Serotonin Reuptake Inhibitors (SSRI) fluoxetine (Prozac), paroxetine (Paxil), citalopram (Celexa), sertraline (Zoloft), escitalopram (Lexapro) Serotonin-Norepinephrine Reuptake Inhibitors (SNRI) venlafaxine (Effexor), Effexor XR, Pristiq, Cymbalta Norepinephrine-Dopamine Reuptake Inhibitors (NDRI) bupropion (Wellbutrin), bupropion sustained release (Wellbutrin SR), bupropion extended release (Wellbutrin XL) Tricyclic Antidepressants (TCA) amitriptyline (Elavil), amoxapine (Ascendin), desipramine (Norpramin), doxepin (Sinequan), imipramine (Tofranil), nortriptyline (Pamelor), protriptyline (Vivactil), trimipramine (Surmontil) Tetracyclic Antidepressants mirtazapine (Remeron) Monoamine Oxidase Inhibitors (MAOI) phenelzine (Nardil), tranylcypromine (Parnate), isocarboxazid (Marplan), Emsam</p>
QL Criteria	2 caps Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 09, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Cymbalta

Products Affected

- CYMBALTA ORAL CAPSULE DELAYED RELEASE PARTICLES 60 MG

PA Criteria	Criteria Details
Covered Uses	Major depressive disorder (MDD) Diabetic peripheral neuropathic pain (DPN) Generalized anxiety disorder (GAD) Fibromyalgia Chronic musculoskeletal pain due to osteoarthritis Chronic musculoskeletal pain due to chronic low back pain
Exclusion Criteria	
Required Medical Information	For major depressive disorder A. Documentation of failure or unresponsiveness to THREE different antidepressants from at least two different therapeutic subclasses For DPN A. Documentation of failure to gabapentin For GAD A. Documentation of failure or unresponsiveness to THREE different antidepressants from at least two different therapeutic subclasses For fibromyalgia A. Documentation of a trial of non-pharmacologic therapies (cognitive behavioral therapies, exercise, etc.) AND B. Documentation of a trial of THREE of the following drugs/drug classes (each agent must be from a different class) 1. tricyclic antidepressant (e.g. amitriptyline), 2. muscle relaxant (e.g. cyclobenzaprine), 3. SSRI, 4. SNRI, 5. gabapentin, 6. tramadol For osteoarthritis A. Documentation of a trial of acetaminophen AND B. Documentation of a trial of TWO NSAIDs (may include COX-2 inhibitor) For chronic low back pain A. Documentation of a trial of non-pharmacologic therapies (cognitive behavioral therapies, exercise, etc.), AND B. Documentation of a trial of THREE of the following drugs/drug classes (each agent must be from a different class) 1. acetaminophen, 2. NSAID (may include COX-2 inhibitor), 3. muscle relaxant, 4. tricyclic antidepressant, 5. tramadol, 6. gabapentin
Age Restrictions	
Prescriber Restrictions	

2015 Aetna Value Plan
 (Updated 12/01/2015)

PA Criteria	Criteria Details
Coverage Duration	3 years
Other Criteria	<p>For coverage of additional quantities: Member requires a dose including half tablets OR Member's dose is being titrated by physician (3-month limit) OR Member has had intolerance to drug administered as a single daily dose OR Member's dose cannot be achieved with proposed qty limits for a given strength (ex. Mm needs 375mg per day and would require 5 capsules of venlafaxine sr cap or Effexor XR 75mg to achieve dose) OR Member has a diagnosis of Diabetic Peripheral Neuropathy (DPN), Major Depressive Disorder (MDD), or General Anxiety Disorder (GAD) -For Cymbalta or duloxetine (60mg strength: 60 capsules in 30 days are allowed)</p> <p>*Note: Examples of antidepressant trials from unique therapeutic subclasses Therapeutic Subclass:Examples: Selective Serotonin Reuptake Inhibitors (SSRI) fluoxetine (Prozac), paroxetine (Paxil), citalopram (Celexa), sertraline (Zoloft), escitalopram (Lexapro) Serotonin-Norepinephrine Reuptake Inhibitors (SNRI) venlafaxine (Effexor), Effexor XR, Pristiq, Cymbalta Norepinephrine-Dopamine Reuptake Inhibitors (NDRI) bupropion (Wellbutrin), bupropion sustained release (Wellbutrin SR), bupropion extended release (Wellbutrin XL) Tricyclic Antidepressants (TCA) amitriptyline (Elavil), amoxapine (Ascendin), desipramine (Norpramin), doxepin (Sinequan), imipramine (Tofranil), nortriptyline (Pamelor), protriptyline (Vivactil), trimipramine (Surmontil) Tetracyclic Antidepressants mirtazapine (Remeron) Monoamine Oxidase Inhibitors (MAOI) phenelzine (Nardil), tranylcypromine (Parnate), isocarboxazid (Marplan), Emsam</p>
QL Criteria	1 caps Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 09, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Cystaran

Products Affected

- CYSTARAN

QL Criteria	4 bottles Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

D.H.E. 45

Products Affected

- D.H.E. 45

QL Criteria	6 ampules Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Daklinza

Products Affected

- DAKLINZA

QL Criteria	1 tablet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Daliresp

Products Affected

- DALIRESP

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Dasetta 1/35

Products Affected

- DASETTA 1/35

QL Criteria	1.5 tab Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Dasetta 7/7/7

Products Affected

- DASETTA 7/7/7

QL Criteria	1.5 tab Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Daysee

Products Affected

- DAYSEE

QL Criteria	1.5 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Daytrana

Products Affected

- DAYTRANA

PA Criteria	Criteria Details
Covered Uses	Attention deficit disorder, Attention deficit hyperactivity disorder
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis of adult ADD or ADHD OR documentation of a diagnosis of childhood ADHD onset with history of previous treatment, and documentation of symptoms significantly impacting, impairing, or compromising the patient's ability to function normally (i.e., attend/maintain academic enrollment or employment), and documentation of intolerance to appropriately dosed and administered regular/immediate acting stimulants.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Step Therapy
ST Criteria	Documented step through 14 days each of THREE of AMPHETAMINE/DEXTROAMPHETAMINE/ SR, DEXMETHYLPHENIDATE/ SR, DEXTROAMPHETAMINE, METHAMPHETAMINE, METHYLPHENIDATE/ ER/ SR, STRATTERA, OR VYVANSE
QL Criteria	1 patch Per 1 day
Notes/ References	
Revision Date	Prior Authorization: October 05, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Delzicol

Products Affected

- DELZICOL

QL Criteria	12 caps Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Depo-Provera

Products Affected

- DEPO-PROVERA INTRAMUSCULAR*
SUSPENSION 150 MG/ML

QL Criteria	1 dose Per 90 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Depo-SubQ Provera 104

Products Affected

- DEPO-SUBQ PROVERA 104

QL Criteria	1 dose Per 90 dayss
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Desogen

Products Affected

- DESOGEN

QL Criteria	1.5 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Desogestrel-Ethinyl Estradiol

Products Affected

- *desogestrel-ethinyl estradiol oral tablet*
0.15-30 mg-mcg

QL Criteria	1.5 tabs Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Desoxyn

Products Affected

- DESOXYN

ST Criteria	Documented step through 14 days each of THREE of AMPHETAMINE/DEXTROAMPHETAMINE/ SR, DEXMETHYLPHENIDATE/ SR, DEXTROAMPHETAMINE, METHAMPHETAMINE, METHYLPHENIDATE/ ER/ SR, STRATTERA, OR VYVANSE
QL Criteria	4 tabs Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Desvenlafaxine ER

Products Affected

- *desvenlafaxine er*

PA Criteria	Criteria Details
Covered Uses	Major depressive disorder
Exclusion Criteria	
Required Medical Information	Diagnosis of major depressive disorder
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	<p>Examples of antidepressant trials from unique therapeutic subclasses Therapeutic Subclass:Examples:</p> <p>Selective Serotonin Reuptake Inhibitors (SSRI) fluoxetine (Prozac), paroxetine (Paxil), citalopram (Celexa), sertraline (Zoloft), escitalopram (Lexapro)</p> <p>Serotonin-Norepinephrine Reuptake Inhibitors (SNRI) venlafaxine (Effexor), Effexor XR, Pristiq, Cymbalta</p> <p>Norepinephrine-Dopamine Reuptake Inhibitors (NDRI) bupropion (Wellbutrin), bupropion sustained release (Wellbutrin SR), bupropion extended release (Wellbutrin XL)</p> <p>Tricyclic Antidepressants (TCA) amitriptyline (Elavil), amoxapine (Ascendin), desipramine (Norpramin), doxepin (Sinequan), imipramine (Tofranil), nortriptyline (Pamelor), protriptyline (Vivactil), trimipramine (Surmontil)</p> <p>Tetracyclic Antidepressants mirtazapine (Remeron)</p> <p>Monoamine Oxidase Inhibitors (MAOI) phenelzine (Nardil), tranylcypromine (Parnate), isocarboxazid (Marplan), Emsam</p> <p>Therapy is required Step</p>
ST Criteria	Documentation of failure or unresponsiveness to THREE different antidepressants from at least two different therapeutic subclasses
QL Criteria	1 tablet Per 1 day

2015 Aetna Value Plan
 (Updated 12/01/2015)

Notes/ References	
Revision Date	Prior Authorization: September 09, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Desvenlafaxine Fumarate ER

Products Affected

- *desvenlafaxine fumarate er*

PA Criteria	Criteria Details
Covered Uses	Major depressive disorder
Exclusion Criteria	
Required Medical Information	Diagnosis of major depressive disorder
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	<p>Examples of antidepressant trials from unique therapeutic subclasses Therapeutic Subclass:Examples:</p> <p>Selective Serotonin Reuptake Inhibitors (SSRI) fluoxetine (Prozac), paroxetine (Paxil), citalopram (Celexa), sertraline (Zoloft), escitalopram (Lexapro)</p> <p>Serotonin-Norepinephrine Reuptake Inhibitors (SNRI) venlafaxine (Effexor), Effexor XR, Pristiq, Cymbalta</p> <p>Norepinephrine-Dopamine Reuptake Inhibitors (NDRI) bupropion (Wellbutrin), bupropion sustained release (Wellbutrin SR), bupropion extended release (Wellbutrin XL)</p> <p>Tricyclic Antidepressants (TCA) amitriptyline (Elavil), amoxapine (Ascendin), desipramine (Norpramin), doxepin (Sinequan), imipramine (Tofranil), nortriptyline (Pamelor), protriptyline (Vivactil), trimipramine (Surmontil)</p> <p>Tetracyclic Antidepressants mirtazapine (Remeron)</p> <p>Monoamine Oxidase Inhibitors (MAOI) phenelzine (Nardil), tranylcypromine (Parnate), isocarboxazid (Marplan), Emsam</p> <p>Therapy is required Step</p>
ST Criteria	Documentation of failure or unresponsiveness to THREE different antidepressants from at least two different therapeutic subclasses
QL Criteria	1 tablet Per 1 day

2015 Aetna Value Plan
 (Updated 12/01/2015)

Notes/ References	
Revision Date	Prior Authorization: September 09, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Detrol LA

Products Affected

- DETROL LA

ST Criteria	Documented step through DITROPAN* or SANCTURA* AND VESICARE or MYRBETRIQ
QL Criteria	1 cap Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Dexedrine

Products Affected

- DEXEDRINE ORAL CAPSULE EXTENDED RELEASE 24 HOUR

ST Criteria	Documented step through 14 days each of THREE of AMPHETAMINE/DEXTROAMPHETAMINE/ SR, DEXMETHYLPHENIDATE/ SR, DEXTROAMPHETAMINE, METHAMPHETAMINE, METHYLPHENIDATE/ ER/ SR, STRATTERA, OR VYVANSE
QL Criteria	3 caps Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Dexilant

Products Affected

- DEXILANT

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	FOR HIGH DOSE ACIPHEX (UP TO 40mg/day): Documentation of trial/failure of one of the following high dose agents: 80 mg/day of Prilosec OTC/Prilosec or Protonix, 60 mg/day of Prevacid 24H OTC OR 80 mg/day of Nexium.
ST Criteria	Documentation of trial and failure of Nexium AND ONE of the following: Prilosec OTC/ Prilosec*, Prevacid 24H OTC, Zegerid OTC, or Protonix*
QL Criteria	1 cap Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 29, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Dexmethylphenidate HCl

Products Affected

- *dexmethylphenidate hcl*

QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Dexmethylphenidate HCl ER

Products Affected

- *dexmethylphenidate hcl er*

QL Criteria	1 capsule Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Dexmethylphenidate HCl ER

Products Affected

- *dexmethylphenidate hcl er*

QL Criteria	1 tablet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Dextroamphetamine Sulfate

Products Affected

- *dextroamphetamine sulfate oral solution*

QL Criteria	40 ML Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Dextroamphetamine Sulfate

Products Affected

- dextroamphetamine sulfate oral tablet*

PA Criteria	Criteria Details
Covered Uses	Attention deficit disorder, Attention deficit hyperactivity disorder
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis of adult ADD or ADHD OR documentation of a diagnosis of childhood ADHD onset with history of previous treatment, and documentation of symptoms significantly impacting, impairing, or compromising the patient's ability to function normally (i.e., attend/maintain academic enrollment or employment), and documentation of intolerance to appropriately dosed and administered regular/immediate acting stimulants.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Step Therapy
QL Criteria	4 tabs Per 1 Day
Notes/References	
Revision Date	Prior Authorization: October 05, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Dextroamphetamine Sulfate ER

Products Affected

- *dextroamphetamine sulfate er*

QL Criteria	3 caps Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Diastat AcuDial

Products Affected

- DIASTAT ACUDIAL

QL Criteria	1 pack Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Diastat Pediatric

Products Affected

- DIASTAT PEDIATRIC

QL Criteria	1 pack Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Diazepam

Products Affected

- *diazepam*

QL Criteria	1 pack Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Diclegis

Products Affected

- DICLEGIS

QL Criteria	60 tabs Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Diclofenac Sodium

Products Affected

- *diclofenac sodium transdermal solution*

QL Criteria	4 ml Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Differin

Products Affected

- DIFFERIN

ST Criteria	Documented step through RETIN-A*
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Dificid

Products Affected

- DIFICID

QL Criteria	20 tabs Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Dihydroergotamine Mesylate

Products Affected

- *dihydroergotamine mesylate injection*

QL Criteria	6 ampules Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Dihydroergotamine Mesylate

Products Affected

- *dihydroergotamine mesylate nasal*

QL Criteria	8 vials Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Diltiazem HCl CD

Products Affected

- *diltiazem hcl cd*

QL Criteria	1 cap Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Diltiazem HCl ER

Products Affected

- diltiazem hcl er oral capsule extended release
24 hour 240 mg*

QL Criteria	2 cap Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Diltiazem HCl ER Beads

Products Affected

- diltiazem hcl er beads oral capsule extended release 24 hour 180 mg, 120 mg, 300 mg, 360 mg*

QL Criteria	1 cap Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Diltiazem HCl ER Beads

Products Affected

- *diltiazem hcl er beads oral capsule extended release 24 hour 240 mg*

QL Criteria	2 caps Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Diltiazem HCl ER Coated Beads

Products Affected

- diltiazem hcl er coated beads oral capsule
extended release 24 hour 360 mg, 300 mg, 120
mg, 180 mg*

QL Criteria	1 cap Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Diltiazem HCl ER Coated Beads

Products Affected

- diltiazem hcl er coated beads oral tablet
extended release 24 hr* 180 mg, 300 mg, 360
mg, 420 mg*

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Diltiazem HCl ER Coated Beads

Products Affected

- *diltiazem hcl er coated beads oral capsule
extended release 24 hour 240 mg*

QL Criteria	2 cap Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Diltiazem HCl ER Coated Beads

Products Affected

- diltiazem hcl er coated beads oral tablet
extended release 24 hr* 240 mg*

QL Criteria	2 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Diovan

Products Affected

- DIOVAN

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Diovan HCT

Products Affected

- DIOVAN HCT

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Dipentum

Products Affected

- DIPENTUM

ST Criteria	Documented step through ONE of the following: ASACOL, ASACOL HD, DELZICOL, LIALDA OR PENTASA
QL Criteria	4 caps Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ditropan XL

Products Affected

- DITROPAN XL ORAL TABLET
EXTENDED RELEASE 24 HR* 10 MG, 15
MG

ST Criteria	Documented step through DITROPAN* or SANCTURA* AND VESICARE or MYRBETRIQ
QL Criteria	2 tabs Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ditropan XL

Products Affected

- DITROPAN XL ORAL TABLET
EXTENDED RELEASE 24 HR* 5 MG

ST Criteria	Documented step through DITROPAN* or SANCTURA* AND VESICARE or MYRBETRIQ
QL Criteria	1 tabs Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Donepezil HCl

Products Affected

- *donepezil hcl oral tablet 10 mg, 5 mg*
- *donepezil hcl oral tablet dispersible*

PA Criteria	Criteria Details
Covered Uses	Alzheimer's Disease
Exclusion Criteria	
Required Medical Information	Documented diagnosis of mild, moderate, severe Alzheimer's Disease
Age Restrictions	less than 40 years old
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 21, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Donepezil HCl

Products Affected

- *donepezil hcl oral tablet 23 mg*

PA Criteria	Criteria Details
Covered Uses	Alzheimer's Disease
Exclusion Criteria	
Required Medical Information	Documented diagnosis of mild, moderate, severe Alzheimer's Disease
Age Restrictions	less than 40 years old
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	1 tab Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 21, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Dovonex

Products Affected

- DOVONEX EXTERNAL CREAM

ST Criteria	Documented step through a MEDIUM TO HIGH POTENCY TOPICAL STEROID
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Doxycycline

Products Affected

- *doxycycline*

QL Criteria	1 capsule Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Dronabinol

Products Affected

- *dronabinol*

QL Criteria	2 caps Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Drospirenone-Ethinyl Estradiol

Products Affected

- *drospirenone-ethinyl estradiol oral tablet*
3-0.03 mg

QL Criteria	1.5 tab Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Duavee

Products Affected

- DUAVEE

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Duetact

Products Affected

- DUETACT

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Dulera

Products Affected

- DULERA

QL Criteria	1 inhaler Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

DULoxetine HCl

Products Affected

- *duloxetine hcl oral capsule delayed release particles 40 mg*

QL Criteria	1 capsule Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

DULoxetine HCl

Products Affected

- *duloxetine hcl oral capsule delayed release particles 20 mg*

PA Criteria	Criteria Details
Covered Uses	<p>Major depressive disorder (MDD) Diabetic peripheral neuropathic pain (DPN) Generalized anxiety disorder (GAD) Fibromyalgia Chronic musculoskeletal pain due to osteoarthritis Chronic musculoskeletal pain due to chronic low back pain</p>
Exclusion Criteria	
Required Medical Information	<p>For major depressive disorder A. Documentation of failure or unresponsiveness to THREE different antidepressants from at least two different therapeutic subclasses For DPN A. Documentation of failure to gabapentin For GAD A. Documentation of failure or unresponsiveness to THREE different antidepressants from at least two different therapeutic subclasses For fibromyalgia A. Documentation of a trial of non-pharmacologic therapies (cognitive behavioral therapies, exercise, etc.) AND B. Documentation of a trial of THREE of the following drugs/drug classes (each agent must be from a different class) 1. tricyclic antidepressant (e.g. amitriptyline), 2. muscle relaxant (e.g. cyclobenzaprine), 3. SSRI, 4. SNRI, 5. gabapentin, 6. tramadol For osteoarthritis A. Documentation of a trial of acetaminophen AND B. Documentation of a trial of TWO NSAIDs (may include COX-2 inhibitor) For chronic low back pain A. Documentation of a trial of non-pharmacologic therapies (cognitive behavioral therapies, exercise, etc.), AND B. Documentation of a trial of THREE of the following drugs/drug classes (each agent must be from a different class) 1. acetaminophen, 2. NSAID (may include COX-2 inhibitor), 3. muscle relaxant, 4. tricyclic antidepressant, 5. tramadol, 6. gabapentin</p>
Age Restrictions	
Prescriber Restrictions	

2015 Aetna Value Plan
 (Updated 12/01/2015)

PA Criteria	Criteria Details
Coverage Duration	1 years
Other Criteria	<p>For coverage of additional quantities: Member requires a dose including half tablets OR Member's dose is being titrated by physician (3-month limit) OR Member has had intolerance to drug administered as a single daily dose OR Member's dose cannot be achieved with proposed qty limits for a given strength (ex. Mm needs 375mg per day and would require 5 capsules of venlafaxine sr cap or Effexor XR 75mg to achieve dose) OR Member has a diagnosis of Diabetic Peripheral Neuropathy (DPN), Major Depressive Disorder (MDD), or General Anxiety Disorder (GAD) -For Cymbalta or duloxetine (60mg strength: 60 capsules in 30 days are allowed)</p> <p>*Note: Examples of antidepressant trials from unique therapeutic subclasses Therapeutic Subclass:Examples: Selective Serotonin Reuptake Inhibitors (SSRI) fluoxetine (Prozac), paroxetine (Paxil), citalopram (Celexa), sertraline (Zoloft), escitalopram (Lexapro) Serotonin-Norepinephrine Reuptake Inhibitors (SNRI) venlafaxine (Effexor), Effexor XR, Pristiq, Cymbalta Norepinephrine-Dopamine Reuptake Inhibitors (NDRI) bupropion (Wellbutrin), bupropion sustained release (Wellbutrin SR), bupropion extended release (Wellbutrin XL) Tricyclic Antidepressants (TCA) amitriptyline (Elavil), amoxapine (Ascendin), desipramine (Norpramin), doxepin (Sinequan), imipramine (Tofranil), nortriptyline (Pamelor), protriptyline (Vivactil), trimipramine (Surmontil) Tetracyclic Antidepressants mirtazapine (Remeron) Monoamine Oxidase Inhibitors (MAOI) phenelzine (Nardil), tranylcypromine (Parnate), isocarboxazid (Marplan), Emsam</p>
QL Criteria	2 tabs Per 1 day
Notes/References	
Revision Date	Prior Authorization: August 11, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

DULoxetine HCl

Products Affected

- *duloxetine hcl oral capsule delayed release particles 60 mg*

PA Criteria	Criteria Details
Covered Uses	<p>Major depressive disorder (MDD) Diabetic peripheral neuropathic pain (DPN) Generalized anxiety disorder (GAD) Fibromyalgia Chronic musculoskeletal pain due to osteoarthritis Chronic musculoskeletal pain due to chronic low back pain</p>
Exclusion Criteria	
Required Medical Information	<p>For major depressive disorder A. Documentation of failure or unresponsiveness to THREE different antidepressants from at least two different therapeutic subclasses For DPN A. Documentation of failure to gabapentin For GAD A. Documentation of failure or unresponsiveness to THREE different antidepressants from at least two different therapeutic subclasses For fibromyalgia A. Documentation of a trial of non-pharmacologic therapies (cognitive behavioral therapies, exercise, etc.) AND B. Documentation of a trial of THREE of the following drugs/drug classes (each agent must be from a different class) 1. tricyclic antidepressant (e.g. amitriptyline), 2. muscle relaxant (e.g. cyclobenzaprine), 3. SSRI, 4. SNRI, 5. gabapentin, 6. tramadol For osteoarthritis A. Documentation of a trial of acetaminophen AND B. Documentation of a trial of TWO NSAIDs (may include COX-2 inhibitor) For chronic low back pain A. Documentation of a trial of non-pharmacologic therapies (cognitive behavioral therapies, exercise, etc.), AND B. Documentation of a trial of THREE of the following drugs/drug classes (each agent must be from a different class) 1. acetaminophen, 2. NSAID (may include COX-2 inhibitor), 3. muscle relaxant, 4. tricyclic antidepressant, 5. tramadol, 6. gabapentin</p>
Age Restrictions	
Prescriber Restrictions	

2015 Aetna Value Plan
 (Updated 12/01/2015)

PA Criteria	Criteria Details
Coverage Duration	1 years
Other Criteria	<p>For coverage of additional quantities: Member requires a dose including half tablets OR Member's dose is being titrated by physician (3-month limit) OR Member has had intolerance to drug administered as a single daily dose OR Member's dose cannot be achieved with proposed qty limits for a given strength (ex. Mm needs 375mg per day and would require 5 capsules of venlafaxine sr cap or Effexor XR 75mg to achieve dose) OR Member has a diagnosis of Diabetic Peripheral Neuropathy (DPN), Major Depressive Disorder (MDD), or General Anxiety Disorder (GAD) -For Cymbalta or duloxetine (60mg strength: 60 capsules in 30 days are allowed)</p> <p>*Note: Examples of antidepressant trials from unique therapeutic subclasses Therapeutic Subclass:Examples: Selective Serotonin Reuptake Inhibitors (SSRI) fluoxetine (Prozac), paroxetine (Paxil), citalopram (Celexa), sertraline (Zoloft), escitalopram (Lexapro) Serotonin-Norepinephrine Reuptake Inhibitors (SNRI) venlafaxine (Effexor), Effexor XR, Pristiq, Cymbalta Norepinephrine-Dopamine Reuptake Inhibitors (NDRI) bupropion (Wellbutrin), bupropion sustained release (Wellbutrin SR), bupropion extended release (Wellbutrin XL) Tricyclic Antidepressants (TCA) amitriptyline (Elavil), amoxapine (Ascendin), desipramine (Norpramin), doxepin (Sinequan), imipramine (Tofranil), nortriptyline (Pamelor), protriptyline (Vivactil), trimipramine (Surmontil) Tetracyclic Antidepressants mirtazapine (Remeron) Monoamine Oxidase Inhibitors (MAOI) phenelzine (Nardil), tranylcypromine (Parnate), isocarboxazid (Marplan), Emsam</p>
QL Criteria	1 tabs Per 1 day
Notes/References	
Revision Date	Prior Authorization: August 11, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

DULoxetine HCl

Products Affected

- *duloxetine hcl oral capsule delayed release particles 30 mg*

PA Criteria	Criteria Details
Covered Uses	<p>Major depressive disorder (MDD) Diabetic peripheral neuropathic pain (DPN) Generalized anxiety disorder (GAD) Fibromyalgia Chronic musculoskeletal pain due to osteoarthritis Chronic musculoskeletal pain due to chronic low back pain</p>
Exclusion Criteria	
Required Medical Information	<p>For major depressive disorder A. Documentation of failure or unresponsiveness to THREE different antidepressants from at least two different therapeutic subclasses For DPN A. Documentation of failure to gabapentin For GAD A. Documentation of failure or unresponsiveness to THREE different antidepressants from at least two different therapeutic subclasses For fibromyalgia A. Documentation of a trial of non-pharmacologic therapies (cognitive behavioral therapies, exercise, etc.) AND B. Documentation of a trial of THREE of the following drugs/drug classes (each agent must be from a different class) 1. tricyclic antidepressant (e.g. amitriptyline), 2. muscle relaxant (e.g. cyclobenzaprine), 3. SSRI, 4. SNRI, 5. gabapentin, 6. tramadol For osteoarthritis A. Documentation of a trial of acetaminophen AND B. Documentation of a trial of TWO NSAIDs (may include COX-2 inhibitor) For chronic low back pain A. Documentation of a trial of non-pharmacologic therapies (cognitive behavioral therapies, exercise, etc.), AND B. Documentation of a trial of THREE of the following drugs/drug classes (each agent must be from a different class) 1. acetaminophen, 2. NSAID (may include COX-2 inhibitor), 3. muscle relaxant, 4. tricyclic antidepressant, 5. tramadol, 6. gabapentin</p>
Age Restrictions	
Prescriber Restrictions	

2015 Aetna Value Plan
 (Updated 12/01/2015)

PA Criteria	Criteria Details
Coverage Duration	1 years
Other Criteria	<p>For coverage of additional quantities: Member requires a dose including half tablets OR Member's dose is being titrated by physician (3-month limit) OR Member has had intolerance to drug administered as a single daily dose OR Member's dose cannot be achieved with proposed qty limits for a given strength (ex. Mm needs 375mg per day and would require 5 capsules of venlafaxine sr cap or Effexor XR 75mg to achieve dose) OR Member has a diagnosis of Diabetic Peripheral Neuropathy (DPN), Major Depressive Disorder (MDD), or General Anxiety Disorder (GAD) -For Cymbalta or duloxetine (60mg strength: 60 capsules in 30 days are allowed)</p> <p>*Note: Examples of antidepressant trials from unique therapeutic subclasses Therapeutic Subclass:Examples: Selective Serotonin Reuptake Inhibitors (SSRI) fluoxetine (Prozac), paroxetine (Paxil), citalopram (Celexa), sertraline (Zoloft), escitalopram (Lexapro) Serotonin-Norepinephrine Reuptake Inhibitors (SNRI) venlafaxine (Effexor), Effexor XR, Pristiq, Cymbalta Norepinephrine-Dopamine Reuptake Inhibitors (NDRI) bupropion (Wellbutrin), bupropion sustained release (Wellbutrin SR), bupropion extended release (Wellbutrin XL) Tricyclic Antidepressants (TCA) amitriptyline (Elavil), amoxapine (Ascendin), desipramine (Norpramin), doxepin (Sinequan), imipramine (Tofranil), nortriptyline (Pamelor), protriptyline (Vivactil), trimipramine (Surmontil) Tetracyclic Antidepressants mirtazapine (Remeron) Monoamine Oxidase Inhibitors (MAOI) phenelzine (Nardil), tranylcypromine (Parnate), isocarboxazid (Marplan), Emsam</p>
QL Criteria	2 tabs Per 1 Day
Notes/References	
Revision Date	Prior Authorization: August 11, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Duragesic-100

Products Affected

- DURAGESIC-100

PA Criteria	Criteria Details
Covered Uses	A. Documented diagnosis of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	20 patches Per 30 days
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Duragesic-12

Products Affected

- DURAGESIC-12

PA Criteria	Criteria Details
Covered Uses	A. Documented diagnosis of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	20 patches Per 30 days
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Duragesic-25

Products Affected

- DURAGESIC-25

PA Criteria	Criteria Details
Covered Uses	A. Documented diagnosis of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	20 patches Per 30 days
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Duragesic-50

Products Affected

- DURAGESIC-50

PA Criteria	Criteria Details
Covered Uses	A. Documented diagnosis of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	20 patches Per 30 days
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Duragesic-75

Products Affected

- DURAGESIC-75

PA Criteria	Criteria Details
Covered Uses	A. Documented diagnosis of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	20 patches Per 30 days
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Dutasteride

Products Affected

- *dutasteride*

QL Criteria	1 capsule Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: November 18, 2015

Edarbi

Products Affected

- EDARBI

ST Criteria	Documented step through TWO of the following: ATACAND*, AVAPRO*, COZAAR*, MICARDIS*
QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Edarbyclor

Products Affected

- EDARBYCLOR

ST Criteria	Documented step through TWO of the following: ATACAND HCT*, AVALIDE*, HYZAAR*, MICARDIS HCT*
QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Edex

Products Affected

- EDEX

QL Criteria	6 syringes Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Edurant

Products Affected

- EDURANT

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Effexor XR

Products Affected

- EFFEXOR XR

QL Criteria	1 cap Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Effient

Products Affected

- EFFIENT

PA Criteria	Criteria Details
Covered Uses	acute coronary syndrome (ACS), which includes angina or myocardial infarction [MI].
Exclusion Criteria	History of Stroke or TIA
Required Medical Information	Member has a documented diagnosis of acute coronary syndrome (ACS), which includes angina or myocardial infarction [MI]) managed by percutaneous coronary intervention (PCI) AND Member has no prior history of stroke or transient ischemic attack (TIA)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	1 tab Per 1 day
Notes/References	
Revision Date	Prior Authorization: October 05, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Elestrin

Products Affected

- ELESTRIN

QL Criteria	1 GM Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Elidel

Products Affected

- ELIDEL

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	Children less than 2 years of age, Children and adults with weakened immune systems, Documentation of hypersensitivity to pimecrolimus, tacrolimus or any component in the product, or Netherton's syndrome
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Authorization beyond 1 year requires documentation that the benefit exceeds the potential risk associated with topical calcineurin inhibitors as defined in the black box warning
QL Criteria	60 grams Per 1 fill
Notes/References	
Revision Date	Prior Authorization: September 29, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Elinest

Products Affected

- ELINEST

QL Criteria	1.5 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Eliquis

Products Affected

- ELIQUIS

QL Criteria	2 tabs Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ella

Products Affected

- ELLA

QL Criteria	2 tablets Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Embeda

Products Affected

- EMBEDA

PA Criteria	Criteria Details
Covered Uses	Chronic pain due to malignant condition or severe pain requiring daily, around the clock, long term opioid treatment
Exclusion Criteria	
Required Medical Information	Documentation of progression through the World Health Organization analgesic ladder
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Step Therapy
ST Criteria	Documented step through one month of MORPHINE SR TAB 12HR (MS CONTIN) AND OXYMORPHONE ER (OPANA ER)
QL Criteria	2 capsules Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 29, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Emend

Products Affected

- EMEND ORAL CAPSULE 80 MG, 125 MG, 40 MG

QL Criteria	3 caps Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Emend

Products Affected

- EMEND ORAL CAPSULE 80 & 125 MG

QL Criteria	3 tri-packs Per 30 fills
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Emoquette

Products Affected

- EMOQUETTE

QL Criteria	1.5 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Emsam

Products Affected

- EMSAM

QL Criteria	1 patch Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Emtriva

Products Affected

- EMTRIVA

QL Criteria	1 cap Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Emtriva

Products Affected

- EMTRIVA

QL Criteria	1 ML Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Enablex

Products Affected

- ENABLEX

ST Criteria	Documented step through DITROPAN* or SANCTURA* AND VESICARE or MYRBETRIQ
QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Enbrel

Products Affected

- ENBREL SUBCUTANEOUS* 25 MG/0.5ML

QL Criteria	8 syringes Per 28 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Enbrel

Products Affected

- ENBREL SUBCUTANEOUS* 50 MG/ML

QL Criteria	4 syringes Per 28 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Enbrel

Products Affected

- ENBREL SUBCUTANEOUS* KIT

QL Criteria	8 syringes Per 28 dayss
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Enbrel SureClick

Products Affected

- ENBREL SURECLICK

QL Criteria	4 syringes Per 28 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Enjuvia

Products Affected

- ENJUVIA

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Enoxaparin Sodium

Products Affected

- *enoxaparin sodium*

QL Criteria	2 syringes Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Enoxaparin Sodium

Products Affected

- *enoxaparin sodium*

PA Criteria	Criteria Details
Covered Uses	<p>For coverage of additional quantities over 21 day supply:</p> <ol style="list-style-type: none"> 1. Perioperative management of oral anticoagulation when an invasive procedure is required based on risk 2. Prevention of VTE in patients undergoing cancer surgery and greater than 60 years of age OR who have previously experienced a VTE 3. Orthopaedic procedures, i.e. Elective hip arthroplasty or fracture repair, elective knee arthroplasty, knee arthroscopy in a high risk patient, elective spine surgery in a high risk patient 4. Treatment of VTE, PE, Superficial thrombophlebitis 5. Pregnancy 6. Neonates with VTE or children greater than 2 months of age experiencing idiopathic or secondary thromboembolism 7. Acute ST-elevated MI 8. Cancer 9. Long Distance Travel 10. Heparin Induced Thrombocytopenia (HIT) (Arixtra only)
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Pending
Other Criteria	Note: Member may receive a total of up to 21 days of initial therapy without a prior authorization for LMWH and fondaparinux
QL Criteria	2 syringes Per 1 day
Notes/References	
Revision Date	<p>Prior Authorization: August 11, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015</p>

2015 Aetna Value Plan
(Updated 12/01/2015)

Enpresse-28

Products Affected

- ENPRESSE-28

QL Criteria	1.5 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Enskyce

Products Affected

- ENSKYCE

QL Criteria	1.5 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Entecavir

Products Affected

- *entecavir*

QL Criteria	1 tablet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Entresto

Products Affected

- ENTRESTO

PA Criteria	Criteria Details
Covered Uses	Heart Failure
Exclusion Criteria	Known or suspected pregnancy
Required Medical Information	A documented diagnosis of chronic heart failure (NYHA Class II-IV) and reduced ejection fraction
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	2 tablets Per 1 Day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Epaned

Products Affected

- EPANED

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	A. Documentation of an inability to swallow
Age Restrictions	13 years or older
Prescriber Restrictions	
Coverage Duration	6 months
Other Criteria	Covered without prior authorization for those 12 years of age or younger
QL Criteria	1 bottle Per 1 fill
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Epiduo

Products Affected

- EPIDUO

ST Criteria	Documented step through RETIN-A*
QL Criteria	1 container Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Epiduo Forte

Products Affected

- EPIDUO FORTE

QL Criteria	1.5 GM Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

EPINEPHrine

Products Affected

- *epinephrine injection 0.15 mg/0.15ml*

QL Criteria	1 pack Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

EPINEPHrine

Products Affected

- *epinephrine injection 0.3 mg/0.3ml*

QL Criteria	2 doses Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

EpiPen 2-Pak

Products Affected

- EPIPEN 2-PAK

QL Criteria	2 doses Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

EpiPen Jr 2-Pak

Products Affected

- EPIPEN JR 2-PAK

QL Criteria	2 doses Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Eprosartan Mesylate

Products Affected

- *eprosartan mesylate*

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Erivedge

Products Affected

- ERIVEDGE

QL Criteria	1 cap Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Errin

Products Affected

- ERRIN

QL Criteria	1.5 tabs Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Esbriet

Products Affected

- ESBRIET

QL Criteria	9 capsules Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Escitalopram Oxalate

Products Affected

- *escitalopram oxalate oral tablet*

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Esomeprazole Magnesium

Products Affected

- *esomeprazole magnesium*

QL Criteria	1 capsule Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Estarylla

Products Affected

- ESTARYLLA

QL Criteria	1.5 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Estradiol

Products Affected

- *estradiol transdermal patch weekly*

QL Criteria	1 box Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Estradiol-Norethindrone Acet

Products Affected

- *estradiol-norethindrone acet*

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Estradiol-Norethindrone Acet

Products Affected

- *estradiol-norethindrone acet*

QL Criteria	1 EA Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Estrogel

Products Affected

- ESTROGEL

QL Criteria	50 grams Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Estrostep Fe

Products Affected

- ESTROSTEP FE

QL Criteria	1.5 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Eszopiclone

Products Affected

- *eszopiclone*

ST Criteria	Documented step through one month of a GENERIC HYPNOTIC, i.e., ZOLPIDEM, TEMAZEPAM, TRIAZOLAM
QL Criteria	1 tab Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Evamist

Products Affected

- EVAMIST

QL Criteria	2 bottles Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Evekeo

Products Affected

- EVEKEO

PA Criteria	Criteria Details
Covered Uses	ADHD, Narcolepsy
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Step Therapy
ST Criteria	Documented step through 14 days each of THREE of AMPHETAMINE/DEXTROAMPHETAMINE/ SR, DEXMETHYLPHENIDATE/ SR, DEXTROAMPHETAMINE, METHAMPHETAMINE, METHYLPHENIDATE/ ER/ SR, STRATTERA, OR VYVANSE
QL Criteria	120 tabs Per 30 Days
Notes/References	
Revision Date	Prior Authorization: November 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Evoxac

Products Affected

- EVOXAC

QL Criteria	3 caps Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Exalgo

Products Affected

- EXALGO

PA Criteria	Criteria Details
Covered Uses	Chronic pain due to malignant condition or severe pain requiring daily, around the clock, long term opioid treatment
Exclusion Criteria	
Required Medical Information	Documentation of progression through the World Health Organization analgesic ladder
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Step Therapy
ST Criteria	Documented step through one month of MORPHINE SR TAB 12HR (MS CONTIN) AND OXYMORPHONE ER (OPANA ER)
QL Criteria	1 tab Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 29, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Exelon

Products Affected

- EXELON TRANSDERMAL

QL Criteria	1 patch Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Exelon

Products Affected

- EXELON ORAL CAPSULE

QL Criteria	2 caps Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Exforge

Products Affected

- EXFORGE ORAL TABLET 5-160 MG,
10-160 MG

ST Criteria	Documented step through TWO of the following: ATACAND*, AVAPRO*, COZAAR*, MICARDIS*
QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Exforge

Products Affected

- EXFORGE ORAL TABLET 10-320 MG,
5-320 MG

ST Criteria	Documented step through TWO of the following: ATACAND*, AVAPRO*, COZAAR*, MICARDIS*
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Exforge HCT

Products Affected

- EXFORGE HCT

ST Criteria	2 of the following: Atacand HCT*, Avalide*, Hyzaar*, Micardis HCT*
QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Extavia

Products Affected

- EXTAVIA

QL Criteria	15 vials Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Fabior

Products Affected

- FABIOR

ST Criteria	Documented step through RETIN-A*
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Factive

Products Affected

- FACTIVE

QL Criteria	7 tabs Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Falmina

Products Affected

- FALMINA

QL Criteria	1.5 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Famciclovir

Products Affected

- *famciclovir oral*

QL Criteria	21 tabs Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Famvir

Products Affected

- FAMVIR

QL Criteria	21 tabs Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Fanapt

Products Affected

- FANAPT

ST Criteria	Trial of 1 month each of: 1 generic (aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone) PLUS Latuda
QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Fanapt Titration Pack

Products Affected

- FANAPT TITRATION PACK

ST Criteria	Trial of 1 month each of: 1 generic (aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone) PLUS Latuda
QL Criteria	8 tabs Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Farxiga

Products Affected

- FARXIGA

ST Criteria	Documented step through one month of INVOKANA (single entity or combo)
QL Criteria	1 tablet Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Farydak

Products Affected

- FARYDAK

QL Criteria	12 capsules Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

FazaClo

Products Affected

- FAZACLO ORAL TABLET DISPERSIBLE
150 MG

QL Criteria	6 tabs Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

FazaClo

Products Affected

- FAZACLO ORAL TABLET DISPERSIBLE
100 MG

QL Criteria	9 tabs Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

FazaClo

Products Affected

- FAZACLO ORAL TABLET DISPERSIBLE
200 MG

QL Criteria	4 tabs Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

FazaClo

Products Affected

- FAZACLO ORAL TABLET DISPERSIBLE
25 MG

QL Criteria	3 tabs Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

FazaClo

Products Affected

- FAZACLO ORAL TABLET DISPERSIBLE
12.5 MG

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Felodipine ER

Products Affected

- *felodipine er*

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Femcon Fe

Products Affected

- FEMCON FE

QL Criteria	1.5 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Femhrt Low Dose

Products Affected

- FEMHRT LOW DOSE

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Femring

Products Affected

- FEMRING

QL Criteria	1 ring Per 90 dayss
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Fenofibrate

Products Affected

- *fenofibrate oral tablet*

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Fenofibrate

Products Affected

- *fenofibrate oral tablet*

QL Criteria	1 tablet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Fenofibrate Micronized

Products Affected

- *fenofibrate micronized*

QL Criteria	1 cap Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Fenofibric Acid

Products Affected

- *fenofibric acid oral capsule delayed release*

QL Criteria	1 cap Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Fenoglide

Products Affected

- FENOGLIDE

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

FentaNYL

Products Affected

- *fentanyl*

QL Criteria	20 patches Per 30 days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

FentaNYL Citrate

Products Affected

- *fentanyl citrate buccal*

QL Criteria	4 lozenge Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Fentora

Products Affected

- FENTORA

PA Criteria	Criteria Details
Covered Uses	For pain due to malignant diagnosis only
Exclusion Criteria	Use in non-malignant pain
Required Medical Information	A. Documentation of already receiving and who are tolerant to opioid therapy, and documentation on intolerance of two (2) other immediate-release opioids including morphine, hydrocodone, oxycodone, or hydromorphone.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months
Other Criteria	FOR SUBSYS: Documentation of intolerance to Actiq. FOR ABSTRAL, FENTORA, LAZANDA, and ONSOLIS: Documentation of intolerance to Actiq AND Subsys.
QL Criteria	4 tabs Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 29, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Fetzima

Products Affected

- FETZIMA

PA Criteria	Criteria Details
Covered Uses	Major depressive disorder
Exclusion Criteria	
Required Medical Information	Diagnosis of major depressive disorder
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	<p>Examples of antidepressant trials from unique therapeutic subclasses Therapeutic Subclass:Examples:</p> <p>Selective Serotonin Reuptake Inhibitors (SSRI) fluoxetine (Prozac), paroxetine (Paxil), citalopram (Celexa), sertraline (Zoloft), escitalopram (Lexapro)</p> <p>Serotonin-Norepinephrine Reuptake Inhibitors (SNRI) venlafaxine (Effexor), Effexor XR, Pristiq, Cymbalta</p> <p>Norepinephrine-Dopamine Reuptake Inhibitors (NDRI) bupropion (Wellbutrin), bupropion sustained release (Wellbutrin SR), bupropion extended release (Wellbutrin XL)</p> <p>Tricyclic Antidepressants (TCA) amitriptyline (Elavil), amoxapine (Ascendin), desipramine (Norpramin), doxepin (Sinequan), imipramine (Tofranil), nortriptyline (Pamelor), protriptyline (Vivactil), trimipramine (Surmontil)</p> <p>Tetracyclic Antidepressants mirtazapine (Remeron)</p> <p>Monoamine Oxidase Inhibitors (MAOI) phenelzine (Nardil), tranylcypromine (Parnate), isocarboxazid (Marplan), Emsam</p> <p>Therapy is required Step</p>
QL Criteria	1 cap Per 1 Day
Notes/References	

Revision Date	Prior Authorization: September 09, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015
----------------------	--

Fetzima Titration

Products Affected

- FETZIMA TITRATION

PA Criteria	Criteria Details
Covered Uses	Major depressive disorder
Exclusion Criteria	
Required Medical Information	Diagnosis of major depressive disorder
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	<p>Examples of antidepressant trials from unique therapeutic subclasses Therapeutic Subclass:Examples:</p> <p>Selective Serotonin Reuptake Inhibitors (SSRI) fluoxetine (Prozac), paroxetine (Paxil), citalopram (Celexa), sertraline (Zoloft), escitalopram (Lexapro)</p> <p>Serotonin-Norepinephrine Reuptake Inhibitors (SNRI) venlafaxine (Effexor), Effexor XR, Pristiq, Cymbalta</p> <p>Norepinephrine-Dopamine Reuptake Inhibitors (NDRI) bupropion (Wellbutrin), bupropion sustained release (Wellbutrin SR), bupropion extended release (Wellbutrin XL)</p> <p>Tricyclic Antidepressants (TCA) amitriptyline (Elavil), amoxapine (Ascendin), desipramine (Norpramin), doxepin (Sinequan), imipramine (Tofranil), nortriptyline (Pamelor), protriptyline (Vivactil), trimipramine (Surmontil)</p> <p>Tetracyclic Antidepressants mirtazapine (Remeron)</p> <p>Monoamine Oxidase Inhibitors (MAOI) phenelzine (Nardil), tranylcypromine (Parnate), isocarboxazid (Marplan), Emsam</p> <p>Therapy is required Step</p>
QL Criteria	1 cap Per 1 Day
Notes/References	

Revision Date	Prior Authorization: September 09, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015
----------------------	--

Fibricor

Products Affected

- FIBRICOR

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Firazyr

Products Affected

- FIRAZYR

QL Criteria	3 syringes Per 30 dayss
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Flovent Diskus

Products Affected

- FLOVENT DISKUS

PA Criteria	Criteria Details
Covered Uses	Asthma
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	Step Therapy. Medical Exception for Flovent Diskus and Flovent HFA: Covered for topical steroid treatment of eosinophilic esophagitis for which other treatments have been unsatisfactory
ST Criteria	Documented step through one month of ASMANEX AND QVAR
QL Criteria	1 inhaler Per 1 month
Notes/References	
Revision Date	Prior Authorization: November 24, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Flovent HFA

Products Affected

- FLOVENT HFA

PA Criteria	Criteria Details
Covered Uses	Asthma
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	Step Therapy. Medical Exception for Flovent Diskus and Flovent HFA: Covered for topical steroid treatment of eosinophilic esophagitis for which other treatments have been unsatisfactory
ST Criteria	Documented step through one month of ASMANEX AND QVAR
QL Criteria	1 inhaler Per 1 month
Notes/References	
Revision Date	Prior Authorization: November 24, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

FLUoxetine HCl

Products Affected

- *fluoxetine hcl oral capsule 40 mg*

QL Criteria	2 caps Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

FLUoxetine HCl

Products Affected

- *fluoxetine hcl oral capsule delayed release*

QL Criteria	4 caps Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

FLUoxetine HCl

Products Affected

- *fluoxetine hcl oral tablet 10 mg*

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

FLUoxetine HCl

Products Affected

- *fluoxetine hcl oral capsule 20 mg*

QL Criteria	4 caps Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

FLUoxetine HCl

Products Affected

- *fluoxetine hcl oral tablet 20 mg*

QL Criteria	4 tabs Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

FLUoxetine HCl

Products Affected

- *fluoxetine hcl oral tablet 60 mg*

QL Criteria	1 tab Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

FLUoxetine HCl

Products Affected

- *fluoxetine hcl oral capsule 10 mg*

QL Criteria	1 cap Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Fluvastatin Sodium

Products Affected

- *fluvastatin sodium*

QL Criteria	2 caps Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Fluvastatin Sodium ER

Products Affected

- *fluvastatin sodium er*

QL Criteria	1 tablet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

FluvoxaMINE Maleate

Products Affected

- *fluvoxamine maleate oral tablet 25 mg, 50 mg*

QL Criteria	1 tab Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

FluvoxaMINE Maleate

Products Affected

- *fluvoxamine maleate oral tablet 100 mg*

QL Criteria	3 tabs Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Fluvoxamine Maleate ER

Products Affected

- *fluvoxamine maleate er*

QL Criteria	2 caps Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Focalin

Products Affected

- FOCALIN

ST Criteria	Documented step through 14 days each of THREE of AMPHETAMINE/DEXTROAMPHETAMINE/ SR, DEXMETHYLPHENIDATE/ SR, DEXTROAMPHETAMINE, METHAMPHETAMINE, METHYLPHENIDATE/ ER/ SR, STRATTERA, OR VYVANSE
QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Focalin XR

Products Affected

- FOCALIN XR

PA Criteria	Criteria Details
Covered Uses	Attention deficit disorder, Attention deficit hyperactivity disorder
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis of adult ADD or ADHD OR documentation of a diagnosis of childhood ADHD onset with history of previous treatment, and documentation of symptoms significantly impacting, impairing, or compromising the patient's ability to function normally (i.e., attend/maintain academic enrollment or employment), and documentation of intolerance to appropriately dosed and administered regular/immediate acting stimulants.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Step Therapy
ST Criteria	Documented step through 14 days each of THREE of AMPHETAMINE/DEXTROAMPHETAMINE/ SR, DEXMETHYLPHENIDATE/ SR, DEXTROAMPHETAMINE, METHAMPHETAMINE, METHYLPHENIDATE/ ER/ SR, STRATTERA, OR VYVANSE
QL Criteria	1 cap Per 1 day
Notes/ References	
Revision Date	Prior Authorization: October 05, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Fondaparinux Sodium

Products Affected

- *fondaparinux sodium*

PA Criteria	Criteria Details
Covered Uses	<p>For coverage of additional quantities over 21 day supply:</p> <ol style="list-style-type: none"> 1. Perioperative management of oral anticoagulation when an invasive procedure is required based on risk 2. Prevention of VTE in patients undergoing cancer surgery and greater than 60 years of age OR who have previously experienced a VTE 3. Orthopaedic procedures, i.e. Elective hip arthroplasty or fracture repair, elective knee arthroplasty, knee arthroscopy in a high risk patient, elective spine surgery in a high risk patient 4. Treatment of VTE, PE, Superficial thrombophlebitis 5. Pregnancy 6. Neonates with VTE or children greater than 2 months of age experiencing idiopathic or secondary thromboembolism 7. Acute ST-elevated MI 8. Cancer 9. Long Distance Travel 10. Heparin Induced Thrombocytopenia (HIT) (Arixtra only)
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Pending
Other Criteria	Note: Member may receive a total of up to 21 days of initial therapy without a prior authorization for LMWH and fondaparinux
QL Criteria	1 syringe Per 1 day
Notes/References	
Revision Date	<p>Prior Authorization: August 11, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015</p>

2015 Aetna Value Plan
(Updated 12/01/2015)

Foradil Aerolizer

Products Affected

- FORADIL AEROLIZER

QL Criteria	2 caps Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Fortesta

Products Affected

- FORTESTA

PA Criteria	Criteria Details
Covered Uses	Primary hypogonadism or hypogonadotropic hypogonadism, gender dysphoria, gender reassignment
Exclusion Criteria	patient with carcinoma of the breast or suspected carcinoma of the prostate, patient will be using therapy for muscle building purposes
Required Medical Information	Documented diagnosis of primary hypogonadism or hypogonadotropic hypogonadism as defined by either one of the following: (1) Member has undergone bilateral orchiectomy (no total fasting serum testosterone levels required), or (2) Having two consecutive low total fasting serum testosterone levels (below the testing laboratory's reference range or below 300ng/dl if reference ranges are not available), or for persons with low normal total testosterone levels (above 300 ng/dL but below 400 ng/dL), two consecutive low free or bioavailable fasting serum testosterone levels (below the testing laboratory's reference range or less than 225 picomoles per liter (pmol/L) (6 ng/dL) if reference ranges are not available)(Note: Two morning samples drawn between 7:00 a.m. and 10:00 a.m. obtained on two different days is required for NEW starts only), or (3) Member has a documented diagnosis of gender dysphoria or documentation of undergoing gender reassignment surgery.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	Documented step through one month each of ANDROGEL AND TESTIM
QL Criteria	4 grams Per 1 month
Notes/References	
Revision Date	Prior Authorization: September 29, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Fortical

Products Affected

- FORTICAL

QL Criteria	1 bottle Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Fosamax

Products Affected

- FOSAMAX

QL Criteria	4 tablets Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Fosamax Plus D

Products Affected

- FOSAMAX PLUS D

ST Criteria	Documented trial and failure of 1 month of generic alendronate weekly (70mg weekly dose)
QL Criteria	4 tabs Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Fragmin

Products Affected

- FRAGMIN

PA Criteria	Criteria Details
Covered Uses	<p>For coverage of additional quantities over 21 day supply:</p> <ol style="list-style-type: none"> 1. Perioperative management of oral anticoagulation when an invasive procedure is required based on risk 2. Prevention of VTE in patients undergoing cancer surgery and greater than 60 years of age OR who have previously experienced a VTE 3. Orthopaedic procedures, i.e. Elective hip arthroplasty or fracture repair, elective knee arthroplasty, knee arthroscopy in a high risk patient, elective spine surgery in a high risk patient 4. Treatment of VTE, PE, Superficial thrombophlebitis 5. Pregnancy 6. Neonates with VTE or children greater than 2 months of age experiencing idiopathic or secondary thromboembolism 7. Acute ST-elevated MI 8. Cancer 9. Long Distance Travel 10. Heparin Induced Thrombocytopenia (HIT) (Arixtra only)
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Pending
Other Criteria	Note: Member may receive a total of up to 21 days of initial therapy without a prior authorization for LMWH and fondaparinux
QL Criteria	1 syringe Per 1 day
Notes/References	
Revision Date	<p>Prior Authorization: August 11, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015</p>

2015 Aetna Value Plan
(Updated 12/01/2015)

Frova

Products Affected

- FROVA

ST Criteria	Documented step through one month of THREE of the following: NARATRIPTAN, RIZATRIPTAN, SUMATRIPTAN, ZOLMITRIPTAN (NSO)
QL Criteria	9 tabs Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Fulyzaq

Products Affected

- FULYZAQ

QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Fycompa

Products Affected

- FYCOMPA

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Gabapentin

Products Affected

- *gabapentin oral capsule*

QL Criteria	6 caps Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Gabapentin

Products Affected

- *gabapentin oral tablet*

QL Criteria	6 tabs Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Gabapentin

Products Affected

- *gabapentin oral solution*

QL Criteria	40 ml Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Gabril

Products Affected

- GABITRIL ORAL TABLET 16 MG

QL Criteria	3 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Gabitril

Products Affected

- GABITRIL ORAL TABLET 2 MG

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Gabitril

Products Affected

- GABITRIL ORAL TABLET 4 MG, 12 MG

QL Criteria	4 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Galantamine Hydrobromide ER

Products Affected

- *galantamine hydrobromide er*

QL Criteria	1 cap Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Gattex

Products Affected

- GATTEX

QL Criteria	1 box Per 30 fillss
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Gelnique

Products Affected

- GELNIQUE

ST Criteria	Documented step through trial of OXYBUTYNIN/ ER, TOLTERODINE/ ER, or TROSPIUM/ ER and MYRBETRIQ and VESICARE
QL Criteria	30 packets Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Generess FE

Products Affected

- GENERESS FE

QL Criteria	1.5 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Geodon

Products Affected

- GEODON ORAL

ST Criteria	Trial of 1 month each of: 1 generic (aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone) PLUS Latuda
QL Criteria	2 caps Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Gianvi

Products Affected

- GIANVI

QL Criteria	1.5 tab Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Giazo

Products Affected

- GIAZO

PA Criteria	Criteria Details
Covered Uses	Ulcerative colitis
Exclusion Criteria	
Required Medical Information	Documented diagnosis of mild to moderate ulcerative colitis in males. Note: Per Product Labeling, Giazo effectiveness was not demonstrated in female patients.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Step Therapy
QL Criteria	6 tabs Per 1 Day
Notes/References	
Revision Date	Prior Authorization: October 05, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Gildagia

Products Affected

- GILDAGIA

QL Criteria	1.5 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Gildess FE 1.5/30

Products Affected

- GILDESS FE 1.5/30

QL Criteria	1.5 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Gildess FE 1/20

Products Affected

- GILDESS FE 1/20

QL Criteria	1.5 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Gilenya

Products Affected

- GILENYA

QL Criteria	1 cap Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Gilotrif

Products Affected

- GILOTRIF

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

GlucaGen HypoKit

Products Affected

- GLUCAGEN HYPOKIT

QL Criteria	1 kit Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Glucagon Emergency

Products Affected

- GLUCAGON EMERGENCY

QL Criteria	1 kit Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Glyxambi

Products Affected

- GLYXAMBI

ST Criteria	Invokana/Invokamet AND Januvia or Onglyza family
QL Criteria	1 tablet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Gralise

Products Affected

- GRALISE ORAL TABLET 600 MG

PA Criteria	Criteria Details
Covered Uses	Post-Herpetic neuralgia
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	Step Therapy
ST Criteria	Documented step through one month of GABAPENTIN
QL Criteria	3 tabs Per 1 day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Gralise

Products Affected

- GRALISE ORAL TABLET 300 MG

PA Criteria	Criteria Details
Covered Uses	Post-Herpetic neuralgia
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	Step Therapy
ST Criteria	Documented step through one month of GABAPENTIN
QL Criteria	1 tab Per 1 day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Gralise Starter

Products Affected

- GRALISE STARTER

PA Criteria	Criteria Details
Covered Uses	Post-Herpetic neuralgia
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	Step Therapy
ST Criteria	Documented step through one month of GABAPENTIN
QL Criteria	1 pack Per 1 fill
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Granix

Products Affected

- GRANIX

PA Criteria	Criteria Details
Covered Uses	Primary prophylactic (first and subsequent-cycle use)
Exclusion Criteria	
Required Medical Information	For primary prophylactic (first and subsequent-cycle use) A. Documentation of previously untreated non-myeloid malignancies and receiving established myelosuppressive chemotherapy that is expected to result in a greater or equal to 20% incidence of febrile neutropenia, OR B. Documentation of at least one increased risk factor for chemotherapy-induced infectious complications because of bone marrow compromise or comorbidity, including one of the following (pre-existing neutropenia due to disease, extensive prior chemotherapy, previous radiotherapy, history of recurrent febrile neutropenia while receiving earlier chemotherapy of similar or less dose-intensity, poor performance status, tumor involvement in the bone marrow, liver/renal dysfunction, open wounds, active infections, recent surgery, or age greater than or equal to 65)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 MONTHS
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 11, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Gynazole-1

Products Affected

- GYNAZOLE-1

QL Criteria	6 grams Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Harvoni

Products Affected

- HARVONI

QL Criteria	1 tab Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Hectorol

Products Affected

- HECTOROL ORAL

ST Criteria	Documented step through ROCALTROL*
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Hepsera

Products Affected

- HEPSERA

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Hetlioz

Products Affected

- HETLIOZ

PA Criteria	Criteria Details
Covered Uses	Non-24 sleep wake-disorder
Exclusion Criteria	Documentation of concimitant sleep disorders (sleep apnea, insomnia)
Required Medical Information	Documentation of non-24 sleep wake-disorder, and documentation of total-blindness with no light perception, and documentation of at least 3 months of difficulty initiating sleep, difficulty awakening in the morning, or excessive daytimes sleepiness.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: October 05, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Horizant

Products Affected

- HORIZANT ORAL TABLET
EXTENDEDRELEASE* 600 MG

QL Criteria	1 tablet Per 2 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Horizant

Products Affected

- HORIZANT ORAL TABLET
EXTENDEDRELEASE* 300 MG

QL Criteria	1 tablet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Humira

Products Affected

- HUMIRA SUBCUTANEOUS* 10 MG/0.2ML

QL Criteria	2 injections Per 28 months
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Humira

Products Affected

- HUMIRA SUBCUTANEOUS* 20
MG/0.4ML, 40 MG/0.8ML

QL Criteria	2 injections Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Humira Pediatric Crohns Start

Products Affected

- HUMIRA PEDIATRIC CROHNS START

QL Criteria	2 injections Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Humira Pen

Products Affected

- HUMIRA PEN

QL Criteria	2 injections Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Humira Pen-Crohns Starter

Products Affected

- HUMIRA PEN-CROHNS STARTER

QL Criteria	1 kit Per 365 months
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Humira Pen-Psoriasis Starter

Products Affected

- HUMIRA PEN-PSORIASIS STARTER

QL Criteria	2 injections Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

HYDRomorphone HCl ER

Products Affected

- *hydromorphone hcl er*

QL Criteria	1 tab Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

HYDRORmorphone HCl ER

Products Affected

- *hydromorphone hcl er*

QL Criteria	1 EA Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Hysingla ER

Products Affected

- HYSINGLA ER

PA Criteria	Criteria Details
Covered Uses	Chronic pain due to malignant condition or severe pain requiring daily, around the clock, long term opioid treatment
Exclusion Criteria	
Required Medical Information	Documentation of progression through the World Health Organization analgesic ladder
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Step Therapy
ST Criteria	Documented step through one month of MORPHINE SR TAB 12HR (MS CONTIN) AND OXYMORPHONE ER (OPANA ER)
QL Criteria	1 tablet Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 29, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ibandronate Sodium

Products Affected

- *ibandronate sodium oral*

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	Step Therapy
QL Criteria	1 tab Per 1 month
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ibrance

Products Affected

- IBRANCE

QL Criteria	21 capsules Per 28 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Iclusig

Products Affected

- ICLUSIG ORAL TABLET 15 MG

QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Iclusig

Products Affected

- ICLUSIG ORAL TABLET 45 MG

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ilaris

Products Affected

- ILARIS

QL Criteria	1 EA Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Imiquimod

Products Affected

- *imiquimod external*

QL Criteria	12 packets Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Imitrex

Products Affected

- IMITREX SUBCUTANEOUS*

QL Criteria	5 vials Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Imitrex

Products Affected

- IMITREX NASAL

QL Criteria	6 sprays Per 30 days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Imitrex

Products Affected

- IMITREX ORAL

QL Criteria	9 tabs Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Imitrex STATdose Refill

Products Affected

- IMITREX STATDOSE REFILL

QL Criteria	4 doses Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Incivek

Products Affected

- INCIVEK

QL Criteria	6 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Incruse Ellipta

Products Affected

- INCRUSE ELLIPTA

QL Criteria	1 blister Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Inlyta

Products Affected

- INLYTA

QL Criteria	4 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

InnoPran XL

Products Affected

- INNOPRAN XL ORAL CAPSULE
EXTENDED RELEASE 24 HOUR 120 MG

QL Criteria	1 cap Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

InnoPran XL

Products Affected

- INNOPRAN XL ORAL CAPSULE
EXTENDED RELEASE 24 HOUR 80 MG

QL Criteria	2 caps Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Inspira

Products Affected

- INSPRA ORAL TABLET 50 MG

QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Inspira

Products Affected

- INSPRA ORAL TABLET 25 MG

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Intelligence

Products Affected

- INTELENCE ORAL TABLET 200 MG

QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Intelligence

Products Affected

- INTELENCE ORAL TABLET 100 MG, 25 MG

QL Criteria	4 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Intermezzo

Products Affected

- INTERMEZZO

QL Criteria	1 tab Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Introvale

Products Affected

- INTROVALE

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Intuniv

Products Affected

- INTUNIV

PA Criteria	Criteria Details
Covered Uses	Attention deficit hyperactivity disorder (ADHD) Note: diagnosis criteria only applies to members greater than 18 years old. Step therapy requirement applies to all member regardless of age.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	18 or older
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	Step Therapy
ST Criteria	Documented step through CLONIDINE, CLONIDINE SR, GUANFACINE, AMPHETAMINE/DEXTROAMPHETAMINE, AMPHETAMINE/DEXTROAMPHETAMINE SR, DEXMETHYLPHENIDATE, DEXMETHYLPHENIDATE SR, DEXTROAMPHETAMINE, METHAMPHETAMINE, METHYLPHENIDATE, METHYLPHENIDATE ER, METHYLPHENIDATE SR, STRATTERA, or VYVANSE
QL Criteria	1 tab Per 1 day
Notes/References	
Revision Date	Prior Authorization: August 11, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Invega

Products Affected

- INVEGA ORAL TABLET EXTENDED
RELEASE 24 HR* 6 MG, 3 MG, 1.5 MG

ST Criteria	Trial of 1 month each of: 1 generic (aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone) PLUS Latuda
QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Invega

Products Affected

- INVEGA ORAL TABLET EXTENDED
RELEASE 24 HR* 9 MG

ST Criteria	Trial of 1 month each of: 1 generic (aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone) PLUS Latuda
QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Invokamet

Products Affected

- INVOKAMET

QL Criteria	2 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Invokana

Products Affected

- INVOKANA

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ipratropium Bromide

Products Affected

- *ipratropium bromide nasal*

QL Criteria	1 bottle Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Iprivask

Products Affected

- IPRIVASK

PA Criteria	Criteria Details
Covered Uses	<p>For coverage of additional quantities over 21 day supply:</p> <ol style="list-style-type: none"> 1. Perioperative management of oral anticoagulation when an invasive procedure is required based on risk 2. Prevention of VTE in patients undergoing cancer surgery and greater than 60 years of age OR who have previously experienced a VTE 3. Orthopaedic procedures, i.e. Elective hip arthroplasty or fracture repair, elective knee arthroplasty, knee arthroscopy in a high risk patient, elective spine surgery in a high risk patient 4. Treatment of VTE, PE, Superficial thrombophlebitis 5. Pregnancy 6. Neonates with VTE or children greater than 2 months of age experiencing idiopathic or secondary thromboembolism 7. Acute ST-elevated MI 8. Cancer 9. Long Distance Travel 10. Heparin Induced Thrombocytopenia (HIT) (Arixtra only)
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Pending
Other Criteria	Note: Member may receive a total of up to 21 days of initial therapy without a prior authorization for LMWH and fondaparinux
Notes/References	
Revision Date	<p>Prior Authorization: August 11, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015</p>

Irbesartan

Products Affected

- *irbesartan*

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Irbesartan-Hydrochlorothiazide

Products Affected

- *irbesartan-hydrochlorothiazide*

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Irenka

Products Affected

- IRENKA

QL Criteria	1 capsule Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Iressa

Products Affected

- IRESSA

QL Criteria	1 tablet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Isentress

Products Affected

- ISENTRESS ORAL TABLET

QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Itraconazole

Products Affected

- *itraconazole oral*

QL Criteria	1 cap Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Jakafi

Products Affected

- JAKAFI

QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Jalyn

Products Affected

- JALYN

ST Criteria	Documented step through PROSCAR*
QL Criteria	1 cap Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Janumet

Products Affected

- JANUMET

QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Janumet XR

Products Affected

- JANUMET XR ORAL TABLET EXTENDED
RELEASE 24 HR* 100-1000 MG, 50-500 MG

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Janumet XR

Products Affected

- JANUMET XR ORAL TABLET EXTENDED
RELEASE 24 HR* 50-1000 MG

QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Januvia

Products Affected

- JANUVIA

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Jardiance

Products Affected

- JARDIANCE

ST Criteria	Documented step through one month of INVOKANA (single entity or combo)
QL Criteria	1 tab Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Jencycla

Products Affected

- JENCYCLA

QL Criteria	1.5 tab Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Jentaduetto

Products Affected

- JENTADUETO

PA Criteria	Criteria Details
Covered Uses	Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	Step Therapy
ST Criteria	1 month each of 2 preferred alternatives: Januvia and Onglyza (single entity or combination)
QL Criteria	2 tabs Per 1 Day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Jolessa

Products Affected

- JOLESSA

QL Criteria	1.5 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Jolivette

Products Affected

- JOLIVETTE

QL Criteria	1.5 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Junel 1.5/30

Products Affected

- JUNEL 1.5/30

QL Criteria	1.5 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Junel 1/20

Products Affected

- JUNEL 1/20

QL Criteria	1.5 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Junel FE 1.5/30

Products Affected

- JUNEL FE 1.5/30

QL Criteria	1.5 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Junel FE 1/20

Products Affected

- JUNEL FE 1/20

QL Criteria	1.5 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Juxtapid

Products Affected

- JUXTAPID ORAL CAPSULE 10 MG, 5 MG

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Juxtapid

Products Affected

- JUXTAPID ORAL CAPSULE 20 MG

QL Criteria	3 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Juxtapid

Products Affected

- JUXTAPID ORAL CAPSULE 30 MG, 40 MG, 60 MG

QL Criteria	1 capsule Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Kadian

Products Affected

- KADIAN ORAL CAPSULE EXTENDED
RELEASE 24 HOUR 20 MG, 200 MG, 80
MG, 100 MG, 30 MG, 50 MG, 60 MG, 10 MG

PA Criteria	Criteria Details
Covered Uses	Chronic pain due to malignant condition or severe pain requiring daily, around the clock, long term opioid treatment
Exclusion Criteria	
Required Medical Information	Documentation of progression through the World Health Organization analgesic ladder
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Step Therapy
ST Criteria	Documented step through one month of MORPHINE SR TAB 12HR (MS CONTIN) AND OXYMORPHONE ER (OPANA ER)
QL Criteria	2 caps Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 29, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Kadian

Products Affected

- KADIAN ORAL CAPSULE EXTENDED
RELEASE 24 HOUR 40 MG

PA Criteria	Criteria Details
Covered Uses	Chronic pain due to malignant condition or severe pain requiring daily, around the clock, long term opioid treatment
Exclusion Criteria	
Required Medical Information	Documentation of progression through the World Health Organization analgesic ladder
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Step Therapy
ST Criteria	Documented step through one month of MORPHINE SR TAB 12HR (MS CONTIN) AND OXYMORPHONE ER (OPANA ER)
QL Criteria	2 caps Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 29, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Kalydeco

Products Affected

- KALYDECO

QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Kalydeco

Products Affected

- KALYDECO

QL Criteria	2 packets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Kapvay

Products Affected

- KAPVAY ORAL TABLET EXTENDED RELEASE 12 HR*

PA Criteria	Criteria Details
Covered Uses	Diagnosis of attention deficit hyperactivity disorder (ADHD)
Exclusion Criteria	
Required Medical Information	
Age Restrictions	18 and older subject to PA requirement
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Step Therapy
ST Criteria	Documented step through CLONIDINE, CLONIDINE SR, GUANFACINE, AMPHETAMINE/DEXTROAMPHETAMINE, AMPHETAMINE/DEXTROAMPHETAMINE SR, DEXMETHYLPHENIDATE, DEXMETHYLPHENIDATE SR, DEXTROAMPHETAMINE, METHAMPHETAMINE, METHYLPHENIDATE, METHYLPHENIDATE ER, METHYLPHENIDATE SR, STRATTERA, OR VYVANSE
QL Criteria	4 tabs Per 1 day
Notes/References	
Revision Date	Prior Authorization: October 05, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Karbinal ER

Products Affected

- KARBINAL ER

ST Criteria	Documented step through OTC CLARITIN, ZYRTEC or ALLEGRA AND CARBINOXAMINE
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Kariva

Products Affected

- KARIVA

QL Criteria	1.5 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Kazano

Products Affected

- KAZANO

PA Criteria	Criteria Details
Covered Uses	Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	Step Therapy
ST Criteria	1 month each of 2 preferred alternatives: Januvia and Onglyza (single entity or combination)
QL Criteria	2 EA Per 1 Day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Kelnor 1/35

Products Affected

- KELNOR 1/35

QL Criteria	1.5 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Keppra XR

Products Affected

- KEPPRA XR ORAL TABLET EXTENDED
RELEASE 24 HR* 500 MG

QL Criteria	6 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Keppra XR

Products Affected

- KEPPRA XR ORAL TABLET EXTENDED
RELEASE 24 HR* 750 MG

QL Criteria	4 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ketek

Products Affected

- KETEK

QL Criteria	20 EA Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ketoconazole

Products Affected

- *ketoconazole oral*

QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ketorolac Tromethamine

Products Affected

- *ketorolac tromethamine oral*

QL Criteria	4 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Keveyis

Products Affected

- KEVEYIS

QL Criteria	4 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Khedeza

Products Affected

- KHEDEZLA

PA Criteria	Criteria Details
Covered Uses	Major depressive disorder
Exclusion Criteria	
Required Medical Information	Diagnosis of major depressive disorder
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	<p>Examples of antidepressant trials from unique therapeutic subclasses Therapeutic Subclass:Examples:</p> <p>Selective Serotonin Reuptake Inhibitors (SSRI) fluoxetine (Prozac), paroxetine (Paxil), citalopram (Celexa), sertraline (Zoloft), escitalopram (Lexapro)</p> <p>Serotonin-Norepinephrine Reuptake Inhibitors (SNRI) venlafaxine (Effexor), Effexor XR, Pristiq, Cymbalta</p> <p>Norepinephrine-Dopamine Reuptake Inhibitors (NDRI) bupropion (Wellbutrin), bupropion sustained release (Wellbutrin SR), bupropion extended release (Wellbutrin XL)</p> <p>Tricyclic Antidepressants (TCA) amitriptyline (Elavil), amoxapine (Ascendin), desipramine (Norpramin), doxepin (Sinequan), imipramine (Tofranil), nortriptyline (Pamelor), protriptyline (Vivactil), trimipramine (Surmontil)</p> <p>Tetracyclic Antidepressants mirtazapine (Remeron)</p> <p>Monoamine Oxidase Inhibitors (MAOI) phenelzine (Nardil), tranylcypromine (Parnate), isocarboxazid (Marplan), Emsam</p> <p>Therapy is required Step</p>
ST Criteria	Documentation of failure or unresponsiveness to THREE different antidepressants from at least two different therapeutic subclasses
QL Criteria	1 tab Per 1 Day

Notes/ References	
Revision Date	Prior Authorization: September 09, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Kombiglyze XR

Products Affected

- KOMBIGLYZE XR ORAL TABLET
EXTENDED RELEASE 24 HR* 5-1000 MG,
5-500 MG

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Kombiglyze XR

Products Affected

- KOMBIGLYZE XR ORAL TABLET
EXTENDED RELEASE 24 HR* 2.5-1000 MG

QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Korlym

Products Affected

- KORLYM

QL Criteria	4 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Kurvelo

Products Affected

- KURVELO

QL Criteria	1.5 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

LaMICtal ODT

Products Affected

- LAMICTAL ODT ORAL TABLET
DISPERSIBLE 100 MG

ST Criteria	Documented trial and failure of 1 month of lamotrigine OR lamotrigine ER
QL Criteria	2 tabs Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

LaMICtal ODT

Products Affected

- LAMICTAL ODT ORAL TABLET
DISPERSIBLE 200 MG

ST Criteria	Documented trial and failure of 1 month of lamotrigine OR lamotrigine ER
QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

LaMICtal ODT

Products Affected

- LAMICTAL ODT ORAL TABLET
DISPERSIBLE 25 MG

ST Criteria	Documented trial and failure of 1 month of lamotrigine OR lamotrigine ER
QL Criteria	6 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

LaMICtal ODT

Products Affected

- LAMICTAL ODT ORAL TABLET
DISPERSIBLE 50 MG

ST Criteria	Documented trial and failure of 1 month of lamotrigine OR lamotrigine ER
QL Criteria	3 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

LaMICtal ODT

Products Affected

- LAMICTAL ODT ORAL KIT

ST Criteria	Documented trial and failure of 1 month of lamotrigine OR lamotrigine ER
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

LaMICtal XR

Products Affected

- LAMICTAL XR ORAL KIT

ST Criteria	Documented trial and failure of 1 month of lamotrigine
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

LaMICtal XR

Products Affected

- LAMICTAL XR ORAL TABLET
EXTENDED RELEASE 24 HR* 25 MG, 50
MG, 100 MG

ST Criteria	Documented trial and failure of 1 month of lamotrigine
QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

LaMICtal XR

Products Affected

- LAMICTAL XR ORAL TABLET
EXTENDED RELEASE 24 HR* 300 MG

ST Criteria	Documented trial and failure of 1 month of lamotrigine
QL Criteria	2 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

LaMICtal XR

Products Affected

- LAMICTAL XR ORAL TABLET
EXTENDED RELEASE 24 HR* 200 MG

ST Criteria	Documented trial and failure of 1 month of lamotrigine
QL Criteria	3 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

LaMICtal XR

Products Affected

- LAMICTAL XR ORAL TABLET
EXTENDED RELEASE 24 HR* 250 MG

ST Criteria	Documented trial and failure of 1 month of lamotrigine
QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

LamISIL

Products Affected

- LAMISIL ORAL PACKET 187.5 MG

QL Criteria	1 pack Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

LamISIL

Products Affected

- LAMISIL ORAL PACKET 125 MG

QL Criteria	2 packs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

LamoTRigine

Products Affected

- *lamotrigine oral tablet dispersible 50 mg*

QL Criteria	3 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

LamoTRigine

Products Affected

- *lamotrigine oral tablet dispersible 25 mg*

QL Criteria	6 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

LamoTRIGine

Products Affected

- *lamotrigine oral tablet dispersible 100 mg, 200 mg*

QL Criteria	2 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

LamoTRigine ER

Products Affected

- *lamotrigine er oral tablet extended release 24 hr* 100 mg, 50 mg, 25 mg*

ST Criteria	Documented trial and failure of 1 month of lamotrigine
QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

LamoTRigine ER

Products Affected

- *lamotrigine er oral tablet extended release 24 hr* 300 mg, 250 mg*

ST Criteria	Documented trial and failure of 1 month of lamotrigine
QL Criteria	2 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

LamoTRigine ER

Products Affected

- *lamotrigine er oral tablet extended release 24 hr* 200 mg*

ST Criteria	Documented trial and failure of 1 month of lamotrigine
QL Criteria	3 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Lastacraft

Products Affected

- LASTACAFT

QL Criteria	1 bottle Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Latanoprost

Products Affected

- *latanoprost ophthalmic*

QL Criteria	3 ML Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Latuda

Products Affected

- LATUDA ORAL TABLET 20 MG

ST Criteria	Trial of 1 month of: 1 generic (aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone)
QL Criteria	1 tab Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Latuda

Products Affected

- LATUDA ORAL TABLET 40 MG, 120 MG, 60 MG

ST Criteria	Trial of 1 month of: 1 generic (aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone)
QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Latuda

Products Affected

- LATUDA ORAL TABLET 80 MG

ST Criteria	Trial of 1 month of: 1 generic (aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone)
QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Lazanda

Products Affected

- LAZANDA

PA Criteria	Criteria Details
Covered Uses	For pain due to malignant diagnosis only
Exclusion Criteria	Use in non-malignant pain
Required Medical Information	A. Documentation of already receiving and who are tolerant to opioid therapy, and documentation on intolerance of two (2) other immediate-release opioids including morphine, hydrocodone, oxycodone, or hydromorphone.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months
Other Criteria	FOR SUBSYS: Documentation of intolerance to Actiq. FOR ABSTRAL, FENTORA, LAZANDA, and ONSOLIS: Documentation of intolerance to Actiq AND Subsys.
QL Criteria	15 bottles Per 1 fill
Notes/References	
Revision Date	Prior Authorization: September 29, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Leena

Products Affected

- LEENA

QL Criteria	1.5 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Leflunomide

Products Affected

- *leflunomide oral*

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Lenvima 10 MG Daily Dose

Products Affected

- LENVIMA 10 MG DAILY DOSE

QL Criteria	30 day supply Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Lenvima 14 MG Daily Dose

Products Affected

- LENVIMA 14 MG DAILY DOSE

QL Criteria	30 day supply Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Lenvima 20 MG Daily Dose

Products Affected

- LENVIMA 20 MG DAILY DOSE

QL Criteria	30 day supply Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Lenvima 24 MG Daily Dose

Products Affected

- LENVIMA 24 MG DAILY DOSE

QL Criteria	30 day supply Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Lescol

Products Affected

- LESCOL

QL Criteria	2 caps Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Lescol XL

Products Affected

- LESCOLO XL

QL Criteria	1 tab Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Lessina

Products Affected

- LESSINA

QL Criteria	1.5 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Levaquin

Products Affected

- LEVAQUIN ORAL SOLUTION

QL Criteria	280 ml Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Levaquin

Products Affected

- LEVAQUIN ORAL TABLET

QL Criteria	14 tabs Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

LevETIRAcetam ER

Products Affected

- *levetiracetam er oral tablet extended release 24 hr* 500 mg*

QL Criteria	6 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

LevETIRAcetam ER

Products Affected

- *levetiracetam er oral tablet extended release 24 hr* 750 mg*

QL Criteria	4 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Levitra

Products Affected

- LEVITRA

ST Criteria	Documented step through CIALIS
QL Criteria	6 tabs Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Levocetirizine Dihydrochloride

Products Affected

- *levocetirizine dihydrochloride oral tablet*

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Levofloxacin

Products Affected

- *levofloxacin oral tablet*

QL Criteria	14 tabs Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Levofloxacin

Products Affected

- *levofloxacin oral solution*

QL Criteria	280 ML Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Levonest

Products Affected

- LEVONEST

QL Criteria	1.5 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Levonorgest-Eth Estrad 91-Day

Products Affected

- *levonorgest-eth estrad 91-day oral tablet*
0.15-0.03 mg, 0.1-0.02 & 0.01 mg

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Levonorgestrel

Products Affected

- *levonorgestrel*

QL Criteria	1 tab Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Levonorgestrel

Products Affected

- *levonorgestrel*

QL Criteria	1 tablet Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Levonorgestrel-Ethinyl Estrad

Products Affected

- *levonorgestrel-ethinyl estrad*

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Levonorgestrel-Ethinyl Estrad

Products Affected

- *levonorgestrel-ethinyl estrad*

QL Criteria	1.5 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Levora 0.15/30 (28)

Products Affected

- LEVORA 0.15/30 (28)

QL Criteria	1.5 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Lexapro

Products Affected

- LEXAPRO ORAL TABLET

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Lialda

Products Affected

- LIALDA

QL Criteria	4 tabs Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Lidocaine

Products Affected

- *lidocaine external patch*

PA Criteria	Criteria Details
Covered Uses	pain associated with post-herpetic neuralgia
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Lidoderm

Products Affected

- LIDODERM

PA Criteria	Criteria Details
Covered Uses	pain associated with post-herpetic neuralgia
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

LidoRx

Products Affected

- *lidorx*

QL Criteria	1 pump Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Lindane

Products Affected

- *lindane external*

QL Criteria	60 ml Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Linezolid

Products Affected

- *linezolid oral*

QL Criteria	28 tablets Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

LinzeSS

Products Affected

- LINZESS

ST Criteria	Documented step through LACTULOSE AND AMITIZA
QL Criteria	1 cap Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Lipitor

Products Affected

- LIPITOR

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Lipofen

Products Affected

- LIPOFEN

QL Criteria	1 cap Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Liptruzet

Products Affected

- LIPTRUZET

ST Criteria	Documented step through ONE GENERIC STATIN, ATORVASTATIN, FLUVASTATIN, LOVASTATIN, PRAVASTATIN, SIMVASTATIN (NSO) AND CRESTOR
QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Livalo

Products Affected

- LIVALO

ST Criteria	Documented step through ONE GENERIC STATIN, ATORVASTATIN, FLUVASTATIN, LOVASTATIN, PRAVASTATIN, SIMVASTATIN (NSO) AND CRESTOR
QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Lo Loestrin Fe

Products Affected

- LO LOESTRIN FE

QL Criteria	1.5 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Lo/Ovral (28)

Products Affected

- LO/OVRAL (28)

QL Criteria	1.5 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Loestrin 1.5/30 (21)

Products Affected

- LOESTRIN 1.5/30 (21)

QL Criteria	1.5 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Loestrin 1/20 (21)

Products Affected

- LOESTRIN 1/20 (21)

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Loestrin Fe 1.5/30

Products Affected

- LOESTRIN FE 1.5/30

QL Criteria	1.5 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Loestrin Fe 1/20

Products Affected

- LOESTRIN FE 1/20

QL Criteria	1.5 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Lofibra

Products Affected

- LOFIBRA

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Lofibra

Products Affected

- LOFIBRA

QL Criteria	1 cap Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Lomedia 24 FE

Products Affected

- LOMEDIA 24 FE

QL Criteria	1.5 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Lonsurf

Products Affected

- LONSURF ORAL TABLET 15-6.14 MG

QL Criteria	100 tablets Per 28 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: December 01, 2015

Lonsurf

Products Affected

- LONSURF ORAL TABLET 20-8.19 MG

QL Criteria	80 tablets Per 28 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Loryna

Products Affected

- LORYNA

QL Criteria	1.5 tab Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

LoSeasonique

Products Affected

- LOSEASONIQUE

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Lotrel

Products Affected

- LOTREL

QL Criteria	1 cap Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Lovastatin

Products Affected

- *lovastatin*

QL Criteria	2 tabs Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Lovaza

Products Affected

- LOVAZA

QL Criteria	4 cap Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Lovenox

Products Affected

- LOVENOX

PA Criteria	Criteria Details
Covered Uses	<p>For coverage of additional quantities over 21 day supply:</p> <ol style="list-style-type: none"> 1. Perioperative management of oral anticoagulation when an invasive procedure is required based on risk 2. Prevention of VTE in patients undergoing cancer surgery and greater than 60 years of age OR who have previously experienced a VTE 3. Orthopaedic procedures, i.e. Elective hip arthroplasty or fracture repair, elective knee arthroplasty, knee arthroscopy in a high risk patient, elective spine surgery in a high risk patient 4. Treatment of VTE, PE, Superficial thrombophlebitis 5. Pregnancy 6. Neonates with VTE or children greater than 2 months of age experiencing idiopathic or secondary thromboembolism 7. Acute ST-elevated MI 8. Cancer 9. Long Distance Travel 10. Heparin Induced Thrombocytopenia (HIT) (Arixtra only)
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Pending
Other Criteria	Note: Member may receive a total of up to 21 days of initial therapy without a prior authorization for LMWH and fondaparinux
QL Criteria	2 syringes Per 1 Day
Notes/References	
Revision Date	<p>Prior Authorization: August 11, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015</p>

2015 Aetna Value Plan
(Updated 12/01/2015)

Low-Ogestrel

Products Affected

- LOW-OGESTREL

QL Criteria	1.5 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Lumigan

Products Affected

- LUMIGAN OPHTHALMIC SOLUTION 0.01
%

PA Criteria	Criteria Details
Covered Uses	open-angle glaucoma ocular hypertension
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	Step Therapy
QL Criteria	3 ML Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 11, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Lunesta

Products Affected

- LUNESTA

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	Documentation of a trial and failure with Ambien IR or Sonata
Age Restrictions	17 years and older
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	Step Therapy
ST Criteria	Documented step through one month of a GENERIC HYPNOTIC, i.e., ZOLPIDEM, TEMAZEPAM, TRIAZOLAM
QL Criteria	1 tab Per 1 Day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Lutera

Products Affected

- LUTERA

QL Criteria	1.5 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Luvox CR

Products Affected

- LUVOX CR

QL Criteria	2 caps Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Lynparza

Products Affected

- LYNPARZA

QL Criteria	480 capsules Per 30 prescriptions
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Lyrica

Products Affected

- LYRICA

ST Criteria	Documented step through one month each of THREE of the following drugs/drug classes: ONE tricyclic antidepressant (i.e., AMITRIPTYLINE), ONE muscle relaxant (i.e., CYCLOBENZAPRINE), SSRI (i.e., CITALOPRAM, ONE SNRI (i.e., VENLAFAXINE), GABAPENTIN, or TRAMADOL
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Lysteda

Products Affected

- LYSTEDA

QL Criteria	30 tabs Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Lyza

Products Affected

- LYZA

QL Criteria	1.5 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Malarone

Products Affected

- MALARONE

PA Criteria	Criteria Details
Covered Uses	Treatment of malaria
Exclusion Criteria	
Required Medical Information	Diagnosis of malaria
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 days (24 tablets)
Other Criteria	
QL Criteria	12 tabs Per 1 fill
Notes/References	
Revision Date	Prior Authorization: September 09, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Marinol

Products Affected

- MARINOL

PA Criteria	Criteria Details
Covered Uses	Anorexia associated with weight loss in patients with AIDS, Chemotherapy-induced nausea and vomiting
Exclusion Criteria	
Required Medical Information	Documented diagnosis of Anorexia associated with weight loss in patients with AIDS, or Chemotherapy-induced nausea and vomiting
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months
Other Criteria	
QL Criteria	2 caps Per 1 day
Notes/References	
Revision Date	Prior Authorization: October 05, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Marlissa

Products Affected

- *marlissa*

QL Criteria	1.5 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Matzim LA

Products Affected

- MATZIM LA ORAL TABLET EXTENDED
RELEASE 24 HR* 180 MG, 360 MG, 300
MG, 420 MG

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Matzim LA

Products Affected

- MATZIM LA ORAL TABLET EXTENDED
RELEASE 24 HR* 240 MG

QL Criteria	2 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Maxalt

Products Affected

- MAXALT

QL Criteria	12 tabs Per 30 days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Maxalt-MLT

Products Affected

- MAXALT-MLT

QL Criteria	12 tabs Per 30 days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

MedroxyPROGESTERone Acetate

Products Affected

- *medroxyprogesterone acetate intramuscular**

QL Criteria	1 dose Per 90 dayss
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Mekinist

Products Affected

- MEKINIST ORAL TABLET 2 MG

PA Criteria	Criteria Details
Covered Uses	All FDA and NCCN 2a and 2b approved indications
Exclusion Criteria	
Required Medical Information	A. Documenttion of unresectable or metastatic melanoma, AND B. Documentation of BRAF V600E ro V600K mutations as defected by an FDA approved test
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 month, extended approval based on therapeutic response
Other Criteria	
QL Criteria	1 tab Per 1 Day
Notes/References	
Revision Date	Prior Authorization: August 11, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Mekinist

Products Affected

- MEKINIST ORAL TABLET 0.5 MG

PA Criteria	Criteria Details
Covered Uses	All FDA and NCCN 2a and 2b approved indications
Exclusion Criteria	
Required Medical Information	A. Documenttion of unresectable or metastatic melanoma, AND B. Documentation of BRAF V600E ro V600K mutations as defected by an FDA approved test
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 month, extended approval based on therapeutic response
Other Criteria	
QL Criteria	3 tabs Per 1 Day
Notes/References	
Revision Date	Prior Authorization: August 11, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Menostar

Products Affected

- MENOSTAR

QL Criteria	4 patches Per 28 fills
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Mepron

Products Affected

- MEPRON

QL Criteria	1 bottle Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Metadate CD

Products Affected

- METADATE CD

PA Criteria	Criteria Details
Covered Uses	Attention deficit disorder, Attention deficit hyperactivity disorder
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis of adult ADD or ADHD OR documentation of a diagnosis of childhood ADHD onset with history of previous treatment, and documentation of symptoms significantly impacting, impairing, or compromising the patient's ability to function normally (i.e., attend/maintain academic enrollment or employment), and documentation of intolerance to appropriately dosed and administered regular/immediate acting stimulants.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Step Therapy
ST Criteria	Documented step through 14 days each of THREE of AMPHETAMINE/DEXTROAMPHETAMINE/ SR, DEXMETHYLPHENIDATE/ SR, DEXTROAMPHETAMINE, METHAMPHETAMINE, METHYLPHENIDATE/ ER/ SR, STRATTERA, OR VYVANSE
QL Criteria	1 cap Per 1 day
Notes/ References	
Revision Date	Prior Authorization: October 05, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Metadate ER

Products Affected

- METADATE ER

QL Criteria	3 tabs Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Metaxalone

Products Affected

- *metaxalone*

QL Criteria	56 tablets Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Methamphetamine HCl

Products Affected

- *methamphetamine hcl*

QL Criteria	4 tabs Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Methylin

Products Affected

- METHYLIN ORAL SOLUTION 10 MG/5ML

PA Criteria	Criteria Details
Covered Uses	Attention deficit hyperactivity disorder (ADHD), Narcolepsy
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Step Therapy
QL Criteria	30 ML Per 1 Day
Notes/References	
Revision Date	Prior Authorization: October 05, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Methylin

Products Affected

- METHYLIN ORAL SOLUTION 5 MG/5ML

PA Criteria	Criteria Details
Covered Uses	Attention deficit hyperactivity disorder (ADHD), Narcolepsy
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Step Therapy
QL Criteria	60 ML Per 1 Day
Notes/References	
Revision Date	Prior Authorization: October 05, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Methylin

Products Affected

- METHYLIN ORAL TABLET CHEWABLE

PA Criteria	Criteria Details
Covered Uses	Attention deficit hyperactivity disorder (ADHD), Narcolepsy
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Step Therapy
QL Criteria	6 tabs Per 1 day
Notes/References	
Revision Date	Prior Authorization: October 05, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Methylphenidate HCl

Products Affected

- *methylphenidate hcl oral solution 10 mg/5ml*

QL Criteria	30 ML Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Methylphenidate HCl

Products Affected

- *methylphenidate hcl oral tablet*

QL Criteria	3 tab Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Methylphenidate HCl

Products Affected

- *methylphenidate hcl oral solution 5 mg/5ml*

QL Criteria	60 ML Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Methylphenidate HCl

Products Affected

- *methylphenidate hcl oral tablet chewable*

QL Criteria	6 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Methylphenidate HCl ER

Products Affected

- *methylphenidate hcl er oral tablet
extendedrelease* 27 mg, 54 mg, 18 mg*

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Methylphenidate HCl ER

Products Affected

- *methylphenidate hcl er oral tablet
extendedrelease* 20 mg*

QL Criteria	3 tabs Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Methylphenidate HCl ER

Products Affected

- *methylphenidate hcl er oral tablet
extendedrelease* 36 mg*

QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Methylphenidate HCl ER (CD)

Products Affected

- *methylphenidate hcl er (cd)*

QL Criteria	1 cap Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Methylphenidate HCl ER (LA)

Products Affected

- *methylphenidate hcl er (la)*

QL Criteria	1 cap Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Metoprolol Succinate ER

Products Affected

- *metoprolol succinate er oral tablet extended release 24 hr* 50 mg, 100 mg*

QL Criteria	1.5 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Metoprolol Succinate ER

Products Affected

- *metoprolol succinate er oral tablet extended release 24 hr* 25 mg*

QL Criteria	1 tab Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Metoprolol Succinate ER

Products Affected

- *metoprolol succinate er oral tablet extended release 24 hr* 200 mg*

QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Metrogel

Products Affected

- METROGEL

ST Criteria	Documented step through METROGEL 0.75%*
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Mevacor

Products Affected

- MEVACOR

QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Miacalcin

Products Affected

- MIACALCIN NASAL

QL Criteria	1 bottle Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Micardis

Products Affected

- MICARDIS

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Micardis HCT

Products Affected

- MICARDIS HCT

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Microgestin 1.5/30

Products Affected

- MICROGESTIN 1.5/30

QL Criteria	1.5 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Microgestin 1/20

Products Affected

- MICROGESTIN 1/20

QL Criteria	1.5 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Microgestin FE 1.5/30

Products Affected

- MICROGESTIN FE 1.5/30

QL Criteria	1.5 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Microgestin FE 1/20

Products Affected

- MICROGESTIN FE 1/20

QL Criteria	1.5 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Migranal

Products Affected

- MIGRANAL

QL Criteria	1 pack Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Mimvey

Products Affected

- MIMVEY

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Minastrin 24 Fe

Products Affected

- MINASTRIN 24 FE

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Minivelle

Products Affected

- MINIVELLE

QL Criteria	8 patches Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Mirapex ER

Products Affected

- MIRAPEX ER

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Mircette

Products Affected

- MIRCETTE

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Mirena

Products Affected

- MIRENA

QL Criteria	1 unit Per 1 year
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Mirtazapine

Products Affected

- *mirtazapine oral tablet dispersible*

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Mirvaso

Products Affected

- MIRVASO

ST Criteria	Documented step through TOPICAL METRONIDAZOLE
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Mitigare

Products Affected

- MITIGARE

PA Criteria	Criteria Details
Covered Uses	Prophylaxis of gout flares in adults
Exclusion Criteria	Known hypersensitivity to colchicine.
Required Medical Information	A documented diagnosis of symptomatic gout; AND The patient has had at least two acute gout attacks in one year, presence of tophi, or radiographic joint damage, AND Planned initiation of urate-lowering pharmacotherapy such as allopurinol or Uloric (Uloric requires trial/failure or contraindication to allopurinol) AND Member has undertaken appropriate life style modifications, i.e. limiting of alcohol consumption and other medications known to precipitate gout attacks have been discontinued/changed when possible.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months
Other Criteria	
QL Criteria	2 capsules Per 1 Day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Modafinil

Products Affected

- *modafinil*

QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Modicon (28)

Products Affected

- MODICON (28)

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Mono-Linyah

Products Affected

- MONO-LINYAH

QL Criteria	1.5 tab Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

MonoNessa

Products Affected

- MONONESSA

QL Criteria	1.5 tabs Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Montelukast Sodium

Products Affected

- *montelukast sodium oral*

QL Criteria	1 tab Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Montelukast Sodium

Products Affected

- *montelukast sodium oral*

QL Criteria	1 pack Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Movantik

Products Affected

- MOVANTIK

PA Criteria	Criteria Details
Covered Uses	Diagnosis of Opioid induced constipation in patients with non-cancer pain
Exclusion Criteria	
Required Medical Information	Patient must have been receiving treatment with opioid narcotics for at least 4 weeks.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	1 tablet Per 1 Day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Moxifloxacin HCl

Products Affected

- *moxifloxacin hcl oral*

QL Criteria	14 tabs Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Multaq

Products Affected

- MULTAQ

QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Muse

Products Affected

- MUSE

QL Criteria	6 units Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Myalept

Products Affected

- MYALEPT

QL Criteria	15 vials Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Myorisan

Products Affected

- MYORISAN ORAL CAPSULE 10 MG, 40 MG, 20 MG

PA Criteria	Criteria Details
Covered Uses	severe recalcitrant nodular or cystic acne
Exclusion Criteria	
Required Medical Information	Member already has evidence of scarring and member is enrolled in the FDA iPLEDGE program (females of childbearing potential ONLY)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	5 months
Other Criteria	For coverage of additional quantities (greater than 2 capsules per day) member must meet the following criteria: Patient requires more than 2 capsules per day to reach the appropriate dose for weight, and this is the members FIRST course of therapy or member now requires a second course of therapy and it has been at least 8 weeks after the first course was initiated (2 month holiday), and member has recieved a cumulative dose of less than 120 mg/kg during a course of therapy lasting 20 weeks or less.
ST Criteria	Documented step through ONE GENERIC ORAL ANTIBIOTIC prescribed for treatment of acne (i.e., MINOCYCLINE OR DOXYCYCLINE)
QL Criteria	2 capsules Per 1 Day
Notes/References	
Revision Date	Prior Authorization: October 05, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Myrbetriq

Products Affected

- MYRBETRIQ

ST Criteria	Documented step through DITROPAN* or SANCTURA*
QL Criteria	1 tab Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Naratriptan HCl

Products Affected

- *naratriptan hcl*

QL Criteria	9 tabs Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Natazia

Products Affected

- NATAZIA

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Natesto

Products Affected

- NATESTO

PA Criteria	Criteria Details
Covered Uses	Primary hypogonadism or hypogonadotropic hypogonadism, gender dysphoria, gender reassignment
Exclusion Criteria	patient with carcinoma of the breast or suspected carcinoma of the prostate, patient will be using therapy for muscle building purposes
Required Medical Information	Documented diagnosis of primary hypogonadism or hypogonadotropic hypogonadism as defined by either one of the following: (1) Member has undergone bilateral orchiectomy (no total fasting serum testosterone levels required), or (2) Having two consecutive low total fasting serum testosterone levels (below the testing laboratory's reference range or below 300ng/dl if reference ranges are not available), or for persons with low normal total testosterone levels (above 300 ng/dL but below 400 ng/dL), two consecutive low free or bioavailable fasting serum testosterone levels (below the testing laboratory's reference range or less than 225 picomoles per liter (pmol/L) (6 ng/dL) if reference ranges are not available)(Note: Two morning samples drawn between 7:00 a.m. and 10:00 a.m. obtained on two different days is required for NEW starts only), or (3) Member has a documented diagnosis of gender dysphoria or documentation of undergoing gender reassignment surgery.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	Documented step through one month each of ANDROGEL AND TESTIM
QL Criteria	3 pumps Per 30 Days
Notes/References	
Revision Date	Prior Authorization: September 29, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2015 Aetna Value Plan
(Updated 12/01/2015)

Natpara

Products Affected

- NATPARA

QL Criteria	2 cartridges Per 28 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Necon 0.5/35 (28)

Products Affected

- NECON 0.5/35 (28)

QL Criteria	1.5 tab Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Necon 1/35 (28)

Products Affected

- NECON 1/35 (28)

QL Criteria	1.5 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Necon 1/50 (28)

Products Affected

- NECON 1/50 (28)

QL Criteria	1.5 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Necon 10/11 (28)

Products Affected

- NECON 10/11 (28)

QL Criteria	1.5 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Nesina

Products Affected

- NESINA

PA Criteria	Criteria Details
Covered Uses	Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	Step Therapy
ST Criteria	1 month each of 2 preferred alternatives: Januvia and Onglyza (single entity or combination)
QL Criteria	1 tab Per 1 Day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Neupro

Products Affected

- NEUPRO

QL Criteria	1 patch Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Neurontin

Products Affected

- NEURONTIN ORAL CAPSULE

QL Criteria	6 caps Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Neurontin

Products Affected

- NEURONTIN ORAL TABLET

QL Criteria	6 tabs Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Nevirapine ER

Products Affected

- *nevirapine er oral tablet extended release 24 hr* 400 mg*

QL Criteria	1 tab Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

NexAVAR

Products Affected

- NEXAVAR

QL Criteria	4 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

NexIUM

Products Affected

- NEXIUM ORAL PACKET 10 MG, 20 MG

QL Criteria	1 pack Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

NexIUM

Products Affected

- NEXIUM ORAL PACKET 40 MG

QL Criteria	1 pack Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

NexIUM

Products Affected

- NEXIUM ORAL CAPSULE DELAYED RELEASE

QL Criteria	1 cap Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Nexplanon

Products Affected

- NEXPLANON

QL Criteria	1 unit Per 1 year
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Next Choice One Dose

Products Affected

- NEXT CHOICE ONE DOSE

QL Criteria	1 tab Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Nicotine

Products Affected

- *nicotine transdermal patch 24 hr*

QL Criteria	1 patch Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Nicotrol

Products Affected

- NICOTROL

QL Criteria	16 cartridges Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Nicotrol NS

Products Affected

- NICOTROL NS

QL Criteria	12 bottles Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Nifedical XL

Products Affected

- NIFEDICAL XL ORAL TABLET
EXTENDED RELEASE 24 HR* 30 MG

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Nifedical XL

Products Affected

- NIFEDICAL XL ORAL TABLET
EXTENDED RELEASE 24 HR* 60 MG

QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

NIFEdipine ER

Products Affected

- *nifedipine er oral tablet extended release 24 hr* 60 mg*

QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

NIFEdipine ER

Products Affected

- *nifedipine er oral tablet extended release 24 hr* 90 mg, 30 mg*

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

NIFEdipine ER Osmotic Release

Products Affected

- *nifedipine er osmotic release oral tablet*
extended release 24 hr 90 mg, 30 mg*

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

NIFEdipine ER Osmotic Release

Products Affected

- *nifedipine er osmotic release oral tablet*
extended release 24 hr 60 mg*

QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Nisoldipine ER

Products Affected

- *nisoldipine er oral tablet extended release 24 hr* 40 mg, 8.5 mg, 17 mg, 34 mg, 20 mg*

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Nisoldipine ER

Products Affected

- *nisoldipine er oral tablet extended release 24 hr* 30 mg*

QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Nora-BE

Products Affected

- NORA-BE

QL Criteria	1.5 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Nordette (28)

Products Affected

- NORDETTE (28)

QL Criteria	1.5 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Norethindrone

Products Affected

- *norethindrone oral*

QL Criteria	1.5 tab Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Norethindrone-Eth Estradiol

Products Affected

- *norethindrone-eth estradiol oral tablet 0.5-2.5 mg-mcg*

QL Criteria	1 tablet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Norethin-Eth Estradiol-Fe

Products Affected

- *norethin-eth estradiol-fe*

QL Criteria	1.5 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Norgestimate-Eth Estradiol

Products Affected

- *norgestimate-eth estradiol*

QL Criteria	1.5 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Norgestim-Eth Estrad Triphasic

Products Affected

- *norgestim-eth estrad triphasic*

QL Criteria	1.5 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Norinyl 1+35 (28)

Products Affected

- NORINYL 1+35 (28)

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Norinyl 1+50 (28)

Products Affected

- NORINYL 1+50 (28)

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Noroxin

Products Affected

- NOROXIN

QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Nor-QD

Products Affected

- NOR-QD

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Northera

Products Affected

- NORTHERA ORAL CAPSULE 200 MG

PA Criteria	Criteria Details
Covered Uses	Orthostatic hypotension
Exclusion Criteria	
Required Medical Information	A documented diagnosis of symptomatic neurogenic orthostatic hypotension (NOH) (i.e., dizziness, light-headedness, faintness) caused by primary autonomic failure (i.e., Parkinson's disease, multiple system atrophy, or pure autonomic failure), dopamine beta-hydroxylase deficiency, or non-diabetic autonomic neuropathy
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Pending
Other Criteria	<p>For coverage of additional quantities, a member's treating physician must request prior authorization through the Pharmacy Management Precertification Unit. A prior authorization will be granted for coverage of additional quantities of this medication for those members who meet the following criteria:</p> <p>For Northera (100, 200 mg) Prescriber is titrating dose (may allow 180 caps in 30 days for 3 months Step Therapy is required</p>
ST Criteria	Documented step through trial of one month of PREFERRED GENERIC ALTERNATIVES, MIDODRINE OR FLUDROCORTISONE
QL Criteria	3 capsules Per 1 Day
Notes/References	
Revision Date	Prior Authorization: August 11, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Northera

Products Affected

- NORTHERA ORAL CAPSULE 100 MG

PA Criteria	Criteria Details
Covered Uses	Orthostatic hypotension
Exclusion Criteria	
Required Medical Information	A documented diagnosis of symptomatic neurogenic orthostatic hypotension (NOH) (i.e., dizziness, light-headedness, faintness) caused by primary autonomic failure (i.e., Parkinson's disease, multiple system atrophy, or pure autonomic failure), dopamine beta-hydroxylase deficiency, or non-diabetic autonomic neuropathy
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Pending
Other Criteria	<p>For coverage of additional quantities, a member's treating physician must request prior authorization through the Pharmacy Management Precertification Unit. A prior authorization will be granted for coverage of additional quantities of this medication for those members who meet the following criteria:</p> <p>For Northera (100, 200 mg) Prescriber is titrating dose (may allow 180 caps in 30 days for 3 months) Step Therapy is required</p>
QL Criteria	3 capsules Per 1 Day
Notes/References	
Revision Date	Prior Authorization: August 11, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Northera

Products Affected

- NORTHERA ORAL CAPSULE 300 MG

PA Criteria	Criteria Details
Covered Uses	Orthostatic hypotension
Exclusion Criteria	
Required Medical Information	A documented diagnosis of symptomatic neurogenic orthostatic hypotension (NOH) (i.e., dizziness, light-headedness, faintness) caused by primary autonomic failure (i.e., Parkinson's disease, multiple system atrophy, or pure autonomic failure), dopamine beta-hydroxylase deficiency, or non-diabetic autonomic neuropathy
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Pending
Other Criteria	<p>For coverage of additional quantities, a member's treating physician must request prior authorization through the Pharmacy Management Precertification Unit. A prior authorization will be granted for coverage of additional quantities of this medication for those members who meet the following criteria:</p> <p>For Northera (100, 200 mg) Prescriber is titrating dose (may allow 180 caps in 30 days for 3 months) Step Therapy is required</p>
QL Criteria	6 capsules Per 1 Day
Notes/References	
Revision Date	Prior Authorization: August 11, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Nortrel 0.5/35 (28)

Products Affected

- NORTREL 0.5/35 (28)

QL Criteria	1.5 tab Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Nortrel 1/35 (21)

Products Affected

- NORTREL 1/35 (21)

QL Criteria	1.5 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Nortrel 1/35 (28)

Products Affected

- NORTREL 1/35 (28)

QL Criteria	1.5 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Nortrel 7/7/7

Products Affected

- NORTREL 7/7/7

QL Criteria	1.5 tabs Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

NovoLOG FlexPen

Products Affected

- NOVOLOG FLEXPEN

ST Criteria	Documented step t hrough HUMALOG product
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Noxafil

Products Affected

- NOXAFIL ORAL SUSPENSION

QL Criteria	105 ml Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Noxafil

Products Affected

- NOXAFIL ORAL TABLET DELAYED RELEASE

QL Criteria	93 tabs Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Nucynta

Products Affected

- NUCYNTA

ST Criteria	Documented step through TWO of the following: MORPHINE, OXYCODONE, HYDROMORPHONE
QL Criteria	6 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Nucynta ER

Products Affected

- NUCYNTA ER

PA Criteria	Criteria Details
Covered Uses	(1)Chronic pain due to malignant condition or severe pain requiring daily, around the clock, long term opioid treatment, (2)Diabetic peripheral neuropathy
Exclusion Criteria	
Required Medical Information	FOR CHRONIC PAIN: Documentation of progression through the World Health Organization analgesic ladder and documentation of a failure to controlled-release morphine sulfate tablets (MS Contin) and oxymorphone extended release (Opana ER). FOR DIABETIC PERIPHERAL NEUROPATHY: Documentation of failure to TWO of the following drugs/drug classes (each agent must be from a different class): gabapentin, tricyclin antidepressant, tramadol, Lyrica, SNRI, and documentenation of failure to controlled release morpine sulfate tabelts (MS Contin)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Step Therapy
ST Criteria	Documented step through one month of MORPHINE SR TAB 12HR (MS CONTIN) AND OXYMORPHONE ER (OPANA ER)
QL Criteria	2 tabs Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 29, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2015 Aetna Value Plan
(Updated 12/01/2015)

Nuedexta

Products Affected

- NUEDEXTA

QL Criteria	2 caps Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

NuvaRing

Products Affected

- NUVARING

QL Criteria	1 ring Per 28 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Nuvigil

Products Affected

- NUVIGIL ORAL TABLET 150 MG, 250 MG, 200 MG

PA Criteria	Criteria Details
Covered Uses	Excessive daytime sleepiness associated with narcolepsy, Excessive daytime sleepiness associated with obstructive sleep apnea/hypopnea syndrome (OSAHS), Shift Work Sleep Disorder
Exclusion Criteria	
Required Medical Information	FOR NARCOLEPSY: Documentation of diagnostic testing and clinical notations supporting diagnosis of Narcolepsy, such as MSLT, clinical progress notes, etc. (Failure to adequately support the diagnosis of narcolepsy may result in denial of coverage). FOR OSAHS: The prescribing physician is a sleep specialist, ear, nose and throat, neurologist or pulmonologist or has obtained a consult from a sleep specialist, and a Standard Diagnostic Nocturnal Polysomnography (NPSG) has confirmed the diagnosis of OSAHS, and the patient has received nasal continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BIPAP) for at least 1 month, and CPAP or BIPAP therapy must be continued on a routine basis in combination with armodafinil therapy, and the daytime fatigue is significantly impacting, impairing, or compromising the patients ability to function normally, and the prescribing physician has established a patient care plan to treat the cause of OSAHS in conjunction with treating the daily fatigue, and patient must be compliant with recommendations for OSAHS treatment.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	
QL Criteria	1 tab Per 1 day
Notes/References	
Revision Date	Prior Authorization: November 09, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Nuvigil

Products Affected

- NUVIGIL ORAL TABLET 50 MG

PA Criteria	Criteria Details
Covered Uses	Excessive daytime sleepiness associated with narcolepsy, Excessive daytime sleepiness associated with obstructive sleep apnea/hypopnea syndrome (OSAHS), Shift Work Sleep Disorder
Exclusion Criteria	
Required Medical Information	FOR NARCOLEPSY: Documentation of diagnostic testing and clinical notations supporting diagnosis of Narcolepsy, such as MSLT, clinical progress notes, etc. (Failure to adequately support the diagnosis of narcolepsy may result in denial of coverage). FOR OSAHS: The prescribing physician is a sleep specialist, ear, nose and throat, neurologist or pulmonologist or has obtained a consult from a sleep specialist, and a Standard Diagnostic Nocturnal Polysomnography (NPSG) has confirmed the diagnosis of OSAHS, and the patient has received nasal continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BIPAP) for at least 1 month, and CPAP or BIPAP therapy must be continued on a routine basis in combination with armodafinil therapy, and the daytime fatigue is significantly impacting, impairing, or compromising the patients ability to function normally, and the prescribing physician has established a patient care plan to treat the cause of OSAHS in conjunction with treating the daily fatigue, and patient must be compliant with recommendations for OSAHS treatment.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	
QL Criteria	2 tabs Per 1 day
Notes/References	
Revision Date	Prior Authorization: November 09, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2015 Aetna Value Plan
(Updated 12/01/2015)

Ocella

Products Affected

- OCELLA

QL Criteria	1.5 tabs Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Odomzo

Products Affected

- ODOMZO

QL Criteria	1 capsule Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ofev

Products Affected

- OFEV

QL Criteria	2 capsules Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ofloxacin

Products Affected

- *ofloxacin oral tablet 400 mg*

QL Criteria	28 tabs Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ogestrel

Products Affected

- OGESTREL

QL Criteria	1.5 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

OLANZapine

Products Affected

- *olanzapine oral tablet 10 mg, 20 mg, 7.5 mg, 15 mg, 5 mg*
- *olanzapine oral tablet dispersible 15 mg, 20 mg, 5 mg*

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

OLANZapine

Products Affected

- *olanzapine oral tablet 2.5 mg*

QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Oleptro

Products Affected

- OLEPTRO ORAL TABLET EXTENDED
RELEASE 24 HR* 150 MG

QL Criteria	45 tabs Per 30 days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Oleptro

Products Affected

- OLEPTRO ORAL TABLET EXTENDED
RELEASE 24 HR* 300 MG

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Olysio

Products Affected

- OLYSIO

QL Criteria	1 capsule Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Omega-3-acid Ethyl Esters

Products Affected

- *omega-3-acid ethyl esters*

QL Criteria	4 tabs Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Omnaris

Products Affected

- OMNARIS

ST Criteria	Trial of 2 weeks each of 2 of the following: fluticasone propionate OR flunisolide nasal spray OR Triamcinolone OR Nasacort 24HR OTC (choose 1) AND Nasonex
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ondansetron

Products Affected

- *ondansetron*

QL Criteria	60 tabs Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ondansetron HCl

Products Affected

- *ondansetron hcl oral tablet 24 mg*

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ondansetron HCl

Products Affected

- *ondansetron hcl oral tablet 8 mg, 4 mg*

QL Criteria	60 tabs Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ondansetron HCl

Products Affected

- *ondansetron hcl oral solution*

QL Criteria	50 ml Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Onexton

Products Affected

- ONEXTON

ST Criteria	one month of the preferred generic alternative, benzoyl peroxide/ clindamycin phosphate gel or benzoyl peroxide/ erythromycin gel
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Onfi

Products Affected

- ONFI ORAL TABLET 20 MG, 10 MG

PA Criteria	Criteria Details
Covered Uses	Seizures associated with Lennox-Gastaut syndrome or refractory(therapy resistant) epilepsy
Exclusion Criteria	
Required Medical Information	A documented diagnosis of seizures associated with Lennox-Gastaut syndrome or refractory(therapy resistant) epilepsy AND Concomitant use of an anticonvulsant drug
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	2 tabs Per 1 day
Notes/References	
Revision Date	Prior Authorization: November 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Onfi

Products Affected

- ONFI ORAL SUSPENSION
- ONFI ORAL TABLET 5 MG

PA Criteria	Criteria Details
Covered Uses	Seizures associated with Lennox-Gastaut syndrome or refractory(therapy resistant) epilepsy
Exclusion Criteria	
Required Medical Information	A documented diagnosis of seizures associated with Lennox-Gastaut syndrome or refractory(therapy resistant) epilepsy AND Concomitant use of an anticonvulsant drug
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: November 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Onglyza

Products Affected

- ONGLYZA

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Opana

Products Affected

- OPANA ORAL

ST Criteria	Documented step through TWO of the following: MORPHINE, OXYCODONE, HYDROMORPHONE
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Opana ER

Products Affected

- OPANA ER ORAL

QL Criteria	4 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Oravig

Products Affected

- ORAVIG

QL Criteria	14 tabs Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Orkambi

Products Affected

- ORKAMBI

QL Criteria	4 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Orsythia

Products Affected

- ORSYTHIA

QL Criteria	1.5 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ortho Evra

Products Affected

- ORTHO EVRA

QL Criteria	3 patches Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ortho Micronor

Products Affected

- ORTHO MICRONOR

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ortho Tri-Cyclen (28)

Products Affected

- ORTHO TRI-CYCLEN (28)

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ortho Tri-Cyclen Lo

Products Affected

- ORTHO TRI-CYCLEN LO

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ortho-Cept (28)

Products Affected

- ORTHO-CEPT (28)

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ortho-Cyclen (28)

Products Affected

- ORTHO-CYCLEN (28)

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ortho-Novum 1/35 (28)

Products Affected

- ORTHO-NOVUM 1/35 (28)

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ortho-Novum 7/7/7 (28)

Products Affected

- ORTHO-NOVUM 7/7/7 (28)

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Oseni

Products Affected

- OSENI

PA Criteria	Criteria Details
Covered Uses	Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	A. Documentation of a trial and failure of metformin (at least 1500mg/day) AND B. Documentation of a trial and failure of pioglitazone, Januvia/Janumet/Janumet XR, or Onglyza/Kombiglyze XR
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	Step Therapy
ST Criteria	1 month each of Pioglitazone in combination with 2 preferred alternatives : januvia AND onglyza (single entity or combination)
QL Criteria	1 tab Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 11, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Osphena

Products Affected

- OSPHENA

ST Criteria	Documented step through VAGIFEM or ESTRACE cream
QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Otezla

Products Affected

- OTEZLA ORAL TABLET

QL Criteria	2 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Otezla

Products Affected

- OTEZLA ORAL

QL Criteria	1 pack Per 1 year
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ovcon-35 (28)

Products Affected

- OVCON-35 (28)

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ovide

Products Affected

- OVIDE

QL Criteria	1 bottle Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Oxtellar XR

Products Affected

- OXTELLAR XR ORAL TABLET
EXTENDED RELEASE 24 HR* 150 MG, 300
MG

ST Criteria	Documented trial and failure of 1 month of oxcarbazepine
QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Oxtellar XR

Products Affected

- OXTELLAR XR ORAL TABLET
EXTENDED RELEASE 24 HR* 600 MG

ST Criteria	Documented trial and failure of 1 month of oxcarbazepine
QL Criteria	4 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Oxybutynin Chloride

Products Affected

- *oxybutynin chloride oral tablet*

QL Criteria	4 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

OxyCODONE HCl ER

Products Affected

- *oxycodone hcl er*

QL Criteria	2 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

OxyCONTIN

Products Affected

- OXYCONTIN

PA Criteria	Criteria Details
Covered Uses	Chronic pain due to malignant condition or severe pain requiring daily, around the clock, long term opioid treatment
Exclusion Criteria	
Required Medical Information	Documentation of progression through the World Health Organization analgesic ladder
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Step Therapy
ST Criteria	Documented step through one month of MORPHINE SR TAB 12HR (MS CONTIN) AND OXYMORPHONE ER (OPANA ER)
QL Criteria	2 tablets Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 29, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Oxymorphone HCl ER

Products Affected

- *oxymorphone hcl er*

QL Criteria	4 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Oxytrol

Products Affected

- OXYTROL

ST Criteria	Documented step through DITROPAN* or SANCTURA* AND VESICARE or MYRBETRIQ
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Paliperidone ER

Products Affected

- *paliperidone er oral tablet extended release 24 hr* 1.5 mg, 6 mg, 3 mg*

QL Criteria	2 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Paliperidone ER

Products Affected

- *paliperidone er oral tablet extended release 24 hr* 9 mg*

QL Criteria	1 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Pancreaze

Products Affected

- PANCREAZE

ST Criteria	Documented step through CREON AND ZENPEP
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Paragard Intrauterine Copper

Products Affected

- PARAGARD INTRAUTERINE COPPER

QL Criteria	1 unit Per 1 year
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

PARoxetine HCl

Products Affected

- *paroxetine hcl oral tablet 30 mg, 40 mg*

QL Criteria	2 tabs Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

PARoxetine HCl

Products Affected

- *paroxetine hcl oral tablet 20 mg, 10 mg*

QL Criteria	1 tab Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

PARoxetine HCl ER

Products Affected

- *paroxetine hcl er*

QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Paxil

Products Affected

- PAXIL ORAL TABLET 20 MG, 10 MG

QL Criteria	1 tab Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Paxil

Products Affected

- PAXIL ORAL SUSPENSION

QL Criteria	30 ML Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Paxil

Products Affected

- PAXIL ORAL TABLET 30 MG, 40 MG

QL Criteria	2 tabs Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Paxil CR

Products Affected

- PAXIL CR

QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

PEG 3350/Electrolytes

Products Affected

- *peg 3350/electrolytes*

QL Criteria	1 bottle Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

PEG-3350/Electrolytes

Products Affected

- *peg-3350/electrolytes*

QL Criteria	1 bottle Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Pennsaid

Products Affected

- PENNSAID TRANSDERMAL SOLUTION 2 %

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Pending
Other Criteria	For coverage of additional quantities: a member's treating physician must request prior authorization through the Pharmacy Management Precertification Unit. Additional quantities of proton pump inhibitors may be considered medically necessary for those meet the following criteria: Member is being treated for both knees.
ST Criteria	Documented Trial of 1 month of Voltaren Gel
QL Criteria	112 ml Per 1 fill
Notes/References	
Revision Date	Prior Authorization: September 09, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Pentasa

Products Affected

- PENTASA ORAL CAPSULE EXTENDED RELEASE* 500 MG

QL Criteria	8 caps Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Pentasa

Products Affected

- PENTASA ORAL CAPSULE EXTENDED RELEASE* 250 MG

QL Criteria	16 caps Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Perforomist

Products Affected

- PERFOROMIST

PA Criteria	Criteria Details
Covered Uses	Chronic Obstructive Pulmonary Disorder (COPD)
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Step Therapy
ST Criteria	Trail of one month each of FORADIL AND SEREVENT
QL Criteria	60 vials Per 1 fill
Notes/References	
Revision Date	Prior Authorization: September 09, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Perindopril Erbumine

Products Affected

- *perindopril erbumine oral tablet 8 mg*

QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Perindopril Erbumine

Products Affected

- *perindopril erbumine oral tablet 2 mg*

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Perindopril Erbumine

Products Affected

- *perindopril erbumine oral tablet 4 mg*

QL Criteria	1 tab Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Pertzye

Products Affected

- PERTZYE

ST Criteria	Documented step through CREON AND ZENPEP
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Philith

Products Affected

- PHILITH

QL Criteria	1.5 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Picato

Products Affected

- PICATO

QL Criteria	1 box Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Pioglitazone HCl

Products Affected

- *pioglitazone hcl*

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Pioglitazone HCl-Glimepiride

Products Affected

- *pioglitazone hcl-glimepiride*

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Pioglitazone HCl-Metformin HCl

Products Affected

- *pioglitazone hcl-metformin hcl*

QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Pirmella 1/35

Products Affected

- PIRMELLA 1/35

QL Criteria	1.5 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Plan B One-Step

Products Affected

- PLAN B ONE-STEP

QL Criteria	1 Pack Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Plavix

Products Affected

- PLAVIX

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Plavix

Products Affected

- PLAVIX

QL Criteria	1 tab Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Plegridy

Products Affected

- PLEGRIDY

QL Criteria	2 syringes Per 28 months
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Plegridy Starter Pack

Products Affected

- PLEGRIDY STARTER PACK

QL Criteria	1 kit Per 365 months
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Plexion

Products Affected

- PLEXION

ST Criteria	Documented step through TWO GENERIC SULFACETAMIDE SODIUM WITH SULFUR products (any formulation)
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Plexion Cleanser

Products Affected

- PLEXION CLEANSER EXTERNAL LIQUID†

ST Criteria	Documented step through TWO GENERIC SULFACETAMIDE SODIUM WITH SULFUR products (any formulation)
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Plexion Cleansing Cloth

Products Affected

- PLEXION CLEANSING CLOTH
EXTERNAL PAD

ST Criteria	Documented step through TWO GENERIC SULFACETAMIDE SODIUM WITH SULFUR products (any formulation)
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Pomalyst

Products Affected

- POMALYST

QL Criteria	1 cap Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Portia-28

Products Affected

- PORTIA-28

QL Criteria	1.5 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Potiga

Products Affected

- POTIGA ORAL TABLET 300 MG, 400 MG

PA Criteria	Criteria Details
Covered Uses	Partial-onset seizure
Exclusion Criteria	
Required Medical Information	A documented diagnosis of partial-onset seizures AND documented concurrent therapy with one of the following: carbamazepine, divalproex dr/er/sprinkle, gabapentin, lamotrigine, levetiracetam/ER, oxcarbazepine, phenytoin, topiramate, valproic acid, or zonisamide
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	3 tabs Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 15, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Potiga

Products Affected

- POTIGA ORAL TABLET 200 MG

PA Criteria	Criteria Details
Covered Uses	Partial-onset seizure
Exclusion Criteria	
Required Medical Information	A documented diagnosis of partial-onset seizures AND documented concurrent therapy with one of the following: carbamazepine, divalproex dr/er/sprinkle, gabapentin, lamotrigine, levetiracetam/ER, oxcarbazepine, phenytoin, topiramate, valproic acid, or zonisamide
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	3 tabs Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 15, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Potiga

Products Affected

- POTIGA ORAL TABLET 50 MG

PA Criteria	Criteria Details
Covered Uses	Partial-onset seizure
Exclusion Criteria	
Required Medical Information	A documented diagnosis of partial-onset seizures AND documented concurrent therapy with one of the following: carbamazepine, divalproex dr/er/sprinkle, gabapentin, lamotrigine, levetiracetam/ER, oxcarbazepine, phenytoin, topiramate, valproic acid, or zonisamide
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	6 tabs Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 15, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Pradaxa

Products Affected

- PRADAXA

ST Criteria	Documented step through ELIQUIS and XARELTO
QL Criteria	2 caps Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Praluent

Products Affected

- PRALUENT

QL Criteria	2 syringes Per 28 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Pramipexole Dihydrochloride ER

Products Affected

- *pramipexole dihydrochloride er*

QL Criteria	1 tablet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

PrandiMet

Products Affected

- PRANDIMET

QL Criteria	2 caps Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Pravachol

Products Affected

- PRAVACHOL

QL Criteria	1 tab Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Pravastatin Sodium

Products Affected

- *pravastatin sodium*

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Prefest

Products Affected

- PREFEST

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Prenate Mini

Products Affected

- PRENATE MINI

QL Criteria	1 capsule Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Prevacid

Products Affected

- PREVACID ORAL CAPSULE DELAYED
RELEASE 15 MG

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Prevacid SoluTab

Products Affected

- PREVACID SOLUTAB

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	A. Documentation of an inability to swallow tablets/capsules, AND B. Documentation of a trial/failure of Nexium granules AND ONE of the following: Prilosec* (capsules may be opened and sprinkled on 1 tablespoon of applesauce), Prevacid 24H OTC (capsule may be opened and sprinkled on 1 tablespoon of applesauce, Ensure pudding, cottage cheese, yogurt, or strained pears, or emptied into 60 mL of apple juice, orange juice, or tomato juice), FIRST-Omeprazole 2mg/ml suspension, or FIRST-Lansoprazole 3mg/ml suspension.
Age Restrictions	1 year of age and greater
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	HIGH DOSE - Up to 60mg/day A. inability to swallow tablets/capsules, AND B. trial/failure on ONE of the following: 80mg/day of Nexium granules, 80 mg/day of Prilosec* (capsules may be opened and sprinkled on 1 tablespoon of applesauce), 60 mg/day of Prevacid 24H OTC (capsule may be opened and sprinkled on 1 tablespoon of applesauce, Ensure pudding, cottage cheese, yogurt, or strained pears, or emptied into 60 mL of apple juice, orange juice, or tomato juice), 80mg/day of FIRST-Omeprazole 2mg/ml suspension, or 60mg/day of FIRST-Lansoprazole 3mg/ml suspension
QL Criteria	1 tab Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 09, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2015 Aetna Value Plan
(Updated 12/01/2015)

Previfem

Products Affected

- PREVIFEM

QL Criteria	1.5 tabs Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Prezista

Products Affected

- PREZISTA ORAL TABLET 150 MG, 75 MG, 600 MG

QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Prezista

Products Affected

- PREZISTA ORAL SUSPENSION

QL Criteria	2 bottles Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Prezista

Products Affected

- PREZISTA ORAL TABLET 800 MG

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Pristiq

Products Affected

- PRISTIQ

PA Criteria	Criteria Details
Covered Uses	Major depressive disorder
Exclusion Criteria	
Required Medical Information	Diagnosis of major depressive disorder
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	<p>Examples of antidepressant trials from unique therapeutic subclasses Therapeutic Subclass:Examples:</p> <p>Selective Serotonin Reuptake Inhibitors (SSRI) fluoxetine (Prozac), paroxetine (Paxil), citalopram (Celexa), sertraline (Zoloft), escitalopram (Lexapro)</p> <p>Serotonin-Norepinephrine Reuptake Inhibitors (SNRI) venlafaxine (Effexor), Effexor XR, Pristiq, Cymbalta</p> <p>Norepinephrine-Dopamine Reuptake Inhibitors (NDRI) bupropion (Wellbutrin), bupropion sustained release (Wellbutrin SR), bupropion extended release (Wellbutrin XL)</p> <p>Tricyclic Antidepressants (TCA) amitriptyline (Elavil), amoxapine (Ascendin), desipramine (Norpramin), doxepin (Sinequan), imipramine (Tofranil), nortriptyline (Pamelor), protriptyline (Vivactil), trimipramine (Surmontil)</p> <p>Tetracyclic Antidepressants mirtazapine (Remeron)</p> <p>Monoamine Oxidase Inhibitors (MAOI) phenelzine (Nardil), tranylcypromine (Parnate), isocarboxazid (Marplan), Emsam</p> <p>Therapy is required Step</p>
ST Criteria	Documentation of failure or unresponsiveness to THREE different antidepressants from at least two different therapeutic subclasses
QL Criteria	1 tab Per 1 day

Notes/ References	
Revision Date	Prior Authorization: September 09, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Pristiq

Products Affected

- PRISTIQ

PA Criteria	Criteria Details
Covered Uses	Major depressive disorder
Exclusion Criteria	
Required Medical Information	Diagnosis of major depressive disorder
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	<p>Examples of antidepressant trials from unique therapeutic subclasses Therapeutic Subclass:Examples:</p> <p>Selective Serotonin Reuptake Inhibitors (SSRI) fluoxetine (Prozac), paroxetine (Paxil), citalopram (Celexa), sertraline (Zoloft), escitalopram (Lexapro)</p> <p>Serotonin-Norepinephrine Reuptake Inhibitors (SNRI) venlafaxine (Effexor), Effexor XR, Pristiq, Cymbalta</p> <p>Norepinephrine-Dopamine Reuptake Inhibitors (NDRI) bupropion (Wellbutrin), bupropion sustained release (Wellbutrin SR), bupropion extended release (Wellbutrin XL)</p> <p>Tricyclic Antidepressants (TCA) amitriptyline (Elavil), amoxapine (Ascendin), desipramine (Norpramin), doxepin (Sinequan), imipramine (Tofranil), nortriptyline (Pamelor), protriptyline (Vivactil), trimipramine (Surmontil)</p> <p>Tetracyclic Antidepressants mirtazapine (Remeron)</p> <p>Monoamine Oxidase Inhibitors (MAOI) phenelzine (Nardil), tranylcypromine (Parnate), isocarboxazid (Marplan), Emsam</p> <p>Therapy is required Step</p>
ST Criteria	Documentation of failure or unresponsiveness to THREE different antidepressants from at least two different therapeutic subclasses
QL Criteria	1 tablet Per 1 Day

Notes/ References	
Revision Date	Prior Authorization: September 09, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

ProAir HFA

Products Affected

- PROAIR HFA

QL Criteria	2 inhalers Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

ProAir RespiClick

Products Affected

- PROAIR RESPICLICK

QL Criteria	2 inhalers Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Procardia XL

Products Affected

- PROCARDIA XL ORAL TABLET
EXTENDED RELEASE 24 HR* 90 MG, 30
MG

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Procardia XL

Products Affected

- PROCARDIA XL ORAL TABLET
EXTENDED RELEASE 24 HR* 60 MG

QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

ProCentra

Products Affected

- PROCENTRA

PA Criteria	Criteria Details
Covered Uses	Attention deficit hyperactivity disorder (ADHD), Narcolepsy
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Step Therapy
QL Criteria	40 ML Per 1 Day
Notes/References	
Revision Date	Prior Authorization: October 05, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Procysbi

Products Affected

- PROCYSBI ORAL CAPSULE DELAYED
RELEASE 75 MG

QL Criteria	750 caps Per 30 monthss
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Procysbi

Products Affected

- PROCYSBI ORAL CAPSULE DELAYED
RELEASE 25 MG

QL Criteria	240 caps Per 30 monthss
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Prolensa

Products Affected

- PROLENSA

QL Criteria	1 bottle Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Promacta

Products Affected

- PROMACTA

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Prometrium

Products Affected

- PROMETRIUM

QL Criteria	2 caps Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Propafenone HCl ER

Products Affected

- *propafenone hcl er*

QL Criteria	2 caps Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Protopic

Products Affected

- PROTOPIC

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	Children less than 2 years of age, children and adults with weakened immune systems, documentation of hypersensitivity to pimecrolimus, tacrolimus or any component in the product, and Nethertons syndrome
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Authorization beyond 1 year requires documentation that the benefit exceeds the potential risk associated with topical calcineurin inhibitors as defined in the black box warning
QL Criteria	60 grams Per 1 fill
Notes/References	
Revision Date	Prior Authorization: September 29, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Proventil HFA

Products Affected

- PROVENTIL HFA

PA Criteria	Criteria Details
Covered Uses	Asthma (Bronchospasm: Treatment and Prophylaxis)
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	Step Therapy
ST Criteria	Documented step through one week each of VENTOLIN HFA AND PROAIR
QL Criteria	2 inhalers Per 1 fill
Notes/References	
Revision Date	Prior Authorization: August 11, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Provigil

Products Affected

- PROVIGIL

PA Criteria	Criteria Details
Covered Uses	Excessive daytime sleepiness associated with narcolepsy, Excessive daytime sleepiness associated with obstructive sleep apnea/hypopnea syndrome (OSAHS), Shift Work Sleep Disorder
Exclusion Criteria	
Required Medical Information	FOR NARCOLEPSY: Documentation of diagnostic testing and clinical notations supporting diagnosis of Narcolepsy, such as MSLT, clinical progress notes, etc. (Failure to adequately support the diagnosis of narcolepsy may result in denial of coverage). FOR OSAHS: The prescribing physician is a sleep specialist, ear, nose and throat, neurologist or pulmonologist or has obtained a consult from a sleep specialist, and a Standard Diagnostic Nocturnal Polysomnography (NPSG) has confirmed the diagnosis of OSAHS, and the patient has received nasal continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BIPAP) for at least 1 month, and CPAP or BIPAP therapy must be continued on a routine basis in combination with armodafinil therapy, and the daytime fatigue is significantly impacting, impairing, or compromising the patients ability to function normally, and the prescribing physician has established a patient care plan to treat the cause of OSAHS in conjunction with treating the daily fatigue, and patient must be compliant with recommendations for OSAHS treatment.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	
QL Criteria	2 tabs Per 1 day
Notes/References	
Revision Date	Prior Authorization: November 09, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2015 Aetna Value Plan
(Updated 12/01/2015)

PROzac

Products Affected

- PROZAC ORAL CAPSULE 40 MG

QL Criteria	2 caps Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

PROzac

Products Affected

- PROZAC ORAL CAPSULE 10 MG

QL Criteria	1 cap Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

PROzac

Products Affected

- PROZAC ORAL CAPSULE 20 MG

QL Criteria	4 caps Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

PROzac Weekly

Products Affected

- PROZAC WEEKLY

QL Criteria	4 caps Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Pulmicort

Products Affected

- PULMICORT

PA Criteria	Criteria Details
Covered Uses	Asthma
Exclusion Criteria	
Required Medical Information	For ages 5-8 documented inability to use metered dose inhalers
Age Restrictions	Less than 8 years of age
Prescriber Restrictions	
Coverage Duration	Up to the age of 8
Other Criteria	No prior authorization required for children 1-4 years of age. Medical Exception for Pulmicort Respules: Covered for topical steroid treatment of eosinophilic esophagitis for which other treatments have been unsatisfactory
Notes/References	
Revision Date	Prior Authorization: November 24, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Pulmicort Flexhaler

Products Affected

- PULMICORT FLEXHALER

PA Criteria	Criteria Details
Covered Uses	Asthma
Exclusion Criteria	
Required Medical Information	For ages 5-8 documented inability to use metered dose inhalers
Age Restrictions	Less than 8 years of age
Prescriber Restrictions	
Coverage Duration	Up to the age of 8
Other Criteria	No prior authorization required for children 1-4 years of age. Medical Exception for Pulmicort Respules: Covered for topical steroid treatment of eosinophilic esophagitis for which other treatments have been unsatisfactory
QL Criteria	1 inhaler Per 1 month
Notes/References	
Revision Date	Prior Authorization: November 24, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Pulmozyme

Products Affected

- PULMOZYME

QL Criteria	60 units Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Purixan

Products Affected

- PURIXAN

QL Criteria	1 bottle Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Qnasl

Products Affected

- QNASL

ST Criteria	Trial of 2 weeks each of 2 of the following: fluticasone propionate OR flunisolide nasal spray OR Triamcinolone OR Nasacort 24HR OTC (choose 1) AND Nasonex
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Qnasl Childrens

Products Affected

- QNASL CHILDRENS

ST Criteria	Trial of 2 weeks each of 2 of the following: fluticasone propionate OR flunisolide nasal spray OR Triamcinolone OR Nasacort 24HR OTC (choose 1) AND Nasonex
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Qualaquin

Products Affected

- QUALAQUIN

QL Criteria	42 caps Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Quartette

Products Affected

- QUARTETTE

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Quasense

Products Affected

- QUASENSE

QL Criteria	1.5 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Qudexy XR

Products Affected

- QUDEXY XR

ST Criteria	trial of one month of the preferred generic alternative, topiramate
QL Criteria	1 capsule Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

QUetiapine Fumarate

Products Affected

- *quetiapine fumarate oral tablet 400 mg, 300 mg*

QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

QUetiapine Fumarate

Products Affected

- *quetiapine fumarate oral tablet 50 mg, 100 mg*

QL Criteria	3 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

QUetiapine Fumarate

Products Affected

- *quetiapine fumarate oral tablet 25 mg*

QL Criteria	6 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

QUetiapine Fumarate

Products Affected

- *quetiapine fumarate oral tablet 200 mg*

QL Criteria	4 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Quillivant XR

Products Affected

- QUILLIVANT XR

PA Criteria	Criteria Details
Covered Uses	Attention deficit disorder, Attention deficit hyperactivity disorder
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis of adult ADD or ADHD OR documentation of a diagnosis of childhood ADHD onset with history of previous treatment, and documentation of symptoms significantly impacting, impairing, or compromising the patient's ability to function normally (i.e., attend/maintain academic enrollment or employment), and documentation of intolerance to appropriately dosed and administered regular/immediate acting stimulants.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Step Therapy
ST Criteria	Documented step through 14 days each of THREE of AMPHETAMINE/DEXTROAMPHETAMINE/ SR, DEXMETHYLPHENIDATE/ SR, DEXTROAMPHETAMINE, METHAMPHETAMINE, METHYLPHENIDATE/ ER/ SR, STRATTERA, OR VYVANSE
QL Criteria	1 bottle Per 1 fill
Notes/References	
Revision Date	Prior Authorization: October 05, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

RABEprazole Sodium

Products Affected

- *rabeprazole sodium*

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ranexa

Products Affected

- RANEXA

QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Rapaflo

Products Affected

- RAPAFLU

QL Criteria	1 cap Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ravicti

Products Affected

- RAVICTI

QL Criteria	20 bottles Per 30 Dayss
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Rayos

Products Affected

- RAYOS

ST Criteria	Documented step through PREDNISONE
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Razadyne ER

Products Affected

- RAZADYNE ER

QL Criteria	1 cap Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Rebetol

Products Affected

- REBETOL ORAL SOLUTION

QL Criteria	500 ml Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Reclipsen

Products Affected

- RECLIPSEN

QL Criteria	1.5 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Rectiv

Products Affected

- RECTIV

QL Criteria	30 grams Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Relenza Diskhaler

Products Affected

- RELENZA DISKHALER

QL Criteria	20 inhalations Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Relpax

Products Affected

- RELPAX

ST Criteria	Documented step through one month of THREE of the following: NARATRIPTAN, RIZATRIPTAN, SUMATRIPTAN, ZOLMITRIPTAN (NSO)
QL Criteria	6 tabs Per 30 days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Remeron SolTab

Products Affected

- REMERON SOLTAB

QL Criteria	1 EA Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Repatha

Products Affected

- REPATHA

QL Criteria	2 injections Per 28 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Repatha SureClick

Products Affected

- REPATHA SURECLICK

QL Criteria	2 injections Per 28 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Requip XL

Products Affected

- REQUIP XL ORAL TABLET EXTENDED
RELEASE 24 HR* 6 MG, 8 MG, 2 MG, 4 MG

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Requip XL

Products Affected

- REQUIP XL ORAL TABLET EXTENDED
RELEASE 24 HR* 12 MG

QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Rescula

Products Affected

- RESCULA

PA Criteria	Criteria Details
Covered Uses	open-angle glaucoma ocular hypertension
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	Step Therapy
QL Criteria	5 ML Per 30 days
Notes/References	
Revision Date	Prior Authorization: August 11, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Restasis

Products Affected

- RESTASIS

QL Criteria	2 vials Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Restoril

Products Affected

- RESTORIL ORAL CAPSULE 22.5 MG, 7.5 MG

QL Criteria	1 cap Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Retin-A

Products Affected

- RETIN-A

QL Criteria	50 grams Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Retin-A Micro

Products Affected

- RETIN-A MICRO

ST Criteria	Documented step through RETIN-A*
QL Criteria	50 grams Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Retin-A Micro Pump

Products Affected

- RETIN-A MICRO PUMP

ST Criteria	Documented step through RETIN-A*
QL Criteria	50 GM Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Revatio

Products Affected

- REVATIO ORAL TABLET

QL Criteria	3 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Revatio

Products Affected

- REVATIO ORAL SUSPENSION
RECONSTITUTED

QL Criteria	2 bottles Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Revlimid

Products Affected

- REVLIMID

QL Criteria	1 cap Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Rexulti

Products Affected

- REXULTI

QL Criteria	1 tablet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Reyataz

Products Affected

- REYATAZ ORAL CAPSULE 150 MG, 300 MG

QL Criteria	1 cap Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Reyataz

Products Affected

- REYATAZ ORAL CAPSULE 200 MG

QL Criteria	2 caps Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Rhinocort Aqua

Products Affected

- RHINOCORT AQUA

ST Criteria	Trial of 2 weeks each of 2 of the following: fluticasone propionate OR flunisolide nasal spray OR Triamcinolone OR Nasacort 24HR OTC (choose 1) AND Nasonex
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Risedronate Sodium

Products Affected

- *risedronate sodium oral tablet delayed release*
- *risedronate sodium oral tablet 35 mg*

QL Criteria	4 tablets Per 28 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Risedronate Sodium

Products Affected

- *risedronate sodium oral tablet 5 mg, 30 mg*

QL Criteria	1 tablet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Risedronate Sodium

Products Affected

- *risedronate sodium oral tablet 150 mg*

ST Criteria	Documented trial and failure of 1 month of generic alendronate weekly (70mg weekly dose)
QL Criteria	1 tablet Per 28 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

RisperDAL

Products Affected

- RISPERDAL ORAL TABLET 1 MG, 2 MG, 0.25 MG, 0.5 MG

QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

RisperDAL

Products Affected

- RISPERDAL ORAL SOLUTION

ST Criteria	Documented step through RISPERDAL* ORAL TABLET
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

RisperDAL

Products Affected

- RISPERDAL ORAL TABLET 4 MG

QL Criteria	4 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

RisperDAL

Products Affected

- RISPERDAL ORAL TABLET 3 MG

QL Criteria	3 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

RisperDAL M-TAB

Products Affected

- RISPERDAL M-TAB ORAL TABLET
DISPERSIBLE 2 MG, 1 MG, 3 MG, 0.5 MG

ST Criteria	Trial of 1 month each of: 1 generic (aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone) PLUS Latuda
QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

RisperDAL M-TAB

Products Affected

- RISPERDAL M-TAB ORAL TABLET
DISPERSIBLE 4 MG

ST Criteria	Trial of 1 month each of: 1 generic (aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone) PLUS Latuda
QL Criteria	4 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

RisperiDONE

Products Affected

- *risperidone oral tablet 1 mg, 0.25 mg, 0.5 mg, 2 mg*
- *risperidone oral tablet dispersible 1 mg, 0.5 mg, 2 mg*

QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

RisperiDONE

Products Affected

- *risperidone oral tablet 3 mg*
- *risperidone oral tablet dispersible 3 mg*

QL Criteria	3 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

RisperiDONE

Products Affected

- *risperidone oral tablet dispersible 0.25 mg*

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

RisperiDONE

Products Affected

- *risperidone oral tablet dispersible 4 mg*
- *risperidone oral tablet 4 mg*

QL Criteria	4 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

RisperiDONE M-TAB

Products Affected

- RISPERIDONE M-TAB ORAL TABLET
DISPERSIBLE 1 MG, 0.5 MG, 2 MG

QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

RisperiDONE M-TAB

Products Affected

- RISPERIDONE M-TAB ORAL TABLET
DISPERSIBLE 3 MG

QL Criteria	3 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

RisperiDONE M-TAB

Products Affected

- RISPERIDONE M-TAB ORAL TABLET
DISPERSIBLE 4 MG

QL Criteria	4 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ritalin

Products Affected

- RITALIN

ST Criteria	Documented step through 14 days each of THREE of AMPHETAMINE/DEXTROAMPHETAMINE/ SR, DEXMETHYLPHENIDATE/ SR, DEXTROAMPHETAMINE, METHAMPHETAMINE, METHYLPHENIDATE/ ER/ SR, STRATTERA, OR VYVANSE
QL Criteria	3 tab Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ritalin LA

Products Affected

- RITALIN LA ORAL CAPSULE EXTENDED RELEASE 24 HOUR 10 MG, 40 MG, 20 MG

PA Criteria	Criteria Details
Covered Uses	Attention deficit disorder, Attention deficit hyperactivity disorder
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis of adult ADD or ADHD OR documentation of a diagnosis of childhood ADHD onset with history of previous treatment, and documentation of symptoms significantly impacting, impairing, or compromising the patient's ability to function normally (i.e., attend/maintain academic enrollment or employment), and documentation of intolerance to appropriately dosed and administered regular/immediate acting stimulants.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Step Therapy
ST Criteria	Documented step through 14 days each of THREE of AMPHETAMINE/DEXTROAMPHETAMINE/ SR, DEXMETHYLPHENIDATE/ SR, DEXTROAMPHETAMINE, METHAMPHETAMINE, METHYLPHENIDATE/ ER/ SR, STRATTERA, OR VYVANSE
QL Criteria	1 cap Per 1 day
Notes/References	
Revision Date	Prior Authorization: October 05, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ritalin LA

Products Affected

- RITALIN LA ORAL CAPSULE EXTENDED
RELEASE 24 HOUR 30 MG

PA Criteria	Criteria Details
Covered Uses	Attention deficit disorder, Attention deficit hyperactivity disorder
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis of adult ADD or ADHD OR documentation of a diagnosis of childhood ADHD onset with history of previous treatment, and documentation of symptoms significantly impacting, impairing, or compromising the patient's ability to function normally (i.e., attend/maintain academic enrollment or employment), and documentation of intolerance to appropriately dosed and administered regular/immediate acting stimulants.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Step Therapy
ST Criteria	Documented step through 14 days each of THREE of AMPHETAMINE/DEXTROAMPHETAMINE/ SR, DEXMETHYLPHENIDATE/ SR, DEXTROAMPHETAMINE, METHAMPHETAMINE, METHYLPHENIDATE/ ER/ SR, STRATTERA, OR VYVANSE
QL Criteria	2 caps Per 1 day
Notes/References	
Revision Date	Prior Authorization: October 05, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ritalin LA

Products Affected

- RITALIN LA ORAL CAPSULE EXTENDED
RELEASE 24 HOUR 60 MG

QL Criteria	1 capsule Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ritalin SR

Products Affected

- RITALIN SR

ST Criteria	Documented step through 14 days each of THREE of AMPHETAMINE/DEXTROAMPHETAMINE/ SR, DEXMETHYLPHENIDATE/ SR, DEXTROAMPHETAMINE, METHAMPHETAMINE, METHYLPHENIDATE/ ER/ SR, STRATTERA, OR VYVANSE
QL Criteria	3 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Rivastigmine

Products Affected

- *rivastigmine*

QL Criteria	1 patch Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Rizatriptan Benzoate

Products Affected

- *rizatriptan benzoate*

QL Criteria	12 tabs Per 30 days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

ROPINIRole HCl ER

Products Affected

- *ropinirole hcl er oral tablet extended release*
24 hr* 2 mg, 4 mg, 6 mg, 8 mg

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

ROPINIRole HCl ER

Products Affected

- *ropinirole hcl er oral tablet extended release*
24 hr 12 mg*

QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Rozerem

Products Affected

- ROZEREM

QL Criteria	1 tab Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Rythmol SR

Products Affected

- RYTHMOL SR

QL Criteria	2 caps Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Sabril

Products Affected

- SABRIL

PA Criteria	Criteria Details
Covered Uses	Infantile spasms Refractory complex partial seizures
Exclusion Criteria	
Required Medical Information	For infantile spasms A. Documentation of infantile spasms B. Age between 1 month and 2 years of age C. Documentation of Sabril being used as monotherapy For refractory complex partial seizures A. Documentation of refractory complex partial seizures established by a neurologist B. Age 10 years or greater C. Documentation of trial and failure of at least four anticonvulsants indicated for partial seizures or inability to use all existing anticonvulsants D. Documentation of use in conjunction with at least one other anticonvulsant
Age Restrictions	See Required Medical Information
Prescriber Restrictions	See Required Medical Information
Coverage Duration	Infantile spasms 1 month Refractory complex partial seizures 1 year
Other Criteria	
QL Criteria	6 packs Per 1 day
Notes/References	
Revision Date	Prior Authorization: August 11, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Safyral

Products Affected

- SAFYRAL

QL Criteria	1.5 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Samsca

Products Affected

- SAMSCA ORAL TABLET 30 MG

QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Samsca

Products Affected

- SAMSCA ORAL TABLET 15 MG

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Sanctura XR

Products Affected

- SANCTURA XR

QL Criteria	1 cap Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Sancuso

Products Affected

- SANCUSO

QL Criteria	1 patch Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

SandoSTATIN

Products Affected

- SANDOSTATIN

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Saphris

Products Affected

- SAPHRIS

QL Criteria	2 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Saphris

Products Affected

- SAPHRIS

ST Criteria	Trial of 1 month each of: 1 generic (aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone) PLUS Latuda
QL Criteria	2 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Savaysa

Products Affected

- SAVAYSA

ST Criteria	Documented Trial of Eliquis AND Xarelto
QL Criteria	1 tablet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Savella

Products Affected

- SAVELLA

PA Criteria	Criteria Details
Covered Uses	Fibromyalgia
Exclusion Criteria	
Required Medical Information	A. Documentation of a trial of non-pharmacologic therapies (cognitive behavioral therapies, exercise, etc.) AND B. Documentation of a trial of THREE of the following drugs/drug classes (each agent must be from a different class) 1. tricyclic antidepressant (e.g. amitriptyline), 2. muscle relaxant (e.g. cyclobenzaprine), 3. SSRI, 4. SNRI, 5. gabapentin, 6. tramadol
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	Step Therapy
ST Criteria	Documented step through one month each of THREE of the following drugs/drug classes: ONE tricyclic antidepressant (i.e., AMITRIPTYLINE), ONE muscle relaxant (i.e., CYCLOBENZAPRINE), SSRI (i.e., CITALOPRAM, ONE SNRI (i.e., VENLAFAXINE), GABAPENTIN, or TRAMADOL (NSO)
QL Criteria	2 tabs Per 1 day
Notes/References	
Revision Date	Prior Authorization: August 11, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Savella Titration Pack

Products Affected

- SAVELLA TITRATION PACK

PA Criteria	Criteria Details
Covered Uses	Fibromyalgia
Exclusion Criteria	
Required Medical Information	A. Documentation of a trial of non-pharmacologic therapies (cognitive behavioral therapies, exercise, etc.) AND B. Documentation of a trial of THREE of the following drugs/drug classes (each agent must be from a different class) 1. tricyclic antidepressant (e.g. amitriptyline), 2. muscle relaxant (e.g. cyclobenzaprine), 3. SSRI, 4. SNRI, 5. gabapentin, 6. tramadol
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	Step Therapy
ST Criteria	Documented step through one month each of THREE of the following drugs/drug classes: ONE tricyclic antidepressant (i.e., AMITRIPTYLINE), ONE muscle relaxant (i.e., CYCLOBENZAPRINE), SSRI (i.e., CITALOPRAM, ONE SNRI (i.e., VENLAFAXINE), GABAPENTIN, or TRAMADOL (NSO)
QL Criteria	2 tabs Per 1 day
Notes/References	
Revision Date	Prior Authorization: August 11, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Saxenda

Products Affected

- SAXENDA

PA Criteria	Criteria Details
Covered Uses	Weightloss
Exclusion Criteria	Members without weightloss benefit. Members not in a state where coverage is mandated.
Required Medical Information	Member must have a body mass index greater than 30 kilograms per meter squared or a body mass index greater than 27 kilograms per meter squared with one or more of the following obesity related risk factors considered serious enough to warrant pharmacotherapy: Hypertension (systolic blood pressure greater than 140 mm Hg or diastolic blood pressure greater than 90 mm Hg on more than one occasion), Dyslipidemia (LDL cholesterol greater than 160 mg/dL, HDL cholesterol less than 35 mg/dL, or Triglycerides greater than 400 mg/dL), Coronary Heart Disease, Type 2 Diabetes Mellitus, or Obstructive Sleep Apnea (OSA)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Initial Coverage 16 weeks
Other Criteria	For reauthorization after initial 16 week coverage: Member has experienced a documented weight loss of at least 4%.
ST Criteria	A documented trial of TWO of the following preferred oral alternatives: Belviq (lorcaserin), Qsymia (phentermine/topiramate), phentermine, phendimetrazine, diethylpropion, benzphetamine)
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Seasonale

Products Affected

- SEASONALE

QL Criteria	1.5 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Seasonique

Products Affected

- SEASONIQUE

QL Criteria	1.5 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Selzentry

Products Affected

- SELZENTRY

QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Sensipar

Products Affected

- SENSIPAR

ST Criteria	Documented step through ROCALTROL* (covered without trials for hyperparathyroidism & parathyroid carcinoma)
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Serevent Diskus

Products Affected

- SEREVENT DISKUS

QL Criteria	1 box Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

SEROquel

Products Affected

- SEROQUEL ORAL TABLET 400 MG

QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

SEROquel

Products Affected

- SEROQUEL ORAL TABLET 200 MG

QL Criteria	4 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

SEROquel

Products Affected

- SEROQUEL ORAL TABLET 25 MG, 100 MG, 300 MG, 50 MG

QL Criteria	3 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

SEROquel XR

Products Affected

- SEROQUEL XR ORAL TABLET
EXTENDED RELEASE 24 HR* 300 MG, 400
MG

PA Criteria	Criteria Details
Covered Uses	Major depressive disorder Bipolar disorder or schizophrenia
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	Step Therapy
QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 11, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

SEROquel XR

Products Affected

- SEROQUEL XR ORAL TABLET
EXTENDED RELEASE 24 HR* 50 MG

PA Criteria	Criteria Details
Covered Uses	Major depressive disorder Bipolar disorder or schizophrenia
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	Step Therapy
QL Criteria	6 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 11, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

SEROquel XR

Products Affected

- SEROQUEL XR ORAL TABLET
EXTENDED RELEASE 24 HR* 200 MG, 150
MG

PA Criteria	Criteria Details
Covered Uses	Major depressive disorder Bipolar disorder or schizophrenia
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	Step Therapy
QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 11, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Sertraline HCl

Products Affected

- *sertraline hcl oral tablet 100 mg*

QL Criteria	2 tabs Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Sertraline HCl

Products Affected

- *sertraline hcl oral tablet 25 mg*

QL Criteria	1 tab Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Sertraline HCl

Products Affected

- *sertraline hcl oral tablet 50 mg*

QL Criteria	1.5 tag Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Sertraline HCl

Products Affected

- *sertraline hcl oral concentrate*

QL Criteria	10 ML Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Signifor

Products Affected

- SIGNIFOR

QL Criteria	2 amps Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Signifor LAR

Products Affected

- SIGNIFOR LAR

QL Criteria	1 injections Per 28 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Sildenafil Citrate

Products Affected

- *sildenafil citrate oral*

QL Criteria	3 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Simbrinza

Products Affected

- SIMBRINZA

QL Criteria	1 bottle Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Simcor

Products Affected

- SIMCOR

QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Simponi

Products Affected

- SIMPONI

QL Criteria	1 pen Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Simvastatin

Products Affected

- *simvastatin oral*

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Singular

Products Affected

- SINGULAIR

QL Criteria	1 pack Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Singular

Products Affected

- SINGULAIR

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Sirturo

Products Affected

- SIRTURO

PA Criteria	Criteria Details
Covered Uses	Multi-drug resistant tuberculosis
Exclusion Criteria	
Required Medical Information	
Age Restrictions	18 years or greater
Prescriber Restrictions	
Coverage Duration	6 months
Other Criteria	
QL Criteria	188 tabs Per 365 dayss
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Sivextro

Products Affected

- SIVEXTRO ORAL

QL Criteria	6 tabs Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Skelaxin

Products Affected

- SKELAXIN

QL Criteria	56 tabs Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Skelid

Products Affected

- SKELID

QL Criteria	2 per Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Skyla

Products Affected

- SKYLA

QL Criteria	1 unit Per 1 year
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Sonata

Products Affected

- SONATA

QL Criteria	1 cap Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Soolantra

Products Affected

- SOOLANTRA

ST Criteria	A documented trial of one month each of any of the preferred topical generic alternatives, metronidazole OR sulfacetamide sodium with sulfu
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Soriatane

Products Affected

- SORIATANE

QL Criteria	2 caps Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Sovaldi

Products Affected

- SOVALDI

QL Criteria	1 tab Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Spiriva HandiHaler

Products Affected

- SPIRIVA HANDIHALER

QL Criteria	1 cap Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Spiriva Respimat

Products Affected

- SPIRIVA RESPIMAT

QL Criteria	1 inhaler Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Sporanox

Products Affected

- SPORANOX ORAL CAPSULE

QL Criteria	1 cap Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Sporanox Pulsepak

Products Affected

- SPORANOX PULSEPAK

QL Criteria	1 cap Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Sprintec 28

Products Affected

- SPRINTEC 28

QL Criteria	1.5 tabs Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Sprix

Products Affected

- SPRIX

QL Criteria	5 bottles Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Sprycel

Products Affected

- SPRYCEL ORAL TABLET 100 MG, 140 MG

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Sprycel

Products Affected

- SPRYCEL ORAL TABLET 20 MG, 70 MG, 50 MG, 80 MG

QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Sronyx

Products Affected

- SRONYX

QL Criteria	1.5 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Staxyn

Products Affected

- STAXYN

ST Criteria	Documented step through CIALIS
QL Criteria	6 tabs Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Stendra

Products Affected

- STENDRA

ST Criteria	Documented step through CIALIS
QL Criteria	6 tabs Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Stimate

Products Affected

- STIMATE

PA Criteria	Criteria Details
Covered Uses	von Willebrand's disease Type 1 Hemophilia A
Exclusion Criteria	
Required Medical Information	Documentation of greater than 5% Factor VIII coagulant activity
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 months, extended approval based on therapeutic response
Other Criteria	
Notes/ References	
Revision Date	Prior Authorization: August 11, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Stiolto Respimat

Products Affected

- STIOLTO RESPIMAT

QL Criteria	1 inhaler Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Stivarga

Products Affected

- STIVARGA

QL Criteria	4 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Strattera

Products Affected

- STRATTERA ORAL CAPSULE 25 MG, 10 MG, 18 MG, 40 MG, 60 MG

QL Criteria	2 caps Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Strattera

Products Affected

- STRATTERA ORAL CAPSULE 100 MG, 80 MG

QL Criteria	1 cap Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Striant

Products Affected

- STRIANT

PA Criteria	Criteria Details
Covered Uses	Primary hypogonadism or hypogonadotropic hypogonadism, gender dysphoria, gender reassignment
Exclusion Criteria	patient with carcinoma of the breast or suspected carcinoma of the prostate, patient will be using therapy for muscle building purposes
Required Medical Information	Documented diagnosis of primary hypogonadism or hypogonadotropic hypogonadism as defined by either one of the following: (1) Member has undergone bilateral orchiectomy (no total fasting serum testosterone levels required), or (2) Having two consecutive low total fasting serum testosterone levels (below the testing laboratory's reference range or below 300ng/dl if reference ranges are not available), or for persons with low normal total testosterone levels (above 300 ng/dL but below 400 ng/dL), two consecutive low free or bioavailable fasting serum testosterone levels (below the testing laboratory's reference range or less than 225 picomoles per liter (pmol/L) (6 ng/dL) if reference ranges are not available)(Note: Two morning samples drawn between 7:00 a.m. and 10:00 a.m. obtained on two different days is required for NEW starts only), or (3) Member has a documented diagnosis of gender dysphoria or documentation of undergoing gender reassignment surgery.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	Documented step through one month each of ANDROGEL AND TESTIM
QL Criteria	2 buccals Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 29, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2015 Aetna Value Plan
(Updated 12/01/2015)

Stribild

Products Affected

- STRIBILD

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Striverdi Respimat

Products Affected

- STRIVERDI RESPIMAT

PA Criteria	Criteria Details
Covered Uses	Chronic Obstructive Pulmonary Disorder (COPD)
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Step Therapy
ST Criteria	trial of one month of one of the preferred alternatives Foradil OR Serevent
QL Criteria	1 inhaler Per 30 Days
Notes/References	
Revision Date	Prior Authorization: September 09, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Suboxone

Products Affected

- SUBOXONE SUBLINGUAL FILM

PA Criteria	Criteria Details
Covered Uses	Opioid dependence
Exclusion Criteria	<p>Medical literature does not support the concurrent use of opioids/Tramadol as part of opioid drug dependence treatment. Abstinence of opioids/Tramadol is required both during and following therapy with Suboxone/Subutex/Zubsolv/Bunavail/buprenorphine, and will only be covered when determined to be medically necessary (defined as short-term use during and following opioid dependence treatment for the treatment of acute pain related to surgery, dental procedure, or an emergency situation or for long-term use following opioid dependence treatment for the treatment of chronic pain. For long term use, the member must be treated by a single provider of their choice, opioids will only be covered when prescribed by this single provider, and this single provider is aware of past buprenorphine use for opioid dependence treatment in which an opioid dependence diagnosis). Physicians can contact (855) 746-0013 with any information related to the medical necessity for opioid/Tramadol therapy.</p>
Required Medical Information	<p>Prescriber provides verbal verification of patient's current and ongoing enrollment in an outpatient drug addiction treatment program/ counseling. If the member is currently enrolled, the approval will be 6 months. If the member is NOT enrolled (answer=no) and prescriber provides verbal verification of patient's agreed commitment to become enrolled in an acceptable drug addiction treatment program counseling, the approval will be for 2 months (Note: 1 time approval ONLY). If after 2 months member does not enroll in a program, then all future requests will be denied until member enrolls in a program.</p>
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months = current enrollement

PA Criteria	Criteria Details
Other Criteria	<p>For coverage of additional quantities, the following conditions must be met: FOR BUPRENORPHONE SL: Member is pregnant or breastfeeding (Up to 120 tablets in 30 days) or member has a documented contraindication, intolerance, or allergy to buprenorphine-naloxone sublingual tablet or Suboxone (will allow up to 90 tablets per month for max length of approval of 6 months). FOR SUBOXONE OR BUPRENORPHINE-NALOXONE SUBLINGUAL TABLET 2mg/0.5mg: Member's dose is being titrated by physician for 7 day induction therapy (max dose 12 mg/daily for total of 42 tablets/films in 7 days). FOR ZUBSOLBV 1.4mg/0.36mg: Member's dose is being titrated by physician for 7 day induction therapy (max dose 8.4 mg/daily for total of 42 tablets/films in 7 days). Note: Aetna considers the following as acceptable programs: Outpatient drug addiction treatment programs and/or counseling, 12- step programs focused on "drug" addiction such as Narcotics Anonymous (N.A.), Other accepted programs can be found at http://findtreatment.samhsa.gov/TreatmentLocator/faces/quickSearch.jspx. Aetna considers the following as non-acceptable programs: On-line programs such as Here to Help, 12-step programs that are not focused on "drug" addiction (ex: Alcoholics Anonymous).</p>
QL Criteria	2 film Per 1 day
Notes/References	
Revision Date	Prior Authorization: November 30, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Subsys

Products Affected

- SUBSYS

PA Criteria	Criteria Details
Covered Uses	For pain due to malignant diagnosis only
Exclusion Criteria	Use in non-malignant pain
Required Medical Information	A. Documentation of already receiving and who are tolerant to opioid therapy, and documentation on intolerance of two (2) other immediate-release opioids including morphine, hydrocodone, oxycodone, or hydromorphone.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months
Other Criteria	FOR SUBSYS: Documentation of intolerance to Actiq. FOR ABSTRAL, FENTORA, LAZANDA, and ONSOLIS: Documentation of intolerance to Actiq AND Subsys.
QL Criteria	8 sprays Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 29, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Sular

Products Affected

- SULAR ORAL TABLET EXTENDED
RELEASE 24 HR* 34 MG, 8.5 MG, 17 MG

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Sulfacetamide Sodium-Sulfur

Products Affected

- *sulfacetamide sodium-sulfur external lotion*
- *sulfacetamide sodium-sulfur external liquid†*
9.8-4.8 %
- *sulfacetamide sodium-sulfur external cream*
9.8-4.8 %

ST Criteria	Documented step through TWO GENERIC SULFACETAMIDE SODIUM WITH SULFUR products (any formulation)
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

SulfaSALazine

Products Affected

- *sulfasalazine oral*

QL Criteria	8 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Sulfazine

Products Affected

- SULFAZINE

QL Criteria	8 tabs Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

SUMAtriptan

Products Affected

- *sumatriptan nasal*

QL Criteria	6 sprays Per 30 days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

SUMAtriptan Succinate

Products Affected

- *sumatriptan succinate oral*

QL Criteria	9 tabs Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

SUMatriptan Succinate

Products Affected

- *sumatriptan succinate subcutaneous**

QL Criteria	2 boxes Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

SUMatriptan Succinate Refill

Products Affected

- *sumatriptan succinate refill*

QL Criteria	2 boxes Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Suprax

Products Affected

- SUPRAX ORAL TABLET CHEWABLE

QL Criteria	20 tabs Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Suprax

Products Affected

- SUPRAX ORAL SUSPENSION
RECONSTITUTED 100 MG/5ML, 200
MG/5ML

QL Criteria	1 bottle Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Sutent

Products Affected

- SUTENT

QL Criteria	1 cap Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Syeda

Products Affected

- SYEDA

QL Criteria	1.5 tab Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Symbicort

Products Affected

- SYMBICORT

QL Criteria	1 inhaler Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Symbyax

Products Affected

- SYMBYAX

QL Criteria	1 cap Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

SymlinPen 120

Products Affected

- SYMLINPEN 120

QL Criteria	4 pens Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

SymlinPen 60

Products Affected

- SYMLINPEN 60

QL Criteria	4 pens Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Synjardy

Products Affected

- SYNJARDY

ST Criteria	Trial of 1 month of Invokana (single entity or combination)
QL Criteria	2 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Taclonex

Products Affected

- TACLONEX EXTERNAL OINTMENT

ST Criteria	Dovonex AND a medium to high potency topical steroid
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tacrolimus

Products Affected

- *tacrolimus external*

QL Criteria	60 grams Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tafinlar

Products Affected

- TAFINLAR

QL Criteria	4 caps Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tamiflu

Products Affected

- TAMIFLU ORAL SUSPENSION
RECONSTITUTED 6 MG/ML

QL Criteria	3 bottles Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tamiflu

Products Affected

- TAMIFLU ORAL CAPSULE

QL Criteria	20 caps Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tanzeum

Products Affected

- TANZEUM

PA Criteria	Criteria Details
Covered Uses	Type 2 Diabetes Mellitus
Exclusion Criteria	Victoza, Tanzeum, Trulicity are not covered for members with: 1) Diagnosis of metabolic syndrome or any other pre-diabetic diagnosis 2) Diagnosis of Type 1 Diabetes 3) Treatment of diabetic ketoacidosis 4) Pediatric patients 5) Patients with severe gastrointestinal diseases, including gastroparesis. 6) Patients with multiple endocrine neoplasia syndrome type 2 (MEN2) 7) History of family history of medullary thyroid carcinoma (MTC) 8) Patients with a history of pancreatitis 9) Concurrent use with alpha-glucosidase inhibitors (Precose, Glyset) or DPP-4 inhibitors/Combo DPP4 Inhibitors (Januvia, Onglyza, Tradjenta, Janumet, Janumet XR, Jentaduento, Kombiglyze, Kazano, Juvisync)
Required Medical Information	A. A1C level is greater than 6.5%, and B. Have failed to obtain adequate glycemic control on 1) Maximum tolerated dose of metformin, unless the patient is not a candidate for metformin therapy: AND 2) A documented trial of one month of the preferred alternative, Bydureon
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	Step Therapy
ST Criteria	Documented step through one month of BYDUREON
QL Criteria	4 pens Per 1 month
Notes/References	
Revision Date	Prior Authorization: August 11, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tarceva

Products Affected

- TARCEVA

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tasigna

Products Affected

- TASIGNA

QL Criteria	4 caps Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tazorac

Products Affected

- TAZORAC

ST Criteria	Documented step through RETIN-A*
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Taztia XT

Products Affected

- TAZTIA XT ORAL CAPSULE EXTENDED
RELEASE 24 HOUR 300 MG, 360 MG, 180
MG, 120 MG

QL Criteria	1 cap Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Taztia XT

Products Affected

- TAZTIA XT ORAL CAPSULE EXTENDED
RELEASE 24 HOUR 240 MG

QL Criteria	2 caps Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tecfidera

Products Affected

- TECFIDERA

QL Criteria	2 caps Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Technivie

Products Affected

- TECHNIVIE

QL Criteria	2 capsules Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tekamlo

Products Affected

- TEKAMLO

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	Documentation of trial and failure with use of THREE (3) antihypertensive drugs from at least TWO (2) different therapeutics subclasses.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	<p>Examples of antihypertensive drugs listed by therapeutic subclasses</p> <p>Diuretics HydroDiuril, Microzide (hydrochlorothiazide), Hygroton (chlorthalidone), Diuril (chlorthiazide), Lasix (furosemide), Midamor (amiloride), Dyazide, Maxzide (triamterene-hydrochlorothiazide)</p> <p>Beta Blockers Tenormin (atenolol), Toprol XL (metoprolol succinate), Lopressor (metoprolol tartrate), Zebeta (bisoprolol), Coreg (carvedilol), Inderal LA (propranolol)</p> <p>Calcium Channel Blockers Adalat CC, Procardia XL (nifedipine), Calan, Isoptin, Verelan (verapamil), Cardizem, Cartia (diltiazem), Norvasc (amlodipine), Sular (nisoldipine), Plendil (felodipine)</p> <p>Angiotensin Converting Enzyme Inhibitors (ACEI) & ACEI combinations Prinivil, Zestril (lisinopril), Lotensin/Lotensin HCT/Lotrel (benazepril), Vasotec (enalapril), Accupril (quinapril), Mavik (trandolapril), Univas (moexipril)</p> <p>Angiotensin Receptor Blocker (ARB) & ARB combinations Cozaar/Hyzaar (losartan), Benicar/Benicar HCT (olmesartan), Micardis/Micardis HCT (telmisartan), Diovan/Diovan HCT (valsartan), Avapro/Avalide (irbesartan), Atacand/Atacand HCT (candesartan), Teveten /Teveten HCT (eprosartan), Edarbi/Edarbyclor (azilsartan)</p>
QL Criteria	1 tab Per 1 day
Notes/References	

2015 Aetna Value Plan
(Updated 12/01/2015)

Revision Date	Prior Authorization: August 11, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015
----------------------	---

Tekturna

Products Affected

- TEKTURNA

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	Documentation of trial and failure with use of THREE (3) antihypertensive drugs from at least TWO (2) different therapeutics subclasses.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	<p>Examples of antihypertensive drugs listed by therapeutic subclasses</p> <p>Diuretics HydroDiuril, Microzide (hydrochlorothiazide), Hygroton (chlorthalidone), Diuril (chlorthiazide), Lasix (furosemide), Midamor (amiloride), Dyazide, Maxzide (triamterene-hydrochlorothiazide)</p> <p>Beta Blockers Tenormin (atenolol), Toprol XL (metoprolol succinate), Lopressor (metoprolol tartrate), Zebeta (bisoprolol), Coreg (carvedilol), Inderal LA (propranolol)</p> <p>Calcium Channel Blockers Adalat CC, Procardia XL (nifedipine), Calan, Isoptin, Verelan (verapamil), Cardizem, Cartia (diltiazem), Norvasc (amlodipine), Sular (nisoldipine), Plendil (felodipine)</p> <p>Angiotensin Converting Enzyme Inhibitors (ACEI) & ACEI combinations Prinivil, Zestril (lisinopril), Lotensin/Lotensin HCT/Lotrel (benazepril), Vasotec (enalapril), Accupril (quinapril), Mavik (trandolapril), Univas (moexipril)</p> <p>Angiotensin Receptor Blocker (ARB) & ARB combinations Cozaar/Hyzaar (losartan), Benicar/Benicar HCT (olmesartan), Micardis/Micardis HCT (telmisartan), Diovan/Diovan HCT (valsartan), Avapro/Avalide (irbesartan), Atacand/Atacand HCT (candesartan), Teveten /Teveten HCT (eprosartan), Edarbi/Edarbyclor (azilsartan)</p>
QL Criteria	1 tab Per 1 day
Notes/References	

2015 Aetna Value Plan
(Updated 12/01/2015)

Revision Date	Prior Authorization: August 11, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015
----------------------	---

Tekturna HCT

Products Affected

- TEKTURNA HCT

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	Documentation of trial and failure with use of THREE (3) antihypertensive drugs from at least TWO (2) different therapeutics subclasses.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	<p>Examples of antihypertensive drugs listed by therapeutic subclasses</p> <p>Diuretics HydroDiuril, Microzide (hydrochlorothiazide), Hygroton (chlorthalidone), Diuril (chlorthiazide), Lasix (furosemide), Midamor (amiloride), Dyazide, Maxzide (triamterene-hydrochlorothiazide)</p> <p>Beta Blockers Tenormin (atenolol), Toprol XL (metoprolol succinate), Lopressor (metoprolol tartrate), Zebeta (bisoprolol), Coreg (carvedilol), Inderal LA (propranolol)</p> <p>Calcium Channel Blockers Adalat CC, Procardia XL (nifedipine), Calan, Isoptin, Verelan (verapamil), Cardizem, Cartia (diltiazem), Norvasc (amlodipine), Sular (nisoldipine), Plendil (felodipine)</p> <p>Angiotensin Converting Enzyme Inhibitors (ACEI) & ACEI combinations Prinivil, Zestril (lisinopril), Lotensin/Lotensin HCT/Lotrel (benazepril), Vasotec (enalapril), Accupril (quinapril), Mavik (trandolapril), Univas (moexipril)</p> <p>Angiotensin Receptor Blocker (ARB) & ARB combinations Cozaar/Hyzaar (losartan), Benicar/Benicar HCT (olmesartan), Micardis/Micardis HCT (telmisartan), Diovan/Diovan HCT (valsartan), Avapro/Avalide (irbesartan), Atacand/Atacand HCT (candesartan), Teveten /Teveten HCT (eprosartan), Edarbi/Edarbyclor (azilsartan)</p>
QL Criteria	1 tab Per 1 day
Notes/References	

2015 Aetna Value Plan
(Updated 12/01/2015)

Revision Date	Prior Authorization: August 11, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015
----------------------	---

Telmisartan

Products Affected

- *telmisartan*

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Telmisartan-Amlodipine

Products Affected

- *telmisartan-amlodipine*

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Telmisartan-HCTZ

Products Affected

- *telmisartan-hctz*

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Temazepam

Products Affected

- *temazepam oral capsule 22.5 mg, 7.5 mg*

QL Criteria	1 cap Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Testim

Products Affected

- TESTIM

PA Criteria	Criteria Details
Covered Uses	Primary hypogonadism or hypogonadotropic hypogonadism, gender dysphoria, gender reassignment
Exclusion Criteria	patient with carcinoma of the breast or suspected carcinoma of the prostate, patient will be using therapy for muscle building purposes
Required Medical Information	Documented diagnosis of primary hypogonadism or hypogonadotropic hypogonadism as defined by either one of the following: (1) Member has undergone bilateral orchiectomy (no total fasting serum testosterone levels required), or (2) Having two consecutive low total fasting serum testosterone levels (below the testing laboratory's reference range or below 300ng/dl if reference ranges are not available), or for persons with low normal total testosterone levels (above 300 ng/dL but below 400 ng/dL), two consecutive low free or bioavailable fasting serum testosterone levels (below the testing laboratory's reference range or less than 225 picomoles per liter (pmol/L) (6 ng/dL) if reference ranges are not available)(Note: Two morning samples drawn between 7:00 a.m. and 10:00 a.m. obtained on two different days is required for NEW starts only), or (3) Member has a documented diagnosis of gender dysphoria or documentation of undergoing gender reassignment surgery.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	10 grams Per 1 fill
Notes/References	
Revision Date	Prior Authorization: September 29, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Testosterone

Products Affected

- *testosterone transdermal 12.5 mg/act (1%)*

PA Criteria	Criteria Details
Covered Uses	Primary hypogonadism or hypogonadotropic hypogonadism, gender dysphoria, gender reassignment
Exclusion Criteria	patient with carcinoma of the breast or suspected carcinoma of the prostate, patient will be using therapy for muscle building purposes
Required Medical Information	Documented diagnosis of primary hypogonadism or hypogonadotropic hypogonadism as defined by either one of the following: (1) Member has undergone bilateral orchiectomy (no total fasting serum testosterone levels required), or (2) Having two consecutive low total fasting serum testosterone levels (below the testing laboratory's reference range or below 300ng/dl if reference ranges are not available), or for persons with low normal total testosterone levels (above 300 ng/dL but below 400 ng/dL), two consecutive low free or bioavailable fasting serum testosterone levels (below the testing laboratory's reference range or less than 225 picomoles per liter (pmol/L) (6 ng/dL) if reference ranges are not available)(Note: Two morning samples drawn between 7:00 a.m. and 10:00 a.m. obtained on two different days is required for NEW starts only), or (3) Member has a documented diagnosis of gender dysphoria or documentation of undergoing gender reassignment surgery.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	10 grams Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 29, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Testosterone

Products Affected

- *testosterone transdermal 10 mg/act (2%)*

PA Criteria	Criteria Details
Covered Uses	Primary hypogonadism or hypogonadotropic hypogonadism, gender dysphoria, gender reassignment
Exclusion Criteria	patient with carcinoma of the breast or suspected carcinoma of the prostate, patient will be using therapy for muscle building purposes
Required Medical Information	Documented diagnosis of primary hypogonadism or hypogonadotropic hypogonadism as defined by either one of the following: (1) Member has undergone bilateral orchiectomy (no total fasting serum testosterone levels required), or (2) Having two consecutive low total fasting serum testosterone levels (below the testing laboratory's reference range or below 300ng/dl if reference ranges are not available), or for persons with low normal total testosterone levels (above 300 ng/dL but below 400 ng/dL), two consecutive low free or bioavailable fasting serum testosterone levels (below the testing laboratory's reference range or less than 225 picomoles per liter (pmol/L) (6 ng/dL) if reference ranges are not available)(Note: Two morning samples drawn between 7:00 a.m. and 10:00 a.m. obtained on two different days is required for NEW starts only), or (3) Member has a documented diagnosis of gender dysphoria or documentation of undergoing gender reassignment surgery.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	4 grams Per 1 month
Notes/References	
Revision Date	Prior Authorization: September 29, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2015 Aetna Value Plan
(Updated 12/01/2015)

Testosterone

Products Affected

- *testosterone transdermal 25 mg/2.5gm (1%)*

PA Criteria	Criteria Details
Covered Uses	Primary hypogonadism or hypogonadotropic hypogonadism, gender dysphoria, gender reassignment
Exclusion Criteria	patient with carcinoma of the breast or suspected carcinoma of the prostate, patient will be using therapy for muscle building purposes
Required Medical Information	Documented diagnosis of primary hypogonadism or hypogonadotropic hypogonadism as defined by either one of the following: (1) Member has undergone bilateral orchiectomy (no total fasting serum testosterone levels required), or (2) Having two consecutive low total fasting serum testosterone levels (below the testing laboratory's reference range or below 300ng/dl if reference ranges are not available), or for persons with low normal total testosterone levels (above 300 ng/dL but below 400 ng/dL), two consecutive low free or bioavailable fasting serum testosterone levels (below the testing laboratory's reference range or less than 225 picomoles per liter (pmol/L) (6 ng/dL) if reference ranges are not available)(Note: Two morning samples drawn between 7:00 a.m. and 10:00 a.m. obtained on two different days is required for NEW starts only), or (3) Member has a documented diagnosis of gender dysphoria or documentation of undergoing gender reassignment surgery.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	2.5 grams Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 29, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Testosterone

Products Affected

- *testosterone transdermal 50 mg/5gm (1%)*

PA Criteria	Criteria Details
Covered Uses	Primary hypogonadism or hypogonadotropic hypogonadism, gender dysphoria, gender reassignment
Exclusion Criteria	patient with carcinoma of the breast or suspected carcinoma of the prostate, patient will be using therapy for muscle building purposes
Required Medical Information	Documented diagnosis of primary hypogonadism or hypogonadotropic hypogonadism as defined by either one of the following: (1) Member has undergone bilateral orchiectomy (no total fasting serum testosterone levels required), or (2) Having two consecutive low total fasting serum testosterone levels (below the testing laboratory's reference range or below 300ng/dl if reference ranges are not available), or for persons with low normal total testosterone levels (above 300 ng/dL but below 400 ng/dL), two consecutive low free or bioavailable fasting serum testosterone levels (below the testing laboratory's reference range or less than 225 picomoles per liter (pmol/L) (6 ng/dL) if reference ranges are not available)(Note: Two morning samples drawn between 7:00 a.m. and 10:00 a.m. obtained on two different days is required for NEW starts only), or (3) Member has a documented diagnosis of gender dysphoria or documentation of undergoing gender reassignment surgery.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	10 grams Per 1 fill
Notes/References	
Revision Date	Prior Authorization: September 29, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Testosterone Cypionate

Products Affected

- *testosterone cypionate intramuscular* solution*
250 mg/ml

QL Criteria	4 ml Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tetrabenazine

Products Affected

- *tetrabenazine oral tablet 12.5 mg*

QL Criteria	8 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tetrabenazine

Products Affected

- *tetrabenazine oral tablet 25 mg*

QL Criteria	4 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Teveten

Products Affected

- TEVETEN ORAL TABLET 600 MG

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Teveten HCT

Products Affected

- TEVETEN HCT

ST Criteria	Documented step through TWO of the following: ATACAND HCT*, AVALIDE*, HYZAAR*, MICARDIS HCT*
QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Theo-24

Products Affected

- THEO-24 ORAL CAPSULE EXTENDED
RELEASE 24 HOUR 100 MG, 200 MG

QL Criteria	1 cap Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

TiaGABine HCl

Products Affected

- *tiagabine hcl oral tablet 2 mg*

QL Criteria	1 tablet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

TiaGABine HCl

Products Affected

- *tiagabine hcl oral tablet 4 mg*

QL Criteria	4 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tiazac

Products Affected

- TIAZAC ORAL CAPSULE EXTENDED
RELEASE 24 HOUR 420 MG, 300 MG, 180
MG, 360 MG, 120 MG

QL Criteria	1 cap Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tiazac

Products Affected

- TIAZAC ORAL CAPSULE EXTENDED
RELEASE 24 HOUR 240 MG

QL Criteria	2 caps Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tilia Fe

Products Affected

- TILIA FE

QL Criteria	1.5 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tindamax

Products Affected

- TINDAMAX ORAL TABLET 500 MG

QL Criteria	12 tabs Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tindamax

Products Affected

- TINDAMAX ORAL TABLET 250 MG

QL Criteria	24 tabs Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tivicay

Products Affected

- TIVICAY

QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tivorbex

Products Affected

- TIVORBEX

QL Criteria	3 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tobi

Products Affected

- TOBI

PA Criteria	Criteria Details
Covered Uses	Cystic Fibrosis
Exclusion Criteria	
Required Medical Information	A. Documentation of a Positive sputum culture for P. aeruginosa, AND B. Documentation of baseline FEV Percent Predicted 25-80% for Tobi, Tobi Podhaler OR 40-80% for Bethkis
Age Restrictions	6 years of age or greater
Prescriber Restrictions	Pulmonologist or Infectious Disease physician
Coverage Duration	3 years
Other Criteria	
QL Criteria	56 vials Per 1 fill
Notes/References	
Revision Date	Prior Authorization: August 11, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tobi Podhaler

Products Affected

- TOBI PODHALER

PA Criteria	Criteria Details
Covered Uses	Cystic Fibrosis
Exclusion Criteria	
Required Medical Information	A. Documentation of a Positive sputum culture for P. aeruginosa, AND B. Documentation of baseline FEV Percent Predicted 25-80% for Tobi, Tobi Podhaler OR 40-80% for Bethkis
Age Restrictions	6 years of age or greater
Prescriber Restrictions	Pulmonologist or Infectious Disease physician
Coverage Duration	3 years
Other Criteria	
QL Criteria	1 box Per 28 dayss
Notes/References	
Revision Date	Prior Authorization: August 11, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tobramycin

Products Affected

- *tobramycin inhalation*

QL Criteria	56 vials Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tolterodine Tartrate ER

Products Affected

- *tolterodine tartrate er*

QL Criteria	1 cap Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Topamax Sprinkle

Products Affected

- TOPAMAX SPRINKLE

QL Criteria	4 caps Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Topiramate

Products Affected

- *topiramate oral capsule sprinkle*

QL Criteria	4 caps Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Toprol XL

Products Affected

- TOPROL XL ORAL TABLET EXTENDED
RELEASE 24 HR* 25 MG

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Toprol XL

Products Affected

- TOPROL XL ORAL TABLET EXTENDED
RELEASE 24 HR* 50 MG, 100 MG

QL Criteria	1.5 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Toprol XL

Products Affected

- TOPROL XL ORAL TABLET EXTENDED
RELEASE 24 HR* 200 MG

QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Toujeo SoloStar

Products Affected

- TOUJEO SOLOSTAR

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes Mellitus Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Step Therapy
ST Criteria	Documented one month trial of LEVEMIR
Notes/References	
Revision Date	Prior Authorization: September 09, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Toviaz

Products Affected

- TOVIAZ

ST Criteria	Documented step through DITROPAN* or SANCTURA* AND VESICARE or MYRBETRIQ
QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tradjenta

Products Affected

- TRADJENTA

PA Criteria	Criteria Details
Covered Uses	Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	Step Therapy
ST Criteria	1 month each of 2 preferred alternatives: Januvia and Onglyza (single entity or combination)
QL Criteria	1 tab Per 1 Day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

TraMADol HCl ER

Products Affected

- *tramadol hcl er oral capsule extended release*
24 hour 300 mg, 200 mg, 100 mg

QL Criteria	1 tablet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tramadol-Acetaminophen

Products Affected

- *tramadol-acetaminophen*

QL Criteria	8 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Travatan Z

Products Affected

- TRAVATAN Z

QL Criteria	3 ml Per 30 dayss
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Travoprost

Products Affected

- *travoprost*

PA Criteria	Criteria Details
Covered Uses	open-angle glaucoma ocular hypertension
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	Step Therapy
Notes/ References	
Revision Date	Prior Authorization: August 11, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tretinoin

Products Affected

- *tretinoin external 0.05 %, 0.025 %*
- *tretinoin external cream*

QL Criteria	50 grams Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tretinoin Microsphere

Products Affected

- *tretinoin microsphere*

ST Criteria	Documented step through RETIN-A*
QL Criteria	50 grams Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tretinoin Microsphere Pump

Products Affected

- *tretinoin microsphere pump*

ST Criteria	Documented step through RETIN-A*
QL Criteria	50 grams Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tretin-X

Products Affected

- TRETIN-X EXTERNAL CREAM 0.0375 %

QL Criteria	50 grams Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Treximet

Products Affected

- TREXIMET

QL Criteria	90 tablets Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Trezix

Products Affected

- TREZIX

QL Criteria	10 capsules Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tribenzor

Products Affected

- TRIBENZOR

ST Criteria	Documented step through AMLODIPINE in combination with TWO of the following: ATACAND HCT*, AVALIDE*, HYZAAR*, MICARDIS HCT*
QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tricor

Products Affected

- TRICOR

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tri-Estarylla

Products Affected

- TRI-ESTARYLLA

QL Criteria	1.5 tab Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Triglide

Products Affected

- TRIGLIDE ORAL TABLET 160 MG

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tri-Legest Fe

Products Affected

- TRI-LEGEST FE

QL Criteria	1.5 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tri-Linyah

Products Affected

- TRI-LINYAH

QL Criteria	1.5 tab Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Trilipix

Products Affected

- TRILIPIX

QL Criteria	1 cap Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

TriNessa (28)

Products Affected

- TRINESSA (28)

QL Criteria	1.5 tabs Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tri-Norinyl (28)

Products Affected

- TRI-NORINYL (28)

QL Criteria	1.5 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tri-Previfem

Products Affected

- TRI-PREVIFEM

QL Criteria	1.5 tabs Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tri-Sprintec

Products Affected

- TRI-SPRINTEC

QL Criteria	1.5 tabs Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Trivora (28)

Products Affected

- TRIVORA (28)

QL Criteria	1.5 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Trokendi XR

Products Affected

- TROKENDI XR ORAL CAPSULE
EXTENDED RELEASE 24 HOUR 100 MG,
25 MG, 50 MG

ST Criteria	Documented step through TOPAMAX*
QL Criteria	1 cap Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Trokendi XR

Products Affected

- TROKENDI XR ORAL CAPSULE
EXTENDED RELEASE 24 HOUR 200 MG

ST Criteria	Documented step through TOPAMAX*
QL Criteria	2 caps Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Trospium Chloride

Products Affected

- *trospium chloride*

QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Trospium Chloride ER

Products Affected

- *trospium chloride er*

QL Criteria	1 cap Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Trulicity

Products Affected

- TRULICITY

QL Criteria	4 injections Per 30 days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tudorza Pressair

Products Affected

- TUDORZA PRESSAIR

PA Criteria	Criteria Details
Covered Uses	Chronic Obstructive Pulmonary Disorder (COPD)
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Step Therapy
ST Criteria	Documented step through one month of SPIRIVA
QL Criteria	1 inhaler Per 1 fill
Notes/References	
Revision Date	Prior Authorization: September 09, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

TussiCaps

Products Affected

- TUSSICAPS

QL Criteria	20 caps Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tussionex Pennkinetic ER

Products Affected

- TUSSIONEX PENNKINETIC ER

QL Criteria	120 ml Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Twynsta

Products Affected

- TWYNSTA

ST Criteria	Documented step through AMLODIPINE in combination with TWO of the following: ATACAND, AVAPRO*, COZAAR*, MICARDIS*
QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tybost

Products Affected

- TYBOST

QL Criteria	1 tablet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tyvaso

Products Affected

- TYVASO

QL Criteria	1 amp Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tyvaso Refill

Products Affected

- TYVASO REFILL

QL Criteria	1 amp Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tyvaso Starter

Products Affected

- TYVASO STARTER

QL Criteria	1 amp Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Tyzeka

Products Affected

- TYZEKA

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Uceris

Products Affected

- UCERIS

ST Criteria	A documented trial of Asacol HD, Delzicol, Lialda or Pentasa
QL Criteria	4 canisters Per 42 months
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Uceris

Products Affected

- UCERIS ORAL

ST Criteria	Documented step through TWO of the following: SULFASALAZINE, COLAZAL, APRISO, ASACOL, ASACOL HD, DELZICOL
QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ulesfia

Products Affected

- ULESFIA

QL Criteria	3 bottles Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Uloric

Products Affected

- ULORIC

ST Criteria	Documented step through ALLOPURINOL
QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ultracet

Products Affected

- ULTRACET

QL Criteria	8 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ultresa

Products Affected

- ULTRESA

ST Criteria	Documented step through CREON AND ZENPEP
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Uroxatral

Products Affected

- UROXATRAL

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

ValACYclovir HCl

Products Affected

- *valacyclovir hcl oral tablet 500 mg*

QL Criteria	42 tabs Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

ValACYclovir HCl

Products Affected

- *valacyclovir hcl oral tablet 1 gm*

QL Criteria	21 tabs Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Valchlor

Products Affected

- VALCHLOR

QL Criteria	1 tube Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Valcyte

Products Affected

- VALCYTE ORAL TABLET

QL Criteria	102 tablets Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

ValGANciclovir HCl

Products Affected

- *valganciclovir hcl*

QL Criteria	102 tablets Per 30 30s
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Valsartan-Hydrochlorothiazide

Products Affected

- *valsartan-hydrochlorothiazide*

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Valtrex

Products Affected

- VALTREX ORAL TABLET 1 GM

QL Criteria	21 tabs Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Valtrex

Products Affected

- VALTREX ORAL TABLET 500 MG

QL Criteria	42 tabs Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Vancocin HCl

Products Affected

- VANCOCIN HCL ORAL CAPSULE 250 MG

QL Criteria	40 caps Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Vancocin HCl

Products Affected

- VANCOCIN HCL ORAL CAPSULE 125 MG

QL Criteria	56 caps Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Vanos

Products Affected

- VANOS

ST Criteria	Documented step through TWO VERY HIGH POTENCY TOPICAL STEROIDS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Vascepa

Products Affected

- VASCEPA

QL Criteria	4 caps Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Vecamyl

Products Affected

- VECAMYL

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	Documentation of trial and failure with four antihypertensive drugs from at least three different therapeutic subclasses, and documentation of moderately severe to severe hypertension (blood pressure greater than or equal to 160/100 mmHg) or documentation of malignant hypertension without complications (blood pressure greater or equal to 180/120 mmHg) with retinal hemorrhages, exudates, or papilledema
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Examples of antihypertensive drugs listed by therapeutic subclasses:DIURETICS: HydroDiuril, Microzide (hydrochlorothiazide), Hygroton (chlorthalidone), Diuril (chlorthiazide), Lasix (furosemide), Midamor (amiloride), Dyazide, Maxzide (triamterene-hydrochlorothiazide). BETA BLOCKERS: Tenormin (atenolol), Toprol XL (metoprolol succinate), Lopressor (metoprolol tartrate), Zebeta (bisoprolol), Coreg (carvedilol), Inderal LA (propranolol). CALCIUM CHANNEL BLOCKERS: Adalat CC, Procardia XL (nifedipine), Calan, Isoptin, Verelan (verapamil), Cardizem, Cartia (diltiazem), Norvasc (amlodipine), Sular (nisoldipine), Plendil (felodipine). ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACEI) & ACEI COMBINATIONS: Prinivil, Zestril (lisinopril), Lotensin/Lotensin HCT/Lotrel (benazepril), Vasotec (enalapril), Accupril (quinapril), Mavik (trandolapril),Univasc (moexipril). ANGIOTENSION RECEPTOR BLOCKER (ARB) & ARB COMBINATIONS: Cozaar/Hyzaar (losartan), Benicar/Benicar HCT (olmesartan), Micardis/Micardis HCT (telmisartan) , Diovan/Diovan HCT (valsartan), Avapro/Avalide (irbesartan), Atacand/Atacand HCT (candesartan), Teveten /Teveten HCT (eprosartan), Edarbi/Edarbyclor (azilsartan)
QL Criteria	2 tabs Per 1 day
Notes/References	

2015 Aetna Value Plan
(Updated 12/01/2015)

Revision Date	Prior Authorization: October 05, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015
----------------------	--

Vectical

Products Affected

- VECTICAL

ST Criteria	Documented step through A MEDIUM TO HIGH POTENCY TOPICAL STEROID
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Velivet

Products Affected

- VELIVET

QL Criteria	1.5 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Veltin

Products Affected

- VELTIN

ST Criteria	Documented step through RETIN-A*
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Venlafaxine HCl

Products Affected

- *venlafaxine hcl oral tablet 50 mg*

QL Criteria	6 tabs Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Venlafaxine HCl

Products Affected

- *venlafaxine hcl oral tablet 100 mg, 25 mg*

QL Criteria	3 tabs Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Venlafaxine HCl

Products Affected

- *venlafaxine hcl oral tablet 75 mg*

QL Criteria	5 tabs Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Venlafaxine HCl

Products Affected

- *venlafaxine hcl oral tablet 37.5 mg*

QL Criteria	4 tabs Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Venlafaxine HCl ER

Products Affected

- *venlafaxine hcl er oral tablet extended release*
24 hr 150 mg*

QL Criteria	2 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Venlafaxine HCl ER

Products Affected

- *venlafaxine hcl er oral tablet extended release*
24 hr* 75 mg, 37.5 mg, 225 mg

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Venlafaxine HCl ER

Products Affected

- *venlafaxine hcl er oral capsule extended release 24 hour 75 mg, 37.5 mg*

QL Criteria	1 cap Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Venlafaxine HCl ER

Products Affected

- *venlafaxine hcl er oral capsule extended release 24 hour 150 mg*

QL Criteria	2 cap Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ventolin HFA

Products Affected

- VENTOLIN HFA

QL Criteria	2 inhalers Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Veramyst

Products Affected

- VERAMYST

ST Criteria	Trial of 2 weeks each of 2 of the following: fluticasone propionate OR flunisolide nasal spray OR Triamcinolone OR Nasacort 24HR OTC (choose 1) AND Nasonex
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Verapamil HCl ER

Products Affected

- *verapamil hcl er oral capsule extended release*
24 hour 200 mg

QL Criteria	2 caps Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Verapamil HCl ER

Products Affected

- *verapamil hcl er oral capsule extended release*
24 hour 300 mg, 100 mg

QL Criteria	1 cap Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Verelan PM

Products Affected

- VERELAN PM ORAL CAPSULE
EXTENDED RELEASE 24 HOUR 300 MG,
100 MG

QL Criteria	1 cap Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Verelan PM

Products Affected

- VERELAN PM ORAL CAPSULE
EXTENDED RELEASE 24 HOUR 200 MG

QL Criteria	2 caps Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Versacloz

Products Affected

- VERSACLOZ

ST Criteria	Documented step through CLOZARIL* TABLETS
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

VESIcare

Products Affected

- VESICARE

ST Criteria	Documented step through DITROPAN* or SANCTURA*
QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Vestura

Products Affected

- VESTURA

QL Criteria	1.5 tab Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Viagra

Products Affected

- VIAGRA

ST Criteria	Documented step through CIALIS
QL Criteria	6 tabs Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Victoza

Products Affected

- VICTOZA

QL Criteria	9 ML Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Victrelis

Products Affected

- VICTRELIS

QL Criteria	12 caps Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Viibryd

Products Affected

- VIIBRYD ORAL KIT

PA Criteria	Criteria Details
Covered Uses	Major depressive disorder
Exclusion Criteria	
Required Medical Information	Diagnosis of major depressive disorder
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	<p>Examples of antidepressant trials from unique therapeutic subclasses Therapeutic Subclass:Examples:</p> <p>Selective Serotonin Reuptake Inhibitors (SSRI) fluoxetine (Prozac), paroxetine (Paxil), citalopram (Celexa), sertraline (Zoloft), escitalopram (Lexapro)</p> <p>Serotonin-Norepinephrine Reuptake Inhibitors (SNRI) venlafaxine (Effexor), Effexor XR, Pristiq, Cymbalta</p> <p>Norepinephrine-Dopamine Reuptake Inhibitors (NDRI) bupropion (Wellbutrin), bupropion sustained release (Wellbutrin SR), bupropion extended release (Wellbutrin XL)</p> <p>Tricyclic Antidepressants (TCA) amitriptyline (Elavil), amoxapine (Ascendin), desipramine (Norpramin), doxepin (Sinequan), imipramine (Tofranil), nortriptyline (Pamelor), protriptyline (Vivactil), trimipramine (Surmontil)</p> <p>Tetracyclic Antidepressants mirtazapine (Remeron)</p> <p>Monoamine Oxidase Inhibitors (MAOI) phenelzine (Nardil), tranylcypromine (Parnate), isocarboxazid (Marplan), Emsam</p> <p>Therapy is required Step</p>
ST Criteria	Documentation of failure or unresponsiveness to THREE different antidepressants from at least two different therapeutic subclasses
QL Criteria	1 pack Per 365 dayss

2015 Aetna Value Plan
 (Updated 12/01/2015)

Notes/ References	
Revision Date	Prior Authorization: September 09, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Viibryd

Products Affected

- VIIBRYD ORAL TABLET

PA Criteria	Criteria Details
Covered Uses	Major depressive disorder
Exclusion Criteria	
Required Medical Information	Diagnosis of major depressive disorder
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	<p>Examples of antidepressant trials from unique therapeutic subclasses Therapeutic Subclass:Examples:</p> <p>Selective Serotonin Reuptake Inhibitors (SSRI) fluoxetine (Prozac), paroxetine (Paxil), citalopram (Celexa), sertraline (Zoloft), escitalopram (Lexapro)</p> <p>Serotonin-Norepinephrine Reuptake Inhibitors (SNRI) venlafaxine (Effexor), Effexor XR, Pristiq, Cymbalta</p> <p>Norepinephrine-Dopamine Reuptake Inhibitors (NDRI) bupropion (Wellbutrin), bupropion sustained release (Wellbutrin SR), bupropion extended release (Wellbutrin XL)</p> <p>Tricyclic Antidepressants (TCA) amitriptyline (Elavil), amoxapine (Ascendin), desipramine (Norpramin), doxepin (Sinequan), imipramine (Tofranil), nortriptyline (Pamelor), protriptyline (Vivactil), trimipramine (Surmontil)</p> <p>Tetracyclic Antidepressants mirtazapine (Remeron)</p> <p>Monoamine Oxidase Inhibitors (MAOI) phenelzine (Nardil), tranylcypromine (Parnate), isocarboxazid (Marplan), Emsam</p> <p>Therapy is required Step</p>
ST Criteria	Documentation of failure or unresponsiveness to THREE different antidepressants from at least two different therapeutic subclasses
QL Criteria	1 tab Per 1 day

2015 Aetna Value Plan
 (Updated 12/01/2015)

Notes/ References	
Revision Date	Prior Authorization: September 09, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Vimpat

Products Affected

- VIMPAT ORAL SOLUTION

QL Criteria	40 ml Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Vimpat

Products Affected

- VIMPAT ORAL TABLET

PA Criteria	Criteria Details
Covered Uses	partial-onset seizures
Exclusion Criteria	
Required Medical Information	A documented diagnosis of partial-onset seizures
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	2 tabs Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 09, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Viokace

Products Affected

- VIOKACE

ST Criteria	Documented step through CREON AND ZENPEP
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Viramune XR

Products Affected

- VIRAMUNE XR ORAL TABLET
EXTENDED RELEASE 24 HR* 400 MG

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Viramune XR

Products Affected

- VIRAMUNE XR ORAL TABLET
EXTENDED RELEASE 24 HR* 100 MG

QL Criteria	3 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Viread

Products Affected

- VIREAD ORAL TABLET

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Vituz

Products Affected

- VITUZ

QL Criteria	120 ml Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Vivelle-Dot

Products Affected

- VIVELLE-DOT

QL Criteria	8 patches Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Vogelxo

Products Affected

- VOGELXO

PA Criteria	Criteria Details
Covered Uses	Primary hypogonadism or hypogonadotropic hypogonadism, gender dysphoria, gender reassignment
Exclusion Criteria	patient with carcinoma of the breast or suspected carcinoma of the prostate, patient will be using therapy for muscle building purposes
Required Medical Information	Documented diagnosis of primary hypogonadism or hypogonadotropic hypogonadism as defined by either one of the following: (1) Member has undergone bilateral orchiectomy (no total fasting serum testosterone levels required), or (2) Having two consecutive low total fasting serum testosterone levels (below the testing laboratory's reference range or below 300ng/dl if reference ranges are not available), or for persons with low normal total testosterone levels (above 300 ng/dL but below 400 ng/dL), two consecutive low free or bioavailable fasting serum testosterone levels (below the testing laboratory's reference range or less than 225 picomoles per liter (pmol/L) (6 ng/dL) if reference ranges are not available)(Note: Two morning samples drawn between 7:00 a.m. and 10:00 a.m. obtained on two different days is required for NEW starts only), or (3) Member has a documented diagnosis of gender dysphoria or documentation of undergoing gender reassignment surgery.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	Documented step through one month each of ANDROGEL AND TESTIM
QL Criteria	10 grams Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 29, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

2015 Aetna Value Plan
(Updated 12/01/2015)

Vogelxo Pump

Products Affected

- VOGELXO PUMP

PA Criteria	Criteria Details
Covered Uses	Primary hypogonadism or hypogonadotropic hypogonadism, gender dysphoria, gender reassignment
Exclusion Criteria	patient with carcinoma of the breast or suspected carcinoma of the prostate, patient will be using therapy for muscle building purposes
Required Medical Information	Documented diagnosis of primary hypogonadism or hypogonadotropic hypogonadism as defined by either one of the following: (1) Member has undergone bilateral orchiectomy (no total fasting serum testosterone levels required), or (2) Having two consecutive low total fasting serum testosterone levels (below the testing laboratory's reference range or below 300ng/dl if reference ranges are not available), or for persons with low normal total testosterone levels (above 300 ng/dL but below 400 ng/dL), two consecutive low free or bioavailable fasting serum testosterone levels (below the testing laboratory's reference range or less than 225 picomoles per liter (pmol/L) (6 ng/dL) if reference ranges are not available)(Note: Two morning samples drawn between 7:00 a.m. and 10:00 a.m. obtained on two different days is required for NEW starts only), or (3) Member has a documented diagnosis of gender dysphoria or documentation of undergoing gender reassignment surgery.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
ST Criteria	Documented step through one month each of ANDROGEL AND TESTIM
QL Criteria	10 grams Per 1 fill
Notes/References	
Revision Date	Prior Authorization: September 29, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Voltaren

Products Affected

- VOLTAREN TRANSDERMAL

QL Criteria	200 grams Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Votrient

Products Affected

- VOTRIENT

QL Criteria	4 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Vytorin

Products Affected

- VYTORIN

ST Criteria	Documented step through ONE GENERIC STATIN, ATORVASTATIN, FLUVASTATIN, LOVASTATIN, PRAVASTATIN, SIMVASTATIN (NSO) AND CRESTOR
QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Vyvanse

Products Affected

- VYVANSE

QL Criteria	1 capsule Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Vyvanse

Products Affected

- VYVANSE

QL Criteria	1 cap Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Wellbutrin

Products Affected

- WELLBUTRIN

QL Criteria	6 tabs Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Wellbutrin SR

Products Affected

- WELLBUTRIN SR

QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Wellbutrin XL

Products Affected

- WELLBUTRIN XL

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Wera

Products Affected

- WERA

QL Criteria	1.5 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

WinRho SDF

Products Affected

- WINRHO SDF

QL Criteria	1 ML Per 365 dayss
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Wymzya Fe

Products Affected

- WYMZYA FE

QL Criteria	1.5 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Xalatan

Products Affected

- XALATAN

QL Criteria	3 ML Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Xalkori

Products Affected

- XALKORI

QL Criteria	2 caps Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Xanax XR

Products Affected

- XANAX XR

QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Xarelto

Products Affected

- XARELTO ORAL TABLET 10 MG

QL Criteria	35 tabs Per 365 days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Xarelto

Products Affected

- XARELTO ORAL TABLET 15 MG

QL Criteria	42 tabs Per 30 days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Xarelto

Products Affected

- XARELTO ORAL TABLET 20 MG

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Xarelto Starter Pack

Products Affected

- XARELTO STARTER PACK

QL Criteria	2 packs Per 365 Days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Xartemis XR

Products Affected

- XARTEMIS XR

ST Criteria	Documented step through TWO of the following: MORPHINE, OXYCODONE, HYDROMORPHONE
QL Criteria	4 tablets Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Xeljanz

Products Affected

- XELJANZ

QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Xenazine

Products Affected

- XENAZINE ORAL TABLET 12.5 MG

QL Criteria	8 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Xenazine

Products Affected

- XENAZINE ORAL TABLET 25 MG

QL Criteria	4 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Xifaxan

Products Affected

- XIFAXAN ORAL TABLET 550 MG

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	A. Documentation of a trial and failure to lactulose
Age Restrictions	18 years or older
Prescriber Restrictions	
Coverage Duration	HEPATIC ENCEPHALOPATHY: 1 year
Other Criteria	
QL Criteria	3 tablets Per 1 day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Xifaxan

Products Affected

- XIFAXAN ORAL TABLET 200 MG

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	A. Documentation of a trial and failure to lactulose
Age Restrictions	18 years or older
Prescriber Restrictions	
Coverage Duration	HEPATIC ENCEPHALOPATHY: 1 year
Other Criteria	
QL Criteria	9 tabs Per 1 fill
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Xigduo XR

Products Affected

- XIGDUO XR

ST Criteria	Documented step through one month of INVOKANA (single entity or combo)
QL Criteria	1 tablet Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Xopenex HFA

Products Affected

- XOPENEX HFA

PA Criteria	Criteria Details
Covered Uses	Asthma (Bronchospasm: Treatment and Prophylaxis)
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	Step Therapy
ST Criteria	Documented step through one week each of VENTOLIN HFA AND PROAIR
QL Criteria	2 inhalers Per 1 fill
Notes/References	
Revision Date	Prior Authorization: August 11, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Xtandi

Products Affected

- XTANDI

QL Criteria	4 caps Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Xulane

Products Affected

- XULANE

QL Criteria	3 patches Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Xyrem

Products Affected

- XYREM

PA Criteria	Criteria Details
Covered Uses	Excessive daytime sleepiness associated with narcolepsy, Cataplexy associated with narcolepsy
Exclusion Criteria	
Required Medical Information	FOR THE TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS IN ASSOCIATION WITH NARCOLEPSY: Documentation of diagnostic testing and clinical notations supporting diagnosis of narcolepsy, such as MSLT, clinical progress notes, and documentation of failure of an adequate trial of at least two of the immediate release stimulants (Dexedrine, Ritalin, Adderall), and documentation of failure of an adequate trial of Nuvigil. FOR THE TREATMENT OF CATAPLEXY IN ASSOCIATION WITH NARCOLEPSY: Documentation of diagnostic testing and clinical notations supporting diagnosis of narcolepsy, such as MSLT, clinical progress notes, and documentation of failure of an adequate trial of at least two of the immediate release stimulants (Dexedrine, Ritalin, Adderall), and documentation of failure of an adequate trial of an antidepressant.
Age Restrictions	
Prescriber Restrictions	Sleep specialist, pulmonologist, neurologist, or psychiatrist
Coverage Duration	3 months, extended approval based on therapeutic response
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: October 05, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Xyzal

Products Affected

- XYZAL

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Xyzal

Products Affected

- XYZAL

QL Criteria	1 ML Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Yasmin 28

Products Affected

- YASMIN 28

QL Criteria	1.5 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

YAZ

Products Affected

- YAZ

QL Criteria	1.5 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zarah

Products Affected

- ZARAH

QL Criteria	1.5 tab Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zavesca

Products Affected

- ZAVESCA

QL Criteria	3 caps Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zecuity

Products Affected

- ZECUITY

QL Criteria	4 patches Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zelapar

Products Affected

- ZELAPAR

QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zelboraf

Products Affected

- ZELBORAF

QL Criteria	8 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zemplar

Products Affected

- ZEMPLAR ORAL

QL Criteria	1 cap Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zenatane

Products Affected

- ZENATANE

PA Criteria	Criteria Details
Covered Uses	severe recalcitrant nodular or cystic acne
Exclusion Criteria	
Required Medical Information	Member already has evidence of scarring and member is enrolled in the FDA iPLEDGE program (females of childbearing potential ONLY)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	5 months
Other Criteria	For coverage of additional quantities (greater than 2 capsules per day) member must meet the following criteria: Patient requires more than 2 capsules per day to reach the appropriate dose for weight, and this is the members FIRST course of therapy or member now requires a second course of therapy and it has been at least 8 weeks after the first course was initiated (2 month holiday), and member has recieved a cumulative dose of less than 120 mg/kg during a course of therapy lasting 20 weeks or less.
ST Criteria	Documented step through ONE GENERIC ORAL ANTIBIOTIC prescribed for treatment of acne (i.e., MINOCYCLINE OR DOXYCYCLINE)
QL Criteria	2 capsules Per 1 Day
Notes/References	
Revision Date	Prior Authorization: October 05, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zenchant

Products Affected

- ZENCHENT

QL Criteria	1.5 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zenchant FE

Products Affected

- ZENCHENT FE

QL Criteria	1.5 tablets Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zenzedi

Products Affected

- ZENZEDI ORAL TABLET 5 MG, 10 MG

ST Criteria	Documented step through 14 days each of THREE of AMPHETAMINE/DEXTROAMPHETAMINE/ SR, DEXMETHYLPHENIDATE/ SR, DEXTROAMPHETAMINE, METHAMPHETAMINE, METHYLPHENIDATE/ ER/ SR, STRATTERA, OR VYVANSE
QL Criteria	4 tabs Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zenzedi

Products Affected

- ZENZEDI ORAL TABLET 7.5 MG, 15 MG, 30 MG, 2.5 MG, 20 MG

ST Criteria	Documented step through 14 days each of THREE of AMPHETAMINE/DEXTROAMPHETAMINE/ SR, DEXMETHYLPHENIDATE/ SR, DEXTROAMPHETAMINE, METHAMPHETAMINE, METHYLPHENIDATE/ ER/ SR, STRATTERA, OR VYVANSE
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zetia

Products Affected

- ZETIA

QL Criteria	1 tab Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zetonna

Products Affected

- ZETONNA

ST Criteria	Trial of 2 weeks each of 2 of the following: fluticasone propionate OR flunisolide nasal spray OR Triamcinolone OR Nasacort 24HR OTC (choose 1) AND Nasonex
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ziana

Products Affected

- ZIANA

ST Criteria	Documented step through RETIN-A*
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zioptan

Products Affected

- ZIOPTAN

PA Criteria	Criteria Details
Covered Uses	open-angle glaucoma ocular hypertension
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	Step Therapy
ST Criteria	Documented step through one week of LATANOPROST AND one week of TRAVATAN Z
QL Criteria	1 unit Per 1 day
Notes/References	
Revision Date	Prior Authorization: August 11, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Ziprasidone HCl

Products Affected

- *ziprasidone hcl*

QL Criteria	2 caps Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zirgan

Products Affected

- ZIRGAN

QL Criteria	1 tube Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zocor

Products Affected

- ZOCOR

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zofran

Products Affected

- ZOFRAN ORAL TABLET

QL Criteria	60 tabs Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zofran

Products Affected

- ZOFRAN ORAL SOLUTION

QL Criteria	50 ml Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zofran ODT

Products Affected

- ZOFRAN ODT

QL Criteria	60 tabs Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zohydro ER

Products Affected

- ZOHYDRO ER

PA Criteria	Criteria Details
Covered Uses	Chronic pain due to malignant condition or severe pain requiring daily, around the clock, long term opioid treatment
Exclusion Criteria	
Required Medical Information	Documentation of progression through the World Health Organization analgesic ladder
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Step Therapy
ST Criteria	Documented step through one month of MORPHINE SR TAB 12HR (MS CONTIN) AND OXYMORPHONE ER (OPANA ER)
QL Criteria	2 capsules Per 1 day
Notes/References	
Revision Date	Prior Authorization: September 29, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zolinza

Products Affected

- ZOLINZA

QL Criteria	4 caps Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

ZOLMitriptan

Products Affected

- *zolmitriptan oral tablet 2.5 mg*
- *zolmitriptan oral tablet dispersible 2.5 mg*

QL Criteria	6 tabs Per 30 days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

ZOLMitriptan

Products Affected

- *zolmitriptan oral tablet dispersible 5 mg*

QL Criteria	3 tablets Per 30 months
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

ZOLMitriptan

Products Affected

- *zolmitriptan oral tablet 5 mg*

QL Criteria	6 tablets Per 1 month
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zoloft

Products Affected

- ZOLOFT ORAL CONCENTRATE

QL Criteria	10 ML Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zoloft

Products Affected

- ZOLOFT ORAL TABLET 50 MG

QL Criteria	1.5 tag Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zoloft

Products Affected

- ZOLOFT ORAL TABLET 100 MG

QL Criteria	2 tabs Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zoloft

Products Affected

- ZOLOFT ORAL TABLET 25 MG

QL Criteria	1 tab Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zolpidem Tartrate

Products Affected

- *zolpidem tartrate*

QL Criteria	2 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zolpidem Tartrate ER

Products Affected

- *zolpidem tartrate er*

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zomig

Products Affected

- ZOMIG

ST Criteria	Documented step through one month of THREE of the following: NARATRIPTAN, RIZATRIPTAN, SUMATRIPTAN, ZOLMITRIPTAN (NSO)
QL Criteria	6 sprays Per 30 fills
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zomig

Products Affected

- ZOMIG

QL Criteria	6 tabs Per 30 days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zomig ZMT

Products Affected

- ZOMIG ZMT

QL Criteria	6 tabs Per 30 days
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zontivity

Products Affected

- ZONTIVITY

QL Criteria	1 tab Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zorvolex

Products Affected

- ZORVOLEX

ST Criteria	Documented step through TWO NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs)
QL Criteria	3 caps Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zovia 1/35E (28)

Products Affected

- ZOVIA 1/35E (28)

QL Criteria	1.5 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zovia 1/50E (28)

Products Affected

- ZOVIA 1/50E (28)

QL Criteria	1.5 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zubsolv

Products Affected

- ZUBSOLV SUBLINGUAL TABLET
SUBLINGUAL 11.4-2.9 MG

PA Criteria	Criteria Details
Covered Uses	Opioid dependence
Exclusion Criteria	Medical literature does not support the concurrent use of opioids/Tramadol as part of opioid drug dependence treatment. Abstinence of opioids/Tramadol is required both during and following therapy with Suboxone/Subutex/Zubsolv/Bunavail/buprenorphine, and will only be covered when determined to be medically necessary (defined as short-term use during and following opioid dependence treatment for the treatment of acute pain related to surgery, dental procedure, or an emergency situation or for long-term use following opioid dependence treatment for the treatment of chronic pain. For long term use, the member must be treated by a single provider of their choice, opioids will only be covered when prescribed by this single provider, and this single provider is aware of past buprenorphine use for opioid dependence treatment in which an opioid dependence diagnosis). Physicians can contact (855) 746-0013 with any information related to the medical necessity for opioid/Tramadol therapy.
Required Medical Information	Prescriber provides verbal verification of patient's current and ongoing enrollment in an outpatient drug addiction treatment program/ counseling. If the member is currently enrolled, the approval will be 6 months. If the member is NOT enrolled (answer=no) and prescriber provides verbal verification of patient's agreed commitment to become enrolled in an acceptable drug addiction treatment program counseling, the approval will be for 2 months (Note: 1 time approval ONLY). If after 2 months member does not enroll in a program, then all future requests will be denied until member enrolls in a program.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months = current enrollment

PA Criteria	Criteria Details
Other Criteria	<p>For coverage of additional quantities, the following conditions must be met: FOR BUPRENORPHONE SL: Member is pregnant or breastfeeding (Up to 120 tablets in 30 days) or member has a documented contraindication, intolerance, or allergy to buprenorphine-naloxone sublingual tablet or Suboxone (will allow up to 90 tablets per month for max length of approval of 6 months). FOR SUBOXONE OR BUPRENORPHINE-NALOXONE SUBLINGUAL TABLET 2mg/0.5mg: Member's dose is being titrated by physician for 7 day induction therapy (max dose 12 mg/daily for total of 42 tablets/films in 7 days). FOR ZUBSOLBV 1.4mg/0.36mg: Member's dose is being titrated by physician for 7 day induction therapy (max dose 8.4 mg/daily for total of 42 tablets/films in 7 days). Note: Aetna considers the following as acceptable programs: Outpatient drug addiction treatment programs and/or counseling, 12- step programs focused on "drug" addiction such as Narcotics Anonymous (N.A.), Other accepted programs can be found at http://findtreatment.samhsa.gov/TreatmentLocator/faces/quickSearch.jspx. Aetna considers the following as non-acceptable programs: On-line programs such as Here to Help, 12-step programs that are not focused on "drug" addiction (ex: Alcoholics Anonymous).</p>
ST Criteria	Documented step through one month of BUPRENORPHINE-NALOXONE SUBLINGUAL TABLET or SUBOXONE FILM
QL Criteria	1 tablet Per 1 Day
Notes/References	
Revision Date	Prior Authorization: November 30, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zubsolv

Products Affected

- ZUBSOLV SUBLINGUAL TABLET
SUBLINGUAL 2.9-0.71 MG

PA Criteria	Criteria Details
Covered Uses	Opioid dependence
Exclusion Criteria	Medical literature does not support the concurrent use of opioids/Tramadol as part of opioid drug dependence treatment. Abstinence of opioids/Tramadol is required both during and following therapy with Suboxone/Subutex/Zubsolv/Bunavail/buprenorphine, and will only be covered when determined to be medically necessary (defined as short-term use during and following opioid dependence treatment for the treatment of acute pain related to surgery, dental procedure, or an emergency situation or for long-term use following opioid dependence treatment for the treatment of chronic pain. For long term use, the member must be treated by a single provider of their choice, opioids will only be covered when prescribed by this single provider, and this single provider is aware of past buprenorphine use for opioid dependence treatment in which an opioid dependence diagnosis). Physicians can contact (855) 746-0013 with any information related to the medical necessity for opioid/Tramadol therapy.
Required Medical Information	Prescriber provides verbal verification of patient's current and ongoing enrollment in an outpatient drug addiction treatment program/ counseling. If the member is currently enrolled, the approval will be 6 months. If the member is NOT enrolled (answer=no) and prescriber provides verbal verification of patient's agreed commitment to become enrolled in an acceptable drug addiction treatment program counseling, the approval will be for 2 months (Note: 1 time approval ONLY). If after 2 months member does not enroll in a program, then all future requests will be denied until member enrolls in a program.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months = current enrollment

PA Criteria	Criteria Details
Other Criteria	<p>For coverage of additional quantities, the following conditions must be met: FOR BUPRENORPHONE SL: Member is pregnant or breastfeeding (Up to 120 tablets in 30 days) or member has a documented contraindication, intolerance, or allergy to buprenorphine-naloxone sublingual tablet or Suboxone (will allow up to 90 tablets per month for max length of approval of 6 months). FOR SUBOXONE OR BUPRENORPHINE-NALOXONE SUBLINGUAL TABLET 2mg/0.5mg: Member's dose is being titrated by physician for 7 day induction therapy (max dose 12 mg/daily for total of 42 tablets/films in 7 days). FOR ZUBSOLBV 1.4mg/0.36mg: Member's dose is being titrated by physician for 7 day induction therapy (max dose 8.4 mg/daily for total of 42 tablets/films in 7 days). Note: Aetna considers the following as acceptable programs: Outpatient drug addiction treatment programs and/or counseling, 12- step programs focused on "drug" addiction such as Narcotics Anonymous (N.A.), Other accepted programs can be found at http://findtreatment.samhsa.gov/TreatmentLocator/faces/quickSearch.jspx. Aetna considers the following as non-acceptable programs: On-line programs such as Here to Help, 12-step programs that are not focused on "drug" addiction (ex: Alcoholics Anonymous).</p>
ST Criteria	Documented step through one month of BUPRENORPHINE-NALOXONE SUBLINGUAL TABLET or SUBOXONE FILM
QL Criteria	3 tablets Per 1 Day
Notes/References	
Revision Date	Prior Authorization: November 30, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zubsolv

Products Affected

- ZUBSOLV SUBLINGUAL TABLET
SUBLINGUAL 5.7-1.4 MG, 1.4-0.36 MG

PA Criteria	Criteria Details
Covered Uses	Opioid dependence
Exclusion Criteria	Medical literature does not support the concurrent use of opioids/Tramadol as part of opioid drug dependence treatment. Abstinence of opioids/Tramadol is required both during and following therapy with Suboxone/Subutex/Zubsolv/Bunavail/buprenorphine, and will only be covered when determined to be medically necessary (defined as short-term use during and following opioid dependence treatment for the treatment of acute pain related to surgery, dental procedure, or an emergency situation or for long-term use following opioid dependence treatment for the treatment of chronic pain. For long term use, the member must be treated by a single provider of their choice, opioids will only be covered when prescribed by this single provider, and this single provider is aware of past buprenorphine use for opioid dependence treatment in which an opioid dependence diagnosis). Physicians can contact (855) 746-0013 with any information related to the medical necessity for opioid/Tramadol therapy.
Required Medical Information	Prescriber provides verbal verification of patient's current and ongoing enrollment in an outpatient drug addiction treatment program/ counseling. If the member is currently enrolled, the approval will be 6 months. If the member is NOT enrolled (answer=no) and prescriber provides verbal verification of patient's agreed commitment to become enrolled in an acceptable drug addiction treatment program counseling, the approval will be for 2 months (Note: 1 time approval ONLY). If after 2 months member does not enroll in a program, then all future requests will be denied until member enrolls in a program.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months = current enrollment

PA Criteria	Criteria Details
Other Criteria	<p>For coverage of additional quantities, the following conditions must be met: FOR BUPRENORPHONE SL: Member is pregnant or breastfeeding (Up to 120 tablets in 30 days) or member has a documented contraindication, intolerance, or allergy to buprenorphine-naloxone sublingual tablet or Suboxone (will allow up to 90 tablets per month for max length of approval of 6 months). FOR SUBOXONE OR BUPRENORPHINE-NALOXONE SUBLINGUAL TABLET 2mg/0.5mg: Member's dose is being titrated by physician for 7 day induction therapy (max dose 12 mg/daily for total of 42 tablets/films in 7 days). FOR ZUBSOLBV 1.4mg/0.36mg: Member's dose is being titrated by physician for 7 day induction therapy (max dose 8.4 mg/daily for total of 42 tablets/films in 7 days). Note: Aetna considers the following as acceptable programs: Outpatient drug addiction treatment programs and/or counseling, 12- step programs focused on "drug" addiction such as Narcotics Anonymous (N.A.), Other accepted programs can be found at http://findtreatment.samhsa.gov/TreatmentLocator/faces/quickSearch.jspx. Aetna considers the following as non-acceptable programs: On-line programs such as Here to Help, 12-step programs that are not focused on "drug" addiction (ex: Alcoholics Anonymous).</p>
ST Criteria	Documented step through one month of BUPRENORPHINE-NALOXONE SUBLINGUAL TABLET or SUBOXONE FILM
QL Criteria	3 tabs Per 1 day
Notes/References	
Revision Date	Prior Authorization: November 30, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zubsolv

Products Affected

- ZUBSOLV SUBLINGUAL TABLET
SUBLINGUAL 8.6-2.1 MG

PA Criteria	Criteria Details
Covered Uses	Opioid dependence
Exclusion Criteria	Medical literature does not support the concurrent use of opioids/Tramadol as part of opioid drug dependence treatment. Abstinence of opioids/Tramadol is required both during and following therapy with Suboxone/Subutex/Zubsolv/Bunavail/buprenorphine, and will only be covered when determined to be medically necessary (defined as short-term use during and following opioid dependence treatment for the treatment of acute pain related to surgery, dental procedure, or an emergency situation or for long-term use following opioid dependence treatment for the treatment of chronic pain. For long term use, the member must be treated by a single provider of their choice, opioids will only be covered when prescribed by this single provider, and this single provider is aware of past buprenorphine use for opioid dependence treatment in which an opioid dependence diagnosis). Physicians can contact (855) 746-0013 with any information related to the medical necessity for opioid/Tramadol therapy.
Required Medical Information	Prescriber provides verbal verification of patient's current and ongoing enrollment in an outpatient drug addiction treatment program/ counseling. If the member is currently enrolled, the approval will be 6 months. If the member is NOT enrolled (answer=no) and prescriber provides verbal verification of patient's agreed commitment to become enrolled in an acceptable drug addiction treatment program counseling, the approval will be for 2 months (Note: 1 time approval ONLY). If after 2 months member does not enroll in a program, then all future requests will be denied until member enrolls in a program.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months = current enrollment

PA Criteria	Criteria Details
Other Criteria	<p>For coverage of additional quantities, the following conditions must be met: FOR BUPRENORPHONE SL: Member is pregnant or breastfeeding (Up to 120 tablets in 30 days) or member has a documented contraindication, intolerance, or allergy to buprenorphine-naloxone sublingual tablet or Suboxone (will allow up to 90 tablets per month for max length of approval of 6 months). FOR SUBOXONE OR BUPRENORPHINE-NALOXONE SUBLINGUAL TABLET 2mg/0.5mg: Member's dose is being titrated by physician for 7 day induction therapy (max dose 12 mg/daily for total of 42 tablets/films in 7 days). FOR ZUBSOLBV 1.4mg/0.36mg: Member's dose is being titrated by physician for 7 day induction therapy (max dose 8.4 mg/daily for total of 42 tablets/films in 7 days). Note: Aetna considers the following as acceptable programs: Outpatient drug addiction treatment programs and/or counseling, 12- step programs focused on "drug" addiction such as Narcotics Anonymous (N.A.), Other accepted programs can be found at http://findtreatment.samhsa.gov/TreatmentLocator/faces/quickSearch.jspx. Aetna considers the following as non-acceptable programs: On-line programs such as Here to Help, 12-step programs that are not focused on "drug" addiction (ex: Alcoholics Anonymous).</p>
ST Criteria	Documented step through one month of BUPRENORPHINE-NALOXONE SUBLINGUAL TABLET or SUBOXONE FILM
QL Criteria	2 tablets Per 1 Day
Notes/References	
Revision Date	Prior Authorization: November 30, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zykadia

Products Affected

- ZYKADIA

QL Criteria	5 caps Per 1 Day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zymaxid

Products Affected

- ZYMAXID

QL Criteria	1 bottle Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

ZyPREXA

Products Affected

- ZYPREXA ORAL

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

ZyPREXA Zydys

Products Affected

- ZYPREXA ZYDIS

QL Criteria	1 tab Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zytiga

Products Affected

- ZYTIGA

QL Criteria	4 tabs Per 1 day
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zyvox

Products Affected

- ZYVOX ORAL TABLET

QL Criteria	28 tabs Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Zyvox

Products Affected

- ZYVOX ORAL SUSPENSION
RECONSTITUTED

QL Criteria	150 ml Per 1 fill
Notes/ References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

Index

ABILIFY DISCMELT	3	AFINITOR DISPERZ	40
ABILIFY ORAL SOLUTION	2	AFREZZA	41
ABILIFY ORAL TABLET	1	AKYNZEO	42
ABSORICA	4	ALDARA	43
ABSTRAL	5	<i>alendronate sodium oral solution</i>	46
<i>acamprosate calcium</i>	6	<i>alendronate sodium oral tablet 10 mg</i>	44
ACEON ORAL TABLET 4 MG	8	<i>alendronate sodium oral tablet 40 mg, 5 mg</i>	47
ACEON ORAL TABLET 8 MG	7	<i>alendronate sodium oral tablet 70 mg, 35 mg</i>	45
ACIPHEX	9	<i>alfuzosin hcl er</i>	48
<i>acitretin oral capsule 10 mg, 25 mg</i>	10	ALINIA ORAL SUSPENSION	
ACTEMRA SUBCUTANEOUS*	11	RECONSTITUTED	49
ACTIQ	12	ALINIA ORAL TABLET	50
ACTIVELLA	13	<i>almotriptan malate</i>	51
ACTONEL ORAL TABLET 150 MG	14	ALORA	52
ACTONEL ORAL TABLET 35 MG	15	<i>alprazolam er</i>	53
ACTONEL ORAL TABLET 5 MG, 30 MG	16	<i>alprazolam xr</i>	54
ACTOPLUS MET	17	ALTAVERA	55
ACTOPLUS MET XR ORAL TABLET		ALTOPREV	56
EXTENDED RELEASE 24 HR* 15-1000 MG ..	18	ALVESCO	57
ACTOPLUS MET XR ORAL TABLET		<i>alyacen 1/35</i>	58
EXTENDED RELEASE 24 HR* 30-1000 MG ..	19	<i>alyacen 7/7/7</i>	59
ACTOS	20	AMBIEN	60
ACUVAIL	21	AMBIEN CR	61
ADALAT CC ORAL TABLET EXTENDED		AMERGE	62
RELEASE 24 HR* 30 MG, 90 MG	23	AMETHIA	63
ADALAT CC ORAL TABLET EXTENDED		AMETHIA LO	64
RELEASE 24 HR* 60 MG	22	AMETHYST	65
ADCIRCA	24	AMITIZA	66
ADDERALL ORAL TABLET 12.5 MG, 30 MG,		<i>amlodipine besy-benazepril hcl</i>	67
15 MG, 7.5 MG, 10 MG, 5 MG	25	<i>amlodipine besylate-valsartan</i>	68
ADDERALL ORAL TABLET 20 MG	26	<i>amlodipine-valsartan-hctz</i>	69
ADDERALL XR	27	AMNESTEEM	70
<i>adefovir dipivoxil</i>	28	<i>amphetamine-dextroamphet er</i>	71
ADEMPAS	29	<i>amphetamine-dextroamphetamine oral tablet 10</i>	
ADRENACLICK	30	<i>mg, 30 mg, 7.5 mg, 15 mg, 12.5 mg, 5 mg</i>	72
ADVAIR DISKUS	31	<i>amphetamine-dextroamphetamine oral tablet 20</i>	
ADVAIR HFA	32	<i>mg</i>	73
ADVICOR ORAL TABLET EXTENDED		AMPYRA	74
RELEASE 24 HR* 1000-20 MG	34	AMTURNIDE	75
ADVICOR ORAL TABLET EXTENDED		ANDRODERM TRANSDERMAL PATCH 24 HR	
RELEASE 24 HR* 1000-40 MG, 500-20 MG,		2 MG/24HR, 4 MG/24HR	78
750-20 MG	33	ANDRODERM TRANSDERMAL PATCH 24 HR	
AEROCHAMBER MV	35	2.5 MG/24HR, 5 MG/24HR	77
AEROSPAN	36	ANDROGEL PUMP TRANSDERMAL 12.5	
AFEDITAB CR ORAL TABLET EXTENDED		MG/ACT (1%)	83
RELEASE 24 HR* 30 MG	37	ANDROGEL PUMP TRANSDERMAL 20.25	
AFEDITAB CR ORAL TABLET EXTENDED		MG/ACT (1.62%)	84
RELEASE 24 HR* 60 MG	38	ANDROGEL TRANSDERMAL 20.25	
AFINITOR	39	MG/1.25GM (1.62%)	79

ANDROGEL TRANSDERMAL 25 MG/2.5GM (1%).....	80	AVANDARYL ORAL TABLET 4-4 MG, 8-4 MG, 4-1 MG, 4-2 MG.....	125
ANDROGEL TRANSDERMAL 40.5 MG/2.5GM (1.62%).....	81	AVANDIA.....	126
ANDROGEL TRANSDERMAL 50 MG/5GM (1%).....	82	AVAPRO.....	127
ANGELIQ.....	85	AVELOX ORAL.....	128
ANORO ELLIPTA.....	86	AVIANE.....	129
ANTARA ORAL CAPSULE 90 MG, 30 MG.....	87	AVINZA.....	130
ANZEMET ORAL.....	88	AVITA.....	131
<i>apap-caff-dihydrocodeine oral capsule</i>	89	AVODART.....	132
APRI.....	90	AVONEX.....	133
APRISO.....	91	AXERT.....	134
APTENSIO XR.....	92	AXIRON.....	135
APTIOM ORAL TABLET 200 MG.....	95	AZILECT.....	136
APTIOM ORAL TABLET 400 MG.....	96	AZOR.....	137
APTIOM ORAL TABLET 600 MG.....	93	AZULFIDINE.....	138
APTIOM ORAL TABLET 800 MG.....	94	AZULFIDINE EN-TABS.....	139
APTIVUS ORAL CAPSULE.....	97	AZURETTE.....	140
ARANELLE.....	98	<i>balsalazide disodium</i>	141
ARAVA.....	99	BALZIVA.....	142
ARCAPTA NEOHALER.....	100	BANZEL ORAL TABLET.....	143
ARICEPT ODT ORAL TABLET DISPERSIBLE 10 MG.....	103	BARACLUDE ORAL TABLET.....	144
ARICEPT ORAL TABLET 23 MG.....	102	BECONASE AQ.....	145
ARICEPT ORAL TABLET 5 MG, 10 MG.....	101	BELSOMRA.....	146
<i>aripiprazole oral solution</i>	104	BELVIQ.....	147
<i>aripiprazole oral tablet</i>	105	BENICAR.....	148
<i>aripiprazole oral tablet dispersible</i>	105	BENICAR HCT.....	149
ARIXTRA.....	106	BENZACLIN.....	150
ARNUITY ELLIPTA.....	107	BEPREVE.....	151
ASACOL HD.....	108	BETASERON.....	152
ASTAGRAF XL ORAL CAPSULE EXTENDED RELEASE 24 HOUR 0.5 MG.....	110	BEYAZ.....	153
ASTAGRAF XL ORAL CAPSULE EXTENDED RELEASE 24 HOUR 1 MG.....	109	BIAXIN ORAL SUSPENSION RECONSTITUTED.....	154
ATACAND.....	111	BIAXIN ORAL TABLET.....	155
ATACAND HCT.....	112	BIAXIN XL.....	156
ADELVIA.....	113	BIAXIN XL PAC.....	157
<i>atorvastatin calcium oral</i>	114	<i>bicalutamide</i>	158
<i>atovaquone-proguanil hcl</i>	115	<i>bimatoprost ophthalmic</i>	159
ATRALIN.....	116	BONIVA ORAL.....	160
ATROVENT.....	117	BOSULIF ORAL TABLET 100 MG.....	162
ATROVENT HFA.....	118	BOSULIF ORAL TABLET 500 MG.....	161
AUBAGIO.....	119	BREO ELLIPTA.....	163
AUGMENTIN XR.....	120	BREO ELLIPTA.....	164
AUVI-Q INJECTION 0.15 MG/0.15ML.....	122	BREVICON (28).....	165
AUVI-Q INJECTION 0.3 MG/0.3ML.....	121	<i>briellyn</i>	166
AVALIDE.....	123	BRILINTA.....	167
AVANDAMET ORAL TABLET 2-500 MG, 2-1000 MG, 4-500 MG.....	124	BRILINTA.....	168
		BRINTELLIX.....	169
		BROVANA.....	171
		BUDEPRION XL.....	172
		<i>budesonide inhalation</i>	173
		BUNAVAIL BUCCAL FILM 2.1-0.3 MG.....	175

BUNAVAIL BUCCAL FILM 4.2-0.7 MG	176	CAVERJECT IMPULSE	217
BUNAVAIL BUCCAL FILM 6.3-1 MG	174	CAYSTON	218
<i>buprenorphine hcl sublingual tablet sublingual 2 mg</i>	177	CAZANT	219
<i>buprenorphine hcl sublingual tablet sublingual 8 mg</i>	179	<i>cefaclor er</i>	220
<i>buprenorphine hcl-naloxone hcl</i>	181	<i>cefixime</i>	221
BUPROBAN	183	CELEBREX	222
<i>bupropion hcl er (smoking det)</i>	185	<i>celecoxib oral</i>	223
<i>bupropion hcl er (sr)</i>	186	CELEXA	224
<i>bupropion hcl er (xl)</i>	187	CENESTIN ORAL TABLET 0.9 MG, 0.625 MG, 0.45 MG	225
<i>bupropion hcl oral</i>	184	CERDELGA	226
<i>butorphanol tartrate nasal</i>	188	CESAMET	227
BUTRANS	189	CHANTIX	228
BYDUREON	190	CHANTIX CONTINUING MONTH PAK	229
BYDUREON	191	CHANTIX STARTING MONTH PAK	230
BYETTA 10 MCG PEN	192	CHATEAL	231
BYETTA 5 MCG PEN	193	CIALIS ORAL TABLET 10 MG, 20 MG	233
BYSTOLIC ORAL TABLET 10 MG, 5 MG, 2.5 MG	194	CIALIS ORAL TABLET 2.5 MG	232
BYSTOLIC ORAL TABLET 20 MG	195	CIALIS ORAL TABLET 5 MG	234
<i>calcitonin (salmon)</i>	196	CIMZIA	235
CAMPRAL	197	CIMZIA PREFILLED	236
CAMRESE	198	CIMZIA STARTER KIT	237
CAMRESE LO	199	CIPRO XR ORAL TABLET EXTENDED RELEASE 24 HR* 1000 MG	239
CANASA	200	CIPRO XR ORAL TABLET EXTENDED RELEASE 24 HR* 500 MG	238
<i>candesartan cilexetil</i>	201	<i>citalopram hydrobromide oral tablet</i>	240
<i>candesartan cilexetil-hctz</i>	202	<i>citalopram hydrobromide oral tablet</i>	241
CAPRELSA ORAL TABLET 100 MG	204	CLARAVIS	242
CAPRELSA ORAL TABLET 300 MG	203	CLARINEX ORAL TABLET	243
CARDIZEM CD ORAL CAPSULE EXTENDED RELEASE 24 HOUR 180 MG, 360 MG, 120 MG, 300 MG	205	CLARINEX-D 12 HOUR	244
CARDIZEM CD ORAL CAPSULE EXTENDED RELEASE 24 HOUR 240 MG	206	<i>clarithromycin er</i>	246
CARDIZEM LA ORAL TABLET EXTENDED RELEASE 24 HR* 240 MG	208	<i>clarithromycin oral suspension reconstituted 250 mg/5ml</i>	245
CARDIZEM LA ORAL TABLET EXTENDED RELEASE 24 HR* 360 MG, 120 MG, 180 MG, 420 MG, 300 MG	207	CLIMARA	247
CARDURA XL	209	CLIMARA PRO	248
CARTIA XT ORAL CAPSULE EXTENDED RELEASE 24 HOUR 180 MG, 120 MG, 300 MG	211	<i>clindamycin phos-benzoyl perox external 1-5 %</i>	249
CARTIA XT ORAL CAPSULE EXTENDED RELEASE 24 HOUR 240 MG	210	<i>clonidine hcl er</i>	251
CASODEX	212	<i>clonidine hcl transdermal patch weekly 0.3 mg/24hr, 0.1 mg/24hr</i>	250
CATAPRES-TTS-1	213	<i>clopidogrel bisulfate</i>	252
CATAPRES-TTS-2	214	<i>clopidogrel bisulfate</i>	253
CATAPRES-TTS-3	215	<i>clozapine oral tablet 100 mg</i>	254
CAVERJECT	216	<i>clozapine oral tablet 200 mg</i>	256
		<i>clozapine oral tablet 50 mg, 25 mg</i>	255
		<i>clozapine oral tablet dispersible 100 mg</i>	254
		<i>clozapine oral tablet dispersible 12.5 mg</i>	259
		<i>clozapine oral tablet dispersible 150 mg</i>	258
		<i>clozapine oral tablet dispersible 200 mg</i>	257
		<i>clozapine oral tablet dispersible 25 mg</i>	255

CLOZARIL ORAL TABLET 100 MG	261	DETROL LA	308
CLOZARIL ORAL TABLET 25 MG	260	DEXEDRINE ORAL CAPSULE EXTENDED	
COARTEM	262	RELEASE 24 HOUR	309
COLAZAL	263	DEXILANT	310
<i>colchicine oral tablet</i>	264	<i>dexmethylphenidate hcl</i>	311
COLCRYS	265	<i>dexmethylphenidate hcl er</i>	312
COLYTE WITH FLAVOR PACKS	266	<i>dexmethylphenidate hcl er</i>	313
COMBIPATCH	267	<i>dextroamphetamine sulfate er</i>	316
COMBIVENT RESPIMAT	268	<i>dextroamphetamine sulfate oral solution</i>	314
COMETRIQ (100 MG DAILY DOSE)	269	<i>dextroamphetamine sulfate oral tablet</i>	315
COMETRIQ (140 MG DAILY DOSE)	270	DIASTAT ACUDIAL	317
COMETRIQ (60 MG DAILY DOSE)	271	DIASTAT PEDIATRIC	318
COMPLERA	272	<i>diazepam</i>	319
CONCERTA ORAL TABLET		DICLEGIS	320
EXTENDEDRELEASE* 18 MG, 54 MG, 27 MG	274	<i>diclofenac sodium transdermal solution</i>	321
CONCERTA ORAL TABLET		DIFFERIN	322
EXTENDEDRELEASE* 36 MG	273	DIFICID	323
CONTRACE	275	<i>dihydroergotamine mesylate injection</i>	324
CORDRAN EXTERNAL TAPE	276	<i>dihydroergotamine mesylate nasal</i>	325
COREG CR	277	<i>diltiazem hcl cd</i>	326
CORLANOR	278	<i>diltiazem hcl er beads oral capsule extended</i>	
CRESTOR	279	<i>release 24 hour 180 mg, 120 mg, 300 mg, 360 mg</i>	328
CRYSSELLE-28	280	<i>diltiazem hcl er beads oral capsule extended</i>	
CYCLAFEM 1/35	281	<i>release 24 hour 240 mg</i>	329
CYCLESSA	282	<i>diltiazem hcl er coated beads oral capsule</i>	
CYCLOSET	283	<i>extended release 24 hour 240 mg</i>	332
CYMBALTA ORAL CAPSULE DELAYED		<i>diltiazem hcl er coated beads oral capsule</i>	
RELEASE PARTICLES 20 MG	286	<i>extended release 24 hour 360 mg, 300 mg, 120 mg,</i>	
CYMBALTA ORAL CAPSULE DELAYED		<i>180 mg</i>	330
RELEASE PARTICLES 30 MG	284	<i>diltiazem hcl er coated beads oral tablet extended</i>	
CYMBALTA ORAL CAPSULE DELAYED		<i>release 24 hr* 180 mg, 300 mg, 360 mg, 420 mg</i>	
RELEASE PARTICLES 60 MG	288		331
CYSTARAN	290	<i>diltiazem hcl er coated beads oral tablet extended</i>	
D.H.E. 45	291	<i>release 24 hr* 240 mg</i>	333
DAKLINZA	292	<i>diltiazem hcl er oral capsule extended release 24</i>	
DALIRESP	293	<i>hour 240 mg</i>	327
DASETTA 1/35	294	DIOVAN	334
DASETTA 7/7/7	295	DIOVAN HCT	335
DAYSEE	296	DIPENTUM	336
DAYTRANA	297	DITROPAN XL ORAL TABLET EXTENDED	
DELZICOL	298	RELEASE 24 HR* 10 MG, 15 MG	337
DEPO-PROVERA INTRAMUSCULAR*		DITROPAN XL ORAL TABLET EXTENDED	
SUSPENSION 150 MG/ML	299	RELEASE 24 HR* 5 MG	338
DEPO-SUBQ PROVERA 104	300	<i>donepezil hcl oral tablet 10 mg, 5 mg</i>	339
DESOGEN	301	<i>donepezil hcl oral tablet 23 mg</i>	340
<i>desogestrel-ethinyl estradiol oral tablet 0.15-30</i>		<i>donepezil hcl oral tablet dispersible</i>	339
<i>mg-mcg</i>	302	DOVONEX EXTERNAL CREAM	341
DESOXYN	303	<i>doxycycline</i>	342
<i>desvenlafaxine er</i>	304	<i>dronabinol</i>	343
<i>desvenlafaxine fumarate er</i>	306		

2015 Aetna Value Plan
(Updated 12/01/2015)

<i>drospirenone-ethinyl estradiol oral tablet 3-0.03 mg</i>	344	EPANED.....	391
DUAVEE.....	345	EPIDUO.....	392
DUETACT.....	346	EPIDUO FORTE.....	393
DULERA.....	347	<i>epinephrine injection 0.15 mg/0.15ml</i>	394
<i>duloxetine hcl oral capsule delayed release particles 20 mg</i>	349	<i>epinephrine injection 0.3 mg/0.3ml</i>	395
<i>duloxetine hcl oral capsule delayed release particles 30 mg</i>	353	EPIPEN 2-PAK.....	396
<i>duloxetine hcl oral capsule delayed release particles 40 mg</i>	348	EPIPEN JR 2-PAK.....	397
<i>duloxetine hcl oral capsule delayed release particles 60 mg</i>	351	<i>eprosartan mesylate</i>	398
DURAGESIC-100.....	355	ERIVEDGE.....	399
DURAGESIC-12.....	356	ERRIN.....	400
DURAGESIC-25.....	357	ESBRIET.....	401
DURAGESIC-50.....	358	<i>escitalopram oxalate oral tablet</i>	402
DURAGESIC-75.....	359	<i>esomeprazole magnesium</i>	403
<i>dutasteride</i>	360	ESTARYLLA.....	404
EDARBI.....	361	<i>estradiol transdermal patch weekly</i>	405
EDARBYCLOR.....	362	<i>estradiol-norethindrone acet</i>	406
EDEX.....	363	<i>estradiol-norethindrone acet</i>	407
EDURANT.....	364	ESTROGEL.....	408
EFFEXOR XR.....	365	ESTROSTEP FE.....	409
EFFIENT.....	366	<i>eszopiclone</i>	410
ELESTRIN.....	367	EVAMIST.....	411
ELIDEL.....	368	EVEKEO.....	412
ELINEST.....	369	EVOXAC.....	413
ELIQUIS.....	370	EXALGO.....	414
ELLA.....	371	EXELON ORAL CAPSULE.....	416
EMBEDA.....	372	EXELON TRANSDERMAL.....	415
EMEND ORAL CAPSULE 80 & 125 MG.....	374	EXFORGE HCT.....	419
EMEND ORAL CAPSULE 80 MG, 125 MG, 40 MG.....	373	EXFORGE ORAL TABLET 10-320 MG, 5-320 MG.....	418
EMOQUETTE.....	375	EXFORGE ORAL TABLET 5-160 MG, 10-160 MG.....	417
EMSAM.....	376	EXTAVIA.....	420
EMTRIVA.....	377	FABIOR.....	421
EMTRIVA.....	378	FACTIVE.....	422
ENABLEX.....	379	FALMINA.....	423
ENBREL SUBCUTANEOUS* 25 MG/0.5ML.....	380	<i>famciclovir oral</i>	424
ENBREL SUBCUTANEOUS* 50 MG/ML.....	381	FAMVIR.....	425
ENBREL SUBCUTANEOUS* KIT.....	382	FANAPT.....	426
ENBREL SURECLICK.....	383	FANAPT TITRATION PACK.....	427
ENJUVA.....	384	FARXIGA.....	428
<i>enoxaparin sodium</i>	385	FARYDAK.....	429
<i>enoxaparin sodium</i>	386	FAZACLO ORAL TABLET DISPERSIBLE 100 MG.....	431
ENPRESSE-28.....	387	FAZACLO ORAL TABLET DISPERSIBLE 12.5 MG.....	434
ENSKYCE.....	388	FAZACLO ORAL TABLET DISPERSIBLE 150 MG.....	430
<i>entecavir</i>	389	FAZACLO ORAL TABLET DISPERSIBLE 200 MG.....	432
ENTRESTO.....	390	FAZACLO ORAL TABLET DISPERSIBLE 25 MG.....	433

<i>felodipine er</i>	435	GELNIQUE.....	487
FEMCON FE.....	436	GENERESS FE.....	488
FEMHRT LOW DOSE.....	437	GEODON ORAL.....	489
FEMRING.....	438	GIANVI.....	490
<i>fenofibrate micronized</i>	441	GIAZO.....	491
<i>fenofibrate oral tablet</i>	439	GILDAGIA.....	492
<i>fenofibrate oral tablet</i>	440	GILDESS FE 1.5/30.....	493
<i>fenofibric acid oral capsule delayed release</i>	442	GILDESS FE 1/20.....	494
FENOGLIDE.....	443	GILENYA.....	495
<i>fentanyl</i>	444	GILOTRIF.....	496
<i>fentanyl citrate buccal</i>	445	GLUCAGEN HYPOKIT.....	497
FENTORA.....	446	GLUCAGON EMERGENCY.....	498
FETZIMA.....	447	GLYXAMBI.....	499
FETZIMA TITRATION.....	449	GRALISE ORAL TABLET 300 MG.....	501
FIBRICOR.....	451	GRALISE ORAL TABLET 600 MG.....	500
FIRAZYR.....	452	GRALISE STARTER.....	502
FLOVENT DISKUS.....	453	GRANIX.....	503
FLOVENT HFA.....	454	GYNAZOLE-1.....	504
<i>fluoxetine hcl oral capsule 10 mg</i>	461	HARVONI.....	505
<i>fluoxetine hcl oral capsule 20 mg</i>	458	HECTOROL ORAL.....	506
<i>fluoxetine hcl oral capsule 40 mg</i>	455	HEPSERA.....	507
<i>fluoxetine hcl oral capsule delayed release</i>	456	HETLIOZ.....	508
<i>fluoxetine hcl oral tablet 10 mg</i>	457	HORIZANT ORAL TABLET EXTENDEDRELEASE* 300 MG.....	510
<i>fluoxetine hcl oral tablet 20 mg</i>	459	HORIZANT ORAL TABLET EXTENDEDRELEASE* 600 MG.....	509
<i>fluoxetine hcl oral tablet 60 mg</i>	460	HUMIRA PEDIATRIC CROHNS START.....	513
<i>fluvastatin sodium</i>	462	HUMIRA PEN.....	514
<i>fluvastatin sodium er</i>	463	HUMIRA PEN-CROHNS STARTER.....	515
<i>fluvoxamine maleate er</i>	466	HUMIRA PEN-PSORIASIS STARTER.....	516
<i>fluvoxamine maleate oral tablet 100 mg</i>	465	HUMIRA SUBCUTANEOUS* 10 MG/0.2ML.....	511
<i>fluvoxamine maleate oral tablet 25 mg, 50 mg</i>	464	HUMIRA SUBCUTANEOUS* 20 MG/0.4ML, 40 MG/0.8ML.....	512
FOCALIN.....	467	<i>hydromorphone hcl er</i>	517
FOCALIN XR.....	468	<i>hydromorphone hcl er</i>	518
<i>fondaparinux sodium</i>	469	HYSINGLA ER.....	519
FORADIL AEROLIZER.....	470	<i>ibandronate sodium oral</i>	520
FORTESTA.....	471	IBRANCE.....	521
FORTICAL.....	472	ICLUSIG ORAL TABLET 15 MG.....	522
FOSAMAX.....	473	ICLUSIG ORAL TABLET 45 MG.....	523
FOSAMAX PLUS D.....	474	ILARIS.....	524
FRAGMIN.....	475	<i>imiquimod external</i>	525
FROVA.....	476	IMITREX NASAL.....	527
FULYZAQ.....	477	IMITREX ORAL.....	528
FYCOMPA.....	478	IMITREX STATDOSE REFILL.....	529
<i>gabapentin oral capsule</i>	479	IMITREX SUBCUTANEOUS*.....	526
<i>gabapentin oral solution</i>	481	INCIVEK.....	530
<i>gabapentin oral tablet</i>	480	INCRUSE ELLIPTA.....	531
GABITRIL ORAL TABLET 16 MG.....	482	INLYTA.....	532
GABITRIL ORAL TABLET 2 MG.....	483		
GABITRIL ORAL TABLET 4 MG, 12 MG.....	484		
<i>galantamine hydrobromide er</i>	485		
GATTEX.....	486		

INNOPRAN XL ORAL CAPSULE EXTENDED RELEASE 24 HOUR 120 MG	533	KADIAN ORAL CAPSULE EXTENDED RELEASE 24 HOUR 40 MG	573
INNOPRAN XL ORAL CAPSULE EXTENDED RELEASE 24 HOUR 80 MG	534	KALYDECO	574
INSPIRA ORAL TABLET 25 MG	536	KALYDECO	575
INSPIRA ORAL TABLET 50 MG	535	KAPVAY ORAL TABLET EXTENDED RELEASE 12 HR*	576
INTELENCE ORAL TABLET 100 MG, 25 MG	538	KARBINAL ER	577
INTELENCE ORAL TABLET 200 MG	537	KARIVA	578
INTERMEZZO	539	KAZANO	579
INTROVALE	540	KELNOR 1/35	580
INTUNIV	541	KEPPRA XR ORAL TABLET EXTENDED RELEASE 24 HR* 500 MG	581
INVEGA ORAL TABLET EXTENDED RELEASE 24 HR* 6 MG, 3 MG, 1.5 MG	542	KEPPRA XR ORAL TABLET EXTENDED RELEASE 24 HR* 750 MG	582
INVEGA ORAL TABLET EXTENDED RELEASE 24 HR* 9 MG	543	KETEK	583
INVOKAMET	544	<i>ketoconazole oral</i>	584
INVOKANA	545	<i>ketorolac tromethamine oral</i>	585
<i>ipratropium bromide nasal</i>	546	KEVEYIS	586
IPRIVASK	547	KHEDEZLA	587
<i>irbesartan</i>	548	KOMBIGLYZE XR ORAL TABLET EXTENDED RELEASE 24 HR* 2.5-1000 MG	590
<i>irbesartan-hydrochlorothiazide</i>	549	KOMBIGLYZE XR ORAL TABLET EXTENDED RELEASE 24 HR* 5-1000 MG, 5-500 MG	589
IRENKA	550	KORLYM	591
IRESSA	551	KURVELO	592
ISENTRESS ORAL TABLET	552	LAMICTAL ODT ORAL KIT	597
<i>itraconazole oral</i>	553	LAMICTAL ODT ORAL TABLET DISPERSIBLE 100 MG	593
JAKAFI	554	LAMICTAL ODT ORAL TABLET DISPERSIBLE 200 MG	594
JALYN	555	LAMICTAL ODT ORAL TABLET DISPERSIBLE 25 MG	595
JANUMET	556	LAMICTAL ODT ORAL TABLET DISPERSIBLE 50 MG	596
JANUMET XR ORAL TABLET EXTENDED RELEASE 24 HR* 100-1000 MG, 50-500 MG	557	LAMICTAL XR ORAL KIT	598
JANUMET XR ORAL TABLET EXTENDED RELEASE 24 HR* 50-1000 MG	558	LAMICTAL XR ORAL TABLET EXTENDED RELEASE 24 HR* 200 MG	601
JANUVIA	559	LAMICTAL XR ORAL TABLET EXTENDED RELEASE 24 HR* 25 MG, 50 MG, 100 MG ...	599
JARDIANCE	560	LAMICTAL XR ORAL TABLET EXTENDED RELEASE 24 HR* 250 MG	602
JENCYCLA	561	LAMICTAL XR ORAL TABLET EXTENDED RELEASE 24 HR* 300 MG	600
JENTADUETO	562	LAMISIL ORAL PACKET 125 MG	604
JOLESSA	563	LAMISIL ORAL PACKET 187.5 MG	603
JOLIVETTE	564	<i>lamotrigine er oral tablet extended release 24 hr* 100 mg, 50 mg, 25 mg</i>	608
JUNEL 1.5/30	565	<i>lamotrigine er oral tablet extended release 24 hr* 200 mg</i>	610
JUNEL 1/20	566		
JUNEL FE 1.5/30	567		
JUNEL FE 1/20	568		
JUXTAPID ORAL CAPSULE 10 MG, 5 MG ..	569		
JUXTAPID ORAL CAPSULE 20 MG	570		
JUXTAPID ORAL CAPSULE 30 MG, 40 MG, 60 MG	571		
KADIAN ORAL CAPSULE EXTENDED RELEASE 24 HOUR 20 MG, 200 MG, 80 MG, 100 MG, 30 MG, 50 MG, 60 MG, 10 MG	572		

<i>lamotrigine er oral tablet extended release 24 hr*</i>	LIVALO	652
300 mg, 250 mg	LO LOESTRIN FE	653
<i>lamotrigine oral tablet dispersible 100 mg, 200 mg</i>	LO/OVRAL (28)	654
	LOESTRIN 1.5/30 (21)	655
<i>lamotrigine oral tablet dispersible 25 mg</i>	LOESTRIN 1/20 (21)	656
<i>lamotrigine oral tablet dispersible 50 mg</i>	LOESTRIN FE 1.5/30	657
LASTACAFT	LOESTRIN FE 1/20	658
<i>latanoprost ophthalmic</i>	LOFIBRA	659
LATUDA ORAL TABLET 20 MG	LOFIBRA	660
LATUDA ORAL TABLET 40 MG, 120 MG, 60	LOMEDIA 24 FE	661
MG	LONSURF ORAL TABLET 15-6.14 MG	662
LATUDA ORAL TABLET 80 MG	LONSURF ORAL TABLET 20-8.19 MG	663
LAZANDA	LORYNA	664
LEENA	LOSEASONIQUE	665
<i>leflunomide oral</i>	LOTREL	666
LENVIMA 10 MG DAILY DOSE	<i>lovastatin</i>	667
LENVIMA 14 MG DAILY DOSE	LOVAZA	668
LENVIMA 20 MG DAILY DOSE	LOVENOX	669
LENVIMA 24 MG DAILY DOSE	LOW-OGESTREL	670
LESCOL	LUMIGAN OPHTHALMIC SOLUTION 0.01 %	
LESCOL XL		671
LESSINA	LUNESTA	672
LEVAQUIN ORAL SOLUTION	LUTERA	673
LEVAQUIN ORAL TABLET	LUVOX CR	674
<i>levetiracetam er oral tablet extended release 24</i>	LYNPARZA	675
<i>hr* 500 mg</i>	LYRICA	676
<i>levetiracetam er oral tablet extended release 24</i>	LYSTEDA	677
<i>hr* 750 mg</i>	LYZA	678
LEVITRA	MALARONE	679
<i>levocetirizine dihydrochloride oral tablet</i>	MARINOL	680
<i>levofloxacin oral solution</i>	<i>marlissa</i>	681
<i>levofloxacin oral tablet</i>	MATZIM LA ORAL TABLET EXTENDED	
LEVONEST	RELEASE 24 HR* 180 MG, 360 MG, 300 MG,	
<i>levonorgest-eth estrad 91-day oral tablet 0.15-0.03</i>	420 MG	682
<i>mg, 0.1-0.02 & 0.01 mg</i>	MATZIM LA ORAL TABLET EXTENDED	
<i>levonorgestrel</i>	RELEASE 24 HR* 240 MG	683
<i>levonorgestrel</i>	MAXALT	684
<i>levonorgestrel-ethinyl estrad</i>	MAXALT-MLT	685
<i>levonorgestrel-ethinyl estrad</i>	<i>medroxyprogesterone acetate intramuscular*</i>	686
LEVORA 0.15/30 (28)	MEKINIST ORAL TABLET 0.5 MG	688
LEXAPRO ORAL TABLET	MEKINIST ORAL TABLET 2 MG	687
LIALDA	MENOSTAR	689
<i>lidocaine external patch</i>	MEPRON	690
LIDODERM	METADATE CD	691
<i>lidorx</i>	METADATE ER	692
<i>lindane external</i>	<i>metaxalone</i>	693
<i>linezolid oral</i>	<i>methamphetamine hcl</i>	694
LINZESS	METHYLIN ORAL SOLUTION 10 MG/5ML	
LIPITOR		695
LIPOFEN	METHYLIN ORAL SOLUTION 5 MG/5ML	696
LIPTRUZET	METHYLIN ORAL TABLET CHEWABLE	697

2015 Aetna Value Plan
(Updated 12/01/2015)

<i>methylphenidate hcl er (cd)</i>	705	<i>naratriptan hcl</i>	742
<i>methylphenidate hcl er (la)</i>	706	NATAZIA.....	743
<i>methylphenidate hcl er oral tablet</i>		NATESTO.....	744
<i>extendedrelease* 20 mg</i>	703	NATPARA.....	745
<i>methylphenidate hcl er oral tablet</i>		NECON 0.5/35 (28).....	746
<i>extendedrelease* 27 mg, 54 mg, 18 mg</i>	702	NECON 1/35 (28).....	747
<i>methylphenidate hcl er oral tablet</i>		NECON 1/50 (28).....	748
<i>extendedrelease* 36 mg</i>	704	NECON 10/11 (28).....	749
<i>methylphenidate hcl oral solution 10 mg/5ml</i>	698	NESINA.....	750
<i>methylphenidate hcl oral solution 5 mg/5ml</i>	700	NEUPRO.....	751
<i>methylphenidate hcl oral tablet</i>	699	NEURONTIN ORAL CAPSULE.....	752
<i>methylphenidate hcl oral tablet chewable</i>	701	NEURONTIN ORAL TABLET.....	753
<i>metoprolol succinate er oral tablet extended</i>		<i>nevirapine er oral tablet extended release 24 hr*</i>	
<i>release 24 hr* 200 mg</i>	709	400 mg.....	754
<i>metoprolol succinate er oral tablet extended</i>		NEXAVAR.....	755
<i>release 24 hr* 25 mg</i>	708	NEXIUM ORAL CAPSULE DELAYED	
<i>metoprolol succinate er oral tablet extended</i>		RELEASE.....	758
<i>release 24 hr* 50 mg, 100 mg</i>	707	NEXIUM ORAL PACKET 10 MG, 20 MG.....	756
METROGEL.....	710	NEXIUM ORAL PACKET 40 MG.....	757
MEVACOR.....	711	NEXPLANON.....	759
MIACALCIN NASAL.....	712	NEXT CHOICE ONE DOSE.....	760
MICARDIS.....	713	<i>nicotine transdermal patch 24 hr</i>	761
MICARDIS HCT.....	714	NICOTROL.....	762
MICROGESTIN 1.5/30.....	715	NICOTROL NS.....	763
MICROGESTIN 1/20.....	716	NIFEDICAL XL ORAL TABLET EXTENDED	
MICROGESTIN FE 1.5/30.....	717	RELEASE 24 HR* 30 MG.....	764
MICROGESTIN FE 1/20.....	718	NIFEDICAL XL ORAL TABLET EXTENDED	
MIGRANAL.....	719	RELEASE 24 HR* 60 MG.....	765
MIMVEY.....	720	<i>nifedipine er oral tablet extended release 24 hr* 60</i>	
MINASTRIN 24 FE.....	721	<i>mg</i>	766
MINIVELLE.....	722	<i>nifedipine er oral tablet extended release 24 hr* 90</i>	
MIRAPEX ER.....	723	<i>mg, 30 mg</i>	767
MIRCETTE.....	724	<i>nifedipine er osmotic release oral tablet extended</i>	
MIRENA.....	725	<i>release 24 hr* 60 mg</i>	769
<i>mirtazapine oral tablet dispersible</i>	726	<i>nifedipine er osmotic release oral tablet extended</i>	
MIRVASO.....	727	<i>release 24 hr* 90 mg, 30 mg</i>	768
MITIGARE.....	728	<i>nisoldipine er oral tablet extended release 24 hr*</i>	
<i>modafinil</i>	729	30 mg.....	771
MODICON (28).....	730	<i>nisoldipine er oral tablet extended release 24 hr*</i>	
MONO-LINYAH.....	731	40 mg, 8.5 mg, 17 mg, 34 mg, 20 mg.....	770
MONONESSA.....	732	NORA-BE.....	772
<i>montelukast sodium oral</i>	733	NORDETTE (28).....	773
<i>montelukast sodium oral</i>	734	<i>norethindrone oral</i>	774
MOVANTIK.....	735	<i>norethindrone-eth estradiol oral tablet 0.5-2.5</i>	
<i>moxifloxacin hcl oral</i>	736	<i>mg-mcg</i>	775
MULTAQ.....	737	<i>norethin-eth estradiol-fe</i>	776
MUSE.....	738	<i>norgestimate-eth estradiol</i>	777
MYALEPT.....	739	<i>norgestim-eth estrad triphasic</i>	778
MYORISAN ORAL CAPSULE 10 MG, 40 MG,		NORINYL 1+35 (28).....	779
20 MG.....	740	NORINYL 1+50 (28).....	780
MYRBETRIQ.....	741	NOROXIN.....	781

NOR-QD	782	ORTHO MICRONOR	825
NORTHERA ORAL CAPSULE 100 MG	784	ORTHO TRI-CYCLEN (28)	826
NORTHERA ORAL CAPSULE 200 MG	783	ORTHO TRI-CYCLEN LO	827
NORTHERA ORAL CAPSULE 300 MG	785	ORTHO-CEPT (28)	828
NORTREL 0.5/35 (28)	786	ORTHO-CYCLEN (28)	829
NORTREL 1/35 (21)	787	ORTHO-NOVUM 1/35 (28)	830
NORTREL 1/35 (28)	788	ORTHO-NOVUM 7/7/7 (28)	831
NORTREL 7/7/7	789	OSENI	832
NOVOLOG FLEXPEN	790	OSPHENA	833
NOXAFIL ORAL SUSPENSION	791	OTEZLA ORAL	835
NOXAFIL ORAL TABLET DELAYED RELEASE	792	OTEZLA ORAL TABLET	834
NUCYNTA	793	OVCON-35 (28)	836
NUCYNTA ER	794	OVIDE	837
NUEDEXTA	795	OXTELLAR XR ORAL TABLET EXTENDED RELEASE 24 HR* 150 MG, 300 MG	838
NUVARING	796	OXTELLAR XR ORAL TABLET EXTENDED RELEASE 24 HR* 600 MG	839
NUVIGIL ORAL TABLET 150 MG, 250 MG, 200 MG	797	<i>oxybutynin chloride oral tablet</i>	840
NUVIGIL ORAL TABLET 50 MG	798	<i>oxycodone hcl er</i>	841
OCELLA	799	OXYCONTIN	842
ODOMZO	800	<i>oxymorphone hcl er</i>	843
OFEV	801	OXYTROL	844
<i>ofloxacin oral tablet 400 mg</i>	802	<i>paliperidone er oral tablet extended release 24 hr* 1.5 mg, 6 mg, 3 mg</i>	845
OGESTREL	803	<i>paliperidone er oral tablet extended release 24 hr* 9 mg</i>	846
<i>olanzapine oral tablet 10 mg, 20 mg, 7.5 mg, 15 mg, 5 mg</i>	804	PANCREAZE	847
<i>olanzapine oral tablet 2.5 mg</i>	805	PARAGARD INTRAUTERINE COPPER	848
<i>olanzapine oral tablet dispersible 15 mg, 20 mg, 5 mg</i>	804	<i>paroxetine hcl er</i>	851
OLEPTRO ORAL TABLET EXTENDED RELEASE 24 HR* 150 MG	806	<i>paroxetine hcl oral tablet 20 mg, 10 mg</i>	850
OLEPTRO ORAL TABLET EXTENDED RELEASE 24 HR* 300 MG	807	<i>paroxetine hcl oral tablet 30 mg, 40 mg</i>	849
OLYSIO	808	PAXIL CR	855
<i>omega-3-acid ethyl esters</i>	809	PAXIL ORAL SUSPENSION	853
OMNARIS	810	PAXIL ORAL TABLET 20 MG, 10 MG	852
<i>ondansetron</i>	811	PAXIL ORAL TABLET 30 MG, 40 MG	854
<i>ondansetron hcl oral solution</i>	814	<i>peg 3350/electrolytes</i>	856
<i>ondansetron hcl oral tablet 24 mg</i>	812	<i>peg-3350/electrolytes</i>	857
<i>ondansetron hcl oral tablet 8 mg, 4 mg</i>	813	PENNSAID TRANSDERMAL SOLUTION 2 %	858
ONEXTON	815	PENTASA ORAL CAPSULE EXTENDED RELEASE* 250 MG	860
ONFI ORAL SUSPENSION	817	PENTASA ORAL CAPSULE EXTENDED RELEASE* 500 MG	859
ONFI ORAL TABLET 20 MG, 10 MG	816	PERFOROMIST	861
ONFI ORAL TABLET 5 MG	817	<i>perindopril erbumine oral tablet 2 mg</i>	863
ONGLYZA	818	<i>perindopril erbumine oral tablet 4 mg</i>	864
OPANA ER ORAL	820	<i>perindopril erbumine oral tablet 8 mg</i>	862
OPANA ORAL	819	PERTZYE	865
ORAVIG	821	PHILITH	866
ORKAMBI	822	PICATO	867
ORSYTHIA	823	<i>pioglitazone hcl</i>	868
ORTHO EVRA	824		

2015 Aetna Value Plan
(Updated 12/01/2015)

<i>pioglitazone hcl-glimepiride</i>	869	PROTOPIC.....	914
<i>pioglitazone hcl-metformin hcl</i>	870	PROVENTIL HFA.....	915
PIRMELLA 1/35.....	871	PROVIGIL.....	916
PLAN B ONE-STEP.....	872	PROZAC ORAL CAPSULE 10 MG.....	918
PLAVIX.....	873	PROZAC ORAL CAPSULE 20 MG.....	919
PLAVIX.....	874	PROZAC ORAL CAPSULE 40 MG.....	917
PLEGRIDY.....	875	PROZAC WEEKLY.....	920
PLEGRIDY STARTER PACK.....	876	PULMICORT.....	921
PLEXION.....	877	PULMICORT FLEXHALER.....	922
PLEXION CLEANSER EXTERNAL LIQUID†		PULMOZYME.....	923
.....	878	PURIXAN.....	924
PLEXION CLEANSING CLOTH EXTERNAL		QNASL.....	925
PAD.....	879	QNASL CHILDRENS.....	926
POMALYST.....	880	QUALAQUIN.....	927
PORTIA-28.....	881	QUARTETTE.....	928
POTIGA ORAL TABLET 200 MG.....	883	QUASENSE.....	929
POTIGA ORAL TABLET 300 MG, 400 MG...	882	QUDEXY XR.....	930
POTIGA ORAL TABLET 50 MG.....	884	<i>quetiapine fumarate oral tablet 200 mg</i>	934
PRADAXA.....	885	<i>quetiapine fumarate oral tablet 25 mg</i>	933
PRALUENT.....	886	<i>quetiapine fumarate oral tablet 400 mg, 300 mg</i>	
<i>pramipexole dihydrochloride er</i>	887	931
PRANDIMET.....	888	<i>quetiapine fumarate oral tablet 50 mg, 100 mg</i>	
PRAVACHOL.....	889	932
<i>pravastatin sodium</i>	890	QUILLIVANT XR.....	935
PREFEST.....	891	<i>rabeprazole sodium</i>	936
PRENATE MINI.....	892	RANEXA.....	937
PREVACID ORAL CAPSULE DELAYED		RAPAFLO.....	938
RELEASE 15 MG.....	893	RAVICTI.....	939
PREVACID SOLUTAB.....	894	RAYOS.....	940
PREVIFEM.....	895	RAZADYNE ER.....	941
PREZISTA ORAL SUSPENSION.....	897	REBETOL ORAL SOLUTION.....	942
PREZISTA ORAL TABLET 150 MG, 75 MG, 600		RECLIPSEN.....	943
MG.....	896	RECTIV.....	944
PREZISTA ORAL TABLET 800 MG.....	898	RELENZA DISKHALER.....	945
PRISTIQ.....	899	RELPAK.....	946
PRISTIQ.....	901	REMERON SOLTAB.....	947
PROAIR HFA.....	903	REPATHA.....	948
PROAIR RESPICLICK.....	904	REPATHA SURECLICK.....	949
PROCARDIA XL ORAL TABLET EXTENDED		REQUIP XL ORAL TABLET EXTENDED	
RELEASE 24 HR* 60 MG.....	906	RELEASE 24 HR* 12 MG.....	951
PROCARDIA XL ORAL TABLET EXTENDED		REQUIP XL ORAL TABLET EXTENDED	
RELEASE 24 HR* 90 MG, 30 MG.....	905	RELEASE 24 HR* 6 MG, 8 MG, 2 MG, 4 MG	
PROCENTRA.....	907	950
PROCYSBI ORAL CAPSULE DELAYED		RESCULA.....	952
RELEASE 25 MG.....	909	RESTASIS.....	953
PROCYSBI ORAL CAPSULE DELAYED		RESTORIL ORAL CAPSULE 22.5 MG, 7.5 MG	
RELEASE 75 MG.....	908	954
PROLENSA.....	910	RETIN-A.....	955
PROMACTA.....	911	RETIN-A MICRO.....	956
PROMETRIUM.....	912	RETIN-A MICRO PUMP.....	957
<i>propafenone hcl er</i>	913		

REVATIO ORAL SUSPENSION		<i>ropinirole hcl er oral tablet extended release 24</i>	
RECONSTITUTED	959	<i>hr* 2 mg, 4 mg, 6 mg, 8 mg</i>	988
REVATIO ORAL TABLET	958	ROZEREM	990
REVLIMID	960	RYTHMOL SR	991
REXULTI	961	SABRIL	992
REYATAZ ORAL CAPSULE 150 MG, 300 MG	962	SAFYRAL	993
		SAMSCA ORAL TABLET 15 MG	995
REYATAZ ORAL CAPSULE 200 MG	963	SAMSCA ORAL TABLET 30 MG	994
RHINOCORT AQUA	964	SANCTURA XR	996
<i>risedronate sodium oral tablet 150 mg</i>	967	SANCUSO	997
<i>risedronate sodium oral tablet 35 mg</i>	965	SANDOSTATIN	998
<i>risedronate sodium oral tablet 5 mg, 30 mg</i>	966	SAPHRIS	999
<i>risedronate sodium oral tablet delayed release</i>	965	SAPHRIS	1000
		SAVAYSA	1001
RISPERDAL M-TAB ORAL TABLET		SAVELLA	1002
DISPERSIBLE 2 MG, 1 MG, 3 MG, 0.5 MG	972	SAVELLA TITRATION PACK	1003
RISPERDAL M-TAB ORAL TABLET		SAXENDA	1004
DISPERSIBLE 4 MG	973	SEASONALE	1005
RISPERDAL ORAL SOLUTION	969	SEASONIQUE	1006
RISPERDAL ORAL TABLET 1 MG, 2 MG, 0.25		SELZENTRY	1007
MG, 0.5 MG	968	SENSIPAR	1008
RISPERDAL ORAL TABLET 3 MG	971	SEREVENT DISKUS	1009
RISPERDAL ORAL TABLET 4 MG	970	SEROQUEL ORAL TABLET 200 MG	1011
RISPERIDONE M-TAB ORAL TABLET		SEROQUEL ORAL TABLET 25 MG, 100 MG,	
DISPERSIBLE 1 MG, 0.5 MG, 2 MG	978	300 MG, 50 MG	1012
RISPERIDONE M-TAB ORAL TABLET		SEROQUEL ORAL TABLET 400 MG	1010
DISPERSIBLE 3 MG	979	SEROQUEL XR ORAL TABLET EXTENDED	
RISPERIDONE M-TAB ORAL TABLET		RELEASE 24 HR* 200 MG, 150 MG	1015
DISPERSIBLE 4 MG	980	SEROQUEL XR ORAL TABLET EXTENDED	
<i>risperidone oral tablet 1 mg, 0.25 mg, 0.5 mg, 2 mg</i>	974	RELEASE 24 HR* 300 MG, 400 MG	1013
		SEROQUEL XR ORAL TABLET EXTENDED	
<i>risperidone oral tablet 3 mg</i>	975	RELEASE 24 HR* 50 MG	1014
<i>risperidone oral tablet 4 mg</i>	977	<i>sertraline hcl oral concentrate</i>	1019
<i>risperidone oral tablet dispersible 0.25 mg</i>	976	<i>sertraline hcl oral tablet 100 mg</i>	1016
<i>risperidone oral tablet dispersible 1 mg, 0.5 mg, 2</i>		<i>sertraline hcl oral tablet 25 mg</i>	1017
<i>mg</i>	974	<i>sertraline hcl oral tablet 50 mg</i>	1018
<i>risperidone oral tablet dispersible 3 mg</i>	975	SIGNIFOR	1020
<i>risperidone oral tablet dispersible 4 mg</i>	977	SIGNIFOR LAR	1021
RITALIN	981	<i>sildenafil citrate oral</i>	1022
RITALIN LA ORAL CAPSULE EXTENDED		SIMBRINZA	1023
RELEASE 24 HOUR 10 MG, 40 MG, 20 MG	982	SIMCOR	1024
		SIMPONI	1025
RITALIN LA ORAL CAPSULE EXTENDED		<i>simvastatin oral</i>	1026
RELEASE 24 HOUR 30 MG	983	SINGULAIR	1027
RITALIN LA ORAL CAPSULE EXTENDED		SINGULAIR	1028
RELEASE 24 HOUR 60 MG	984	SIRTURO	1029
RITALIN SR	985	SIVEXTRO ORAL	1030
<i>rivastigmine</i>	986	SKELAXIN	1031
<i>rizatriptan benzoate</i>	987	SKELID	1032
<i>ropinirole hcl er oral tablet extended release 24</i>		SKYLA	1033
<i>hr* 12 mg</i>	989	SONATA	1034

2015 Aetna Value Plan
(Updated 12/01/2015)

SOOLANTRA	1035	SYNJARDY	1076
SORIATANE	1036	TACLONEX EXTERNAL OINTMENT	1077
SOVALDI	1037	<i>tacrolimus external</i>	1078
SPIRIVA HANDIHALER	1038	TAFINLAR	1079
SPIRIVA RESPIMAT	1039	TAMIFLU ORAL CAPSULE	1081
SPORANOX ORAL CAPSULE	1040	TAMIFLU ORAL SUSPENSION	
SPORANOX PULSEPAK	1041	RECONSTITUTED 6 MG/ML	1080
SPRINTEC 28	1042	TANZEUM	1082
SPRIX	1043	TARCEVA	1083
SPRYCEL ORAL TABLET 100 MG, 140 MG		TASIGNA	1084
	1044	TAZORAC	1085
SPRYCEL ORAL TABLET 20 MG, 70 MG, 50		TAZTIA XT ORAL CAPSULE EXTENDED	
MG, 80 MG	1045	RELEASE 24 HOUR 240 MG	1087
SRONYX	1046	TAZTIA XT ORAL CAPSULE EXTENDED	
STAXYN	1047	RELEASE 24 HOUR 300 MG, 360 MG, 180 MG,	
STENDRA	1048	120 MG	1086
STIMATE	1049	TECFIDERA	1088
STIOLTO RESPIMAT	1050	TECHNIVIE	1089
STIVARGA	1051	TEKAMLO	1090
STRATTERA ORAL CAPSULE 100 MG, 80 MG		TEKTURNA	1092
	1053	TEKTURNA HCT	1094
STRATTERA ORAL CAPSULE 25 MG, 10 MG,		<i>telmisartan</i>	1096
18 MG, 40 MG, 60 MG	1052	<i>telmisartan-amlodipine</i>	1097
STRIANT	1054	<i>telmisartan-hctz</i>	1098
STRIBILD	1055	<i>temazepam oral capsule 22.5 mg, 7.5 mg</i>	1099
STRIVERDI RESPIMAT	1056	TESTIM	1100
SUBOXONE SUBLINGUAL FILM	1057	<i>testosterone cypionate intramuscular* solution</i>	250
SUBSYS	1059	<i>mg/ml</i>	1105
SULAR ORAL TABLET EXTENDED RELEASE		<i>testosterone transdermal 10 mg/act (2%)</i>	1102
24 HR* 34 MG, 8.5 MG, 17 MG	1060	<i>testosterone transdermal 12.5 mg/act (1%)</i>	1101
<i>sulfacetamide sodium-sulfur external cream 9.8-4.8</i>		<i>testosterone transdermal 25 mg/2.5gm (1%)</i>	1103
<i>%</i>	1061	<i>testosterone transdermal 50 mg/5gm (1%)</i>	1104
<i>sulfacetamide sodium-sulfur external liquid†</i>		<i>tetrabenazine oral tablet 12.5 mg</i>	1106
<i>9.8-4.8 %</i>	1061	<i>tetrabenazine oral tablet 25 mg</i>	1107
<i>sulfacetamide sodium-sulfur external lotion</i>	1061	TEVETEN HCT	1109
<i>sulfasalazine oral</i>	1062	TEVETEN ORAL TABLET 600 MG	1108
SULFAZINE	1063	THEO-24 ORAL CAPSULE EXTENDED	
<i>sumatriptan nasal</i>	1064	RELEASE 24 HOUR 100 MG, 200 MG	1110
<i>sumatriptan succinate oral</i>	1065	<i>tiagabine hcl oral tablet 2 mg</i>	1111
<i>sumatriptan succinate refill</i>	1067	<i>tiagabine hcl oral tablet 4 mg</i>	1112
<i>sumatriptan succinate subcutaneous*</i>	1066	TIAZAC ORAL CAPSULE EXTENDED	
SUPRAX ORAL SUSPENSION		RELEASE 24 HOUR 240 MG	1114
RECONSTITUTED 100 MG/5ML, 200 MG/5ML		TIAZAC ORAL CAPSULE EXTENDED	
	1069	RELEASE 24 HOUR 420 MG, 300 MG, 180 MG,	
SUPRAX ORAL TABLET CHEWABLE	1068	360 MG, 120 MG	1113
SUTENT	1070	TILIA FE	1115
SYEDA	1071	TINDAMAX ORAL TABLET 250 MG	1117
SYMBICORT	1072	TINDAMAX ORAL TABLET 500 MG	1116
SYMBYAX	1073	TIVICAY	1118
SYMLINPEN 120	1074	TIVORBEX	1119
SYMLINPEN 60	1075	TOBI	1120

TOBI PODHALER.....	1121	TYBOST.....	1163
<i>tobramycin inhalation</i>	1122	TYVASO.....	1164
<i>tolterodine tartrate er</i>	1123	TYVASO REFILL.....	1165
TOPAMAX SPRINKLE.....	1124	TYVASO STARTER.....	1166
<i>topiramate oral capsule sprinkle</i>	1125	TYZEKA.....	1167
TOPROL XL ORAL TABLET EXTENDED		UCERIS.....	1168
RELEASE 24 HR* 200 MG.....	1128	UCERIS ORAL.....	1169
TOPROL XL ORAL TABLET EXTENDED		ULESFIA.....	1170
RELEASE 24 HR* 25 MG.....	1126	ULORIC.....	1171
TOPROL XL ORAL TABLET EXTENDED		ULTRACET.....	1172
RELEASE 24 HR* 50 MG, 100 MG.....	1127	ULTRESA.....	1173
TOUJEO SOLOSTAR.....	1129	UROXATRAL.....	1174
TOVIAZ.....	1130	<i>valacyclovir hcl oral tablet 1 gm</i>	1176
TRADJENTA.....	1131	<i>valacyclovir hcl oral tablet 500 mg</i>	1175
<i>tramadol hcl er oral capsule extended release 24</i>		VALCHLOR.....	1177
<i>hour 300 mg, 200 mg, 100 mg</i>	1132	VALCYTE ORAL TABLET.....	1178
<i>tramadol-acetaminophen</i>	1133	<i>valganciclovir hcl</i>	1179
TRAVATAN Z.....	1134	<i>valsartan-hydrochlorothiazide</i>	1180
<i>travoprost</i>	1135	VALTREX ORAL TABLET 1 GM.....	1181
<i>tretinoin external 0.05 %, 0.025 %</i>	1136	VALTREX ORAL TABLET 500 MG.....	1182
<i>tretinoin external cream</i>	1136	VANCOGIN HCL ORAL CAPSULE 125 MG	
<i>tretinoin microsphere</i>	1137	1184
<i>tretinoin microsphere pump</i>	1138	VANCOGIN HCL ORAL CAPSULE 250 MG	
TRETIN-X EXTERNAL CREAM 0.0375 %		1183
.....	1139	VANOS.....	1185
TREXIMET.....	1140	VASCEPA.....	1186
TREZIX.....	1141	VECAMYL.....	1187
TRIBENZOR.....	1142	VECTICAL.....	1189
TRICOR.....	1143	VELIVET.....	1190
TRI-ESTARYLLA.....	1144	VELTIN.....	1191
TRIGLIDE ORAL TABLET 160 MG.....	1145	<i>venlafaxine hcl er oral capsule extended release 24</i>	
TRI-LEGEST FE.....	1146	<i>hour 150 mg</i>	1199
TRI-LINYAH.....	1147	<i>venlafaxine hcl er oral capsule extended release 24</i>	
TRILIPIX.....	1148	<i>hour 75 mg, 37.5 mg</i>	1198
TRINESSA (28).....	1149	<i>venlafaxine hcl er oral tablet extended release 24</i>	
TRI-NORINYL (28).....	1150	<i>hr* 150 mg</i>	1196
TRI-PREVIFEM.....	1151	<i>venlafaxine hcl er oral tablet extended release 24</i>	
TRI-SPRINTEC.....	1152	<i>hr* 75 mg, 37.5 mg, 225 mg</i>	1197
TRIVORA (28).....	1153	<i>venlafaxine hcl oral tablet 100 mg, 25 mg</i>	1193
TROKENDI XR ORAL CAPSULE EXTENDED		<i>venlafaxine hcl oral tablet 37.5 mg</i>	1195
RELEASE 24 HOUR 100 MG, 25 MG, 50 MG		<i>venlafaxine hcl oral tablet 50 mg</i>	1192
.....	1154	<i>venlafaxine hcl oral tablet 75 mg</i>	1194
TROKENDI XR ORAL CAPSULE EXTENDED		VENTOLIN HFA.....	1200
RELEASE 24 HOUR 200 MG.....	1155	VERAMYST.....	1201
<i>trospium chloride</i>	1156	<i>verapamil hcl er oral capsule extended release 24</i>	
<i>trospium chloride er</i>	1157	<i>hour 200 mg</i>	1202
TRULICITY.....	1158	<i>verapamil hcl er oral capsule extended release 24</i>	
TUDORZA PRESSAIR.....	1159	<i>hour 300 mg, 100 mg</i>	1203
TUSSICAPS.....	1160	VERELAN PM ORAL CAPSULE EXTENDED	
TUSSIONEX PENNKINETIC ER.....	1161	RELEASE 24 HOUR 200 MG.....	1205
TWYNSTA.....	1162		

2015 Aetna Value Plan
(Updated 12/01/2015)

VERELAN PM ORAL CAPSULE EXTENDED		XYZAL	1255
RELEASE 24 HOUR 300 MG, 100 MG	1204	XYZAL	1256
VERSACLOZ	1206	YASMIN 28	1257
VESICARE	1207	YAZ	1258
VESTURA	1208	ZARAH	1259
VIAGRA	1209	ZAVESCA	1260
VICTOZA	1210	ZECUITY	1261
VICTRELIS	1211	ZELAPAR	1262
VIIIBRYD ORAL KIT	1212	ZELBORAF	1263
VIIIBRYD ORAL TABLET	1214	ZEMPLAR ORAL	1264
VIMPAT ORAL SOLUTION	1216	ZENATANE	1265
VIMPAT ORAL TABLET	1217	ZENCHENT	1266
VIOKACE	1218	ZENCHENT FE	1267
VIRAMUNE XR ORAL TABLET EXTENDED		ZENZEDI ORAL TABLET 5 MG, 10 MG	1268
RELEASE 24 HR* 100 MG	1220	ZENZEDI ORAL TABLET 7.5 MG, 15 MG, 30	
VIRAMUNE XR ORAL TABLET EXTENDED		MG, 2.5 MG, 20 MG	1269
RELEASE 24 HR* 400 MG	1219	ZETIA	1270
VIREAD ORAL TABLET	1221	ZETONNA	1271
VITUZ	1222	ZIANA	1272
VIVELLE-DOT	1223	ZIOPTAN	1273
VOGELXO	1224	<i>ziprasidone hcl</i>	1274
VOGELXO PUMP	1225	ZIRGAN	1275
VOLTAREN TRANSDERMAL	1226	ZOCOR	1276
VOTRIENT	1227	ZOFRAN ODT	1279
VYTORIN	1228	ZOFRAN ORAL SOLUTION	1278
VYVANSE	1229	ZOFRAN ORAL TABLET	1277
VYVANSE	1230	ZOHYDRO ER	1280
WELLBUTRIN	1231	ZOLINZA	1281
WELLBUTRIN SR	1232	<i>zolmitriptan oral tablet 2.5 mg</i>	1282
WELLBUTRIN XL	1233	<i>zolmitriptan oral tablet 5 mg</i>	1284
WERA	1234	<i>zolmitriptan oral tablet dispersible 2.5 mg</i>	1282
WINRHO SDF	1235	<i>zolmitriptan oral tablet dispersible 5 mg</i>	1283
WYMZYA FE	1236	ZOLOFT ORAL CONCENTRATE	1285
XALATAN	1237	ZOLOFT ORAL TABLET 100 MG	1287
XALKORI	1238	ZOLOFT ORAL TABLET 25 MG	1288
XANAX XR	1239	ZOLOFT ORAL TABLET 50 MG	1286
XARELTO ORAL TABLET 10 MG	1240	<i>zolpidem tartrate</i>	1289
XARELTO ORAL TABLET 15 MG	1241	<i>zolpidem tartrate er</i>	1290
XARELTO ORAL TABLET 20 MG	1242	ZOMIG	1291
XARELTO STARTER PACK	1243	ZOMIG	1292
XARTEMIS XR	1244	ZOMIG ZMT	1293
XELJANZ	1245	ZONTIVITY	1294
XENAZINE ORAL TABLET 12.5 MG	1246	ZORVOLEX	1295
XENAZINE ORAL TABLET 25 MG	1247	ZOVIA 1/35E (28)	1296
XIFAXAN ORAL TABLET 200 MG	1249	ZOVIA 1/50E (28)	1297
XIFAXAN ORAL TABLET 550 MG	1248	ZUBSOLV SUBLINGUAL TABLET	
XIGDUO XR	1250	SUBLINGUAL 11.4-2.9 MG	1298
XOPENEX HFA	1251	ZUBSOLV SUBLINGUAL TABLET	
XTANDI	1252	SUBLINGUAL 2.9-0.71 MG	1300
XULANE	1253	ZUBSOLV SUBLINGUAL TABLET	
XYREM	1254	SUBLINGUAL 5.7-1.4 MG, 1.4-0.36 MG	1302

ZUBSOLV SUBLINGUAL TABLET	
SUBLINGUAL 8.6-2.1 MG	1304
ZYKADIA	1306
ZYMAXID	1307
ZYPREXA ORAL	1308
ZYPREXA ZYDIS	1309
ZYTIGA	1310
ZYVOX ORAL SUSPENSION	
RECONSTITUTED	1312
ZYVOX ORAL TABLET	1311